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In wilderness I sense the miracle of life 
and behind it  
our scientific accomplishments fade to trivia 
                                                                                                                           
     Charles Lindbergh (1902-1974) 
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Abstract 
 
 
 
 
 
 
Tissue engineering aims at replacing or regenerating tissue structures. In 
tissue engineering, the most limiting factor is the successful 
vascularization of the transplanted construct or the transplantation area. 
The current major hurdle is the lack of a therapeutic method that would 
rapidly induce adequate vascularization which would also remain in tissue. 
The proper method for induction of vascularization  would help several 
tissue engineering applications as well as numerous patients suffering from 
ischemic diseases, chronic wounds and soft tissue defects. In addition to 
the tissue engineering applications, investigation of the angiogenesis 
process is important for the treatment of different other diseases such as 
cancers. Therefore, in vitro angiogenesis assays that can predict human 
effects are required. Understanding the role of angiogenesis in adipose 
tissue is of especial importance, as vasculature regulates both the adipose 
tissue mass development and adipose tissue reduction and  obesity  is  a  
cause of a distruction in normal adipose tissue homeostasis. 
The aim of the current study was to study angiogenesis and 
adipogenesis induction in in vitro assays and in vivo. In the first part of the 
study, acellular angiogenic and adipogenic agent was extracted from 
adipose tissue and the bioactivity of the extract was tested in vitro and in 
vivo. In cell culture studies, this adipose tissue extract was shown to 
stimulate angiogenesis and adipose tissue stromal cell maturation towards 
adipocytes. In vivo, when combined with hyaluronan hydrogel, the extract 
was shown to induce sustained soft tissue formation. No hypersensitivity 
or foreign body reactions were seen. Adipose tissue extract has therefore 
potential to be used as an acellular alternative in the treatment of soft 
tissue defects for reintroducing soft tissue at the defect sites. Adipose 
tissue extract has also potential to be used to induce revascularization in 
ischemic tissues and to be used in other tissue engineering products that 
fail due to inadequate vascularization. Moreover, adipose tissue extract can 
be used as an inducer in an in vitro model of natural adipogenesis. 
The second part of the study focused on developing in vitro methods 
for angiogenesis induction. We created a multilayered adipose stromal cell 
vascular network with properties of maturating vessels that can be used for 
studying angiogenesis in vitro, and especially, in the development of in 
vitro three dimensional tissue models as well as possibly as a vascularized 
platform in implantable soft tissue constructs. We also intra-laboratory 
validated an in vitro angiogenesis assay to be used as a routine cell assay 
for drug and chemical screening. The currently validated in vitro assay is a 
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relevant-to-human bioassay that can be used for preclinical drug efficacy 
screening studies, and in addition, is applicable also for testing 
angiotoxicity of chemicals.  
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Tiivistelmä 
Kudosteknologia pyrkii korvaamaan tai tuottamaan uusia kudosrakenteita. 
Suurin ongelma kudosteknologisten sovellusten kehittämisessä on 
verisuonituksen puuttuminen ja riittävän verisuonituksen 
muodostuminen. Sellainen terapeuttinen menetelmä, joka aikaansaisi 
nopean verisuonien muodostumisen korjattavalla alueella ja jonka 
aikaansaama uudisverisuonitus pysyisi kudoksessa pitkään, hyödyttäisi 
lukuista joukkoa niin pehmytkudosvammoista kärsiviä potilaita kuin 
kroonisten haavojen tai iskeemisten kudosten hoitoa tarvitsevia potilaita. 
Verisuonituksen muodostumisen ja sen estämisen tutkiminen on lisäksi 
tärkeää useissa muissa sairauksissa kuten syövissä, ja tämä vuoksi 
ihmiskudoksen verisuonitusta mallittavia solutason testimenetelmiä 
verisuonimuodostuksen tutkimiseksi tarvitaan. Verisuonimuodostuksen 
tutkiminen rasvakudoksessa on erityisen tärkeää siksi, että verisuonitus 
säätelee rasvakudoksen määrää ja lihvauuteen johtavaa rasvakudoksen 
liiallista kertymistä. 
Tässä tutkimuksessa tutkittiin verisuonituksen ja pehmytkudoksen 
syntymistä. Rasvakudoksesta eristettiin solutonta verisuonituksen ja 
rasvan muodostumista edistävää materiaalia, rasvakudosekstraktia, ja 
tutkittiin sen kykyä indusoida sekä verisuonitusta että pehmytkudoksen 
muodostumista soluviljelmissä ja implantointikokein. Soluviljelmissä 
rasvakudosekstraktin todettiin aikaansaavan verisuonirakenteiden 
muodostumista sekä triglyseridien kertymistä rasvakudoksen 
kantasoluihin. Implantointikokeissa materiaalia yhdistettiin 
hyaluronihappohydrogeeliin ja todettiin, että rasvakudosekstrakti indusoi 
nopeaa verisuonituksen muodostumista ihonalaiskudoksessa, sekä kypsän, 
pysyvän rasvakudoksen syntymistä. Materiaalin todettiin olevan 
kudosyhteensopiva. Täten työssä tutkittu rasvakudosekstrakti on lupaava 
soluton hoitomuoto verisuonimuodostuksen ja rasvakudoksen 
aikaansaamiseksi pehmytkudosvaurioissa. Rasvakudoksekstraktia voidaan 
käyttää lisäksi verisuonituksen parantamiseen erilaisissa 
kudosteknologisissa sovelluksissa. Rasvakudosekstraktia avulla voidaan 
mallintaa luonnolllisen rasvamuodostuksen mallittamiseen 
soluviljelmässä.  
Työn toisessa osassa tutkittiin ja kehitettiin ihmissolumalleja 
verisuonituksen muodostumisen tutkimiseen. Tutkimuksessa kehitettiin 
rasvakudoksen kantasoluihin perustuva kolmiulotteinen verisuonimalli, 
jota voidaan käyttää verisuonitutkimuksessa tai luotaessa edistyneitä 
kudosmalleja soluviljelmissä tai tehtäessä kudosrakenteita 
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soluterapiatarkoituksiin. Työssä kehitettiin lisäksi laadultaan 
korkeatasoinen ja toistettava testimenetelmä käytettäväksi prekliinisen 
vaiheessa verisuonimuodostuksen tutkimiseksi lääkeaineiden ja 
kemikaalien turvallisuuden ja tehon testausta varten. 
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Abbreviations 
AB/AM  antibiotic antimycotic mixture 
ACBP  acyl-coenzyme A – binding protein 
Ang-1  angiopoietin 1 
Ang-2  angiopoietin 2 
ANOVA  analysis of variance 
AgRP   agouti-related protein 
ap2  fatty acid binding protein 
APC  allophycocyanin 
ASC  adipose stromal cell 
ATE   adipose tissue extract 
Axl   AXL receptor tyrosine kinase  
BMI  body mass index 
BMP-2  bone morphogenetic protein 2 
BMP-4  bone morphogenetic protein 4 
BSA  bovine serum albumin 
cAMP  cyclic adenosine monophosphate 
CCL5 (RANTES)  chemokine (C-C motif) ligand 5  
C/EBPɄ  CCAAT/enhancer binding protein Ʉ 
C/EBPɅ  CCAAT/enhancer binding protein Ʌ 
C/EBPɈ  CCAAT/enhancer binding protein Ɉ 
CNTF  ciliary neurotrophic factor 
CREB  cyclic adenosine monophosphate responsive 
element binding protein 
COL I   collagen I 
COL III   collagen III 
COL IV  collagen IV 
COL XVIII  collagen XVIII 
CTACK   cutaneous T cell-attracting chemokine  
CV  coefficient of variation 
DLL4  delta-like ligand 4 
Dtk  growth factor receptor tyrosine kinase  
DMEM  Dulbecco’s Modified Eagle’s Medium 
DMEM/F12  Dulbecco’s modified Eagle’s medium: Nutrient 
mixture F-12 
DMSO  dimethyl sulphoxide 
EBM-2  endothelial cell basal medium -2 
ECM  extracellular matrix 
EGF  epidermal growth factor 
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EGM-2  endothelial cell growth medium -2 
EGF-R  epidermal growth factor receptor  
ELISA  enzyme-linked immunosorbent assay 
ENA-78    epithelial neutrophil activating peptide-78 
FAS fatty acid synthase 
Fas/TNFRSF6 Fibroblast-associated/Tumour necrosis factor 
receptor superfamily member 6 
FBS  fetal bovine serum 
FITC  fluorescein isothiocyanate  
FGF  fibroblast growth factor 
Flk-1 Fetal liver kinase-1, transmembrane tyrosine 
kinase, vascular endothelial growth factor 
receptor 2 
Flt-1 Fms-like tyrosine kinase 1, vascular endothelial 
growth factor receptor 1 
Flt-3 ligand Fms-like tyrosine kinase 3 ligand 
bFGF  basic fibroblast growth factor 
FGF-4   fibroblast growth factor 4  
FGF-6   fibroblast growth factor 6  
FGF-9   fibroblast growth factor 2  
GFP  green fluorescence protein 
GLP  good laboratory practice 
GLUT4  glucose transporter 4 
HA  hyaluronic acid 
hASC  human adipose stromal cells 
hATE  human adipose tissue extract 
HGF  hepatocyte growth factor 
hpf  high power field 
hr  hour 
hrs  hours 
HS  human serum 
HUVEC  human umbilical vein endothelial cells 
IFN-ɇ  interferon ɇ 
IGF-I  insulin-like growth factor I 
GCSF   granulocyte colony-stimulating factor  
GH  growth hormone 
GITR   glucocorticoid-induced tumor necrosis factor 
receptor 
GITR-ligand  glucocorticoid-induced tumor necrosis factor 
receptor ligand  
GRO   cytokine-induced neutrophil chemoattractant 1 
growth related oncogene  
HE  hematoxylin eosin 
IGF-1   insulin-like growth factor 1 
IGF-1 SR   insulin-like growth factor 1 soluble receptor  
IGFBP-3   insulin-like growth factor binding protein 3  
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IGFBP-6   insulin-like growth factor binding protein 6  
IL-1Ʌ  interleukin 1Ʌ 
IL-6   interleukin 6  
IL-8   interleukin 8 
IL-10  interleukin 10  
IL-11   interleukin 11 
iNOS  inducible nitric oxide synthase 
ISO  International Organization of Standardization 
I-TAC   Interferon-inducible T-cell alpha chemoattractant  
L-glut  L-glutamine 
LIF  leukemia inducible factor 
LIGHT   homologous to lymphotoxin, exhibits inducible 
expression, and competes with HSV glycoprotein 
D for herpes virus entry mediator, a receptor 
expressed by T lymphocytes 
MCP-1   monocyte chemoattractant protein-1  
MCP-2   monocyte chemoattractant protein-2  
MCP-3   monocyte chemoattractant protein-3  
MEM  minimal essential medium 
MIF   macrophage migration inhibitory factor 
min  minutes  
MIP-1Ʉ   macrophage inflammatory protein-1Ʉ 
MIP-1Ʌ   macrophage inflammatory protein-1Ʌ  
MIP-3Ʌ   macrophage inflammatory protein-3Ʌ  
MSP-Ʉ   macrophage stimulating protein Ʉ  
NEAA  non essential amino acids 
NAP-2   neutrophil activating protein-2  
NF-68  neurofilament 68 
NGF  nerve growth factor 
NR  neutral red 
NRU  neutral red uptake 
NT-4   neurotrophin 4  
OECD  Organisation for Economic Co-operation and 
Development 
ORO  oil-red-O 
PAI-1  plasmin activator inhibitor 1 
PBS  phosphate buffered saline 
PDGF-B  platelet derived growth factor beta 
PDGFRɅ  platelet derived growth factor receptor beta 
PE  phycoerythrin 
PECAM-1    platelet/endothelial cell adhesion molecule-1 
PlGF   placental growth factor  
P/S  penicillin/streptomycin 
qRT-PCR  quantitative reverse transcriptase polymerase 
chain reaction 
rATE  rat adipose tissue extract 
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RANTES   regulated upon activation, normal T-cell 
expressed and secreted)/CCL5 (CC chemokine 
ligand 5 
RNA  ribonucleic acid 
RPLP0  ribosomal protein large P0 
RT  room temperature 
RT-PCR  reverse transcriptase polymerase chain reaction 
ɄSMA  alfa smooth muscle actin 
SMMHC  smooth muscle myosin heavy chain 
SREBP1c  sterol-regulatory element binding protein 1c 
SVF  stromal vascular fraction 
TGF-Ʌ  transforming growth factor-Ʌ 
Tie-1  tyrosine kinase (T) with Ig (I) and epidermal (E) 
growth factor homology domain 2 
Tie-2  tyrosine kinase (T) with Ig (I) and epidermal (E) 
growth factor homology domain 2 
TIMP-1   tissue inhibitor of matrix metalloproteinase-1  
TIMP-2    tissue inhibitor of matrix metalloproteinase-2  
TNF-Ʉ  tumor necrose factor Ʉ 
tPA  tissue-type plasminogen activator 
TRAIL R3   tumor necrosis factor-related apoptosis-inducing 
ligand receptor 3 
TRAIL R4   tumor necrosis factor-related apoptosis-inducing 
ligand receptor 4  
TRITC  tetramethyl rhodamine isothiocyanate 
Tsp-1  thrombospondin 1 
Tsp-2   thrombospondin 2 
UBS  umbilical cord buffer solution 
uPA   urokinase-type plasminogen activator  
VEGF(-A)   vascular endothelial growth factor  
VEGF-B   vascular endothelial growth factor B 
VEGF-C   vascular endothelial growth factor C 
VEGF-D   vascular endothelial growth factor D 
VEGFR-1  vascular endothelial growth factor receptor 1 
VEGFR-2  vascular endothelial growth factor receptor 2 
VEGFR-3  vascular endothelial growth factor receptor 3 
vWf  von Willebrand factor 
 
Abbreviations are defined at first mention in the review of the literature 
(and used only for concepts that occur more than once). 
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Introduction 
There is a tremendous need for tissue engineered organs. The loss of tissue 
or failure of organ is currently one of the most common and most 
expensive challenges to clinical health care (Laschke et al. 2006). The 
demand for organ and tissue transplants is much higher than the 
availability, and every year thousands of patients die while waiting for a 
suitable organ (Jain et al. 2005). The field of tissue engineering has 
emerged in the 1980s with the aim of creating biological substitutes for 
restoring human tissues. The tissue engineering could provide help for a 
number of diseases, but several challenges exist, such as isolation and 
expansion of specific cells, the organization of cells in constructs, as well as 
the optimal microenvironment for growth and differentiation (Jain et al. 
2005). 
The most crucial problem in tissue engineering is the vascularization of 
the tissue constructs (Jain et al.  2005; Wu et al.  2007; Rivron et al.  2008), 
and inadequate vascularization limits the size of engineered structures 
(Moioli et al. 2010; Patel and Mikos 2004; Wu et al. 2007). Until recently, 
the tissue engineered structures have been avascular tissues like skin 
(Kremer et al. 2000) and cartilage (Vacanti and Upton 1994). An effective 
method for angiogenesis induction is urgently needed, and the ability to 
vascularize tissue constructs would be a crucial step in tissue engineering 
(Jain et al. 2005). Techniques for vascularization can be divided into two: in 
vitro and in vivo engineered vascular networks (Lokmic and Mitchell 
2008). In both situations appropriate cells or their precursors, extracellular 
matrix and proangiogenic microenvironment, are needed for the 
development of vascular structures (Lokmic and Mitchell 2008).  
The stimulation of blood vessel formation in vivo has  been tried to  be  
improved by biomaterial modifications and by addition of 
glycosaminoglycans or growth factors into bioscaffolds (Nillesen et al. 
2007). The use of vascular endothelial growth factor (VEGF) has been 
promising, however, not sufficient alone to create mature and stable 
vasculature (Blau and Banfi 2001). The use of a cocktail of growth factors 
e.g. VEGF, placental growth factor (PlGF), Angiopoietin-1 (Ang-1), platelet 
derived growth factor beta (PDGF-B) and transforming growth factor-Ʌ 
(TGF-Ʌ), has been more successful in therapeutic angiogenesis (Jain et al. 
2005). Nevertheless, finding the optimal cocktail and adequate factors for 
inducing angiogenesis in tissue remains an unsolved task (Jain et al. 2005). 
Another solution is to insert the cellular components of vessels, i.e. 
endothelial cells and pericytes directly to the tissue graft. These cells 
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assemble into vascular structures in vivo and/or induce the host 
vasculature remodeling and neovascularization by secreting angiogenic 
growth factors (Jain et al. 2005). A problem with cell-seeded grafts is the 
cell death associated with implantation (Koc and Gerson 2003). However, 
in vitro prevascularization of certain tissue constructs has shown to 
improve their functionality in vivo (Levenberg et al. 2005).  
Adipose tissue engineering has traditionally focused on restoring the 
volume loss with no or much less emphasis on tissue function (Vermette et 
al. 2007). Tissue engineered fat in vitro and in vivo has been studied 
tremendously during the last decade, but most current therapy approaches 
for soft tissue induction, due to inadequate vascularization (Nillesen et al. 
2007; Verseijden et al. 2009; Wu et al. 2007), fail to produce satisfactory, 
reproducible and sustained result (Patrick 2001).   
Angiogenesis is suggested to be the “organizing principle in biology and 
medicine” (Folkman 2007). Already at 1970s Folkman presented findings 
that in the absence of vascularization tumors could not obtain larger 
diameter than 2-3 mm (Folkman 1971) and that the growth of tissue was 
dependent on neovascularization which was mediated by stimulating 
factors (Folkman 1971; Folkman 1990). In addition to tissue engineering 
applications, the investigation of induction of vascularization is important 
in numerous other normal and pathological conditions. To succeed in 
angiogenesis induction, we must be able to create and mimic the 
biochemical cocktail of blood and the biophysical environment during 
blood flow (Ko et al. 2007). In this study, the development of 
vascularization in vitro and in vivo as well as inductive adipogenesis, are of 
especial interest.  
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Review of the literature 
Vascular network 
Vascular network regulates the body homeostasis by transporting oxygen, 
liquids, nutrients, cells and signaling molecules to all parts of the body and 
by disposing waste from tissues (Rivron et al. 2008). The circulatory system 
aids immune system cells to protect the body from harmful attacks and 
contributes to the control of body temperature and blood pressure (Ko et 
al. 2007). The vascular system also aids in tissue regeneration and in the 
communication between organs (Rivron et al. 2008). As blood vessels are 
spread throughout the body, the changes in normal vessel growth and 
maintenance contribute to a wide number of diseases (Carmeliet and Jain 
2011).  
The cardiovascular system is the first system to develop in the embryo 
(Haigh 2008). The adult vasculature has a total surface area of 
approximately 1000 m2 (Buschmann and Schaper 1999). The smallest blood 
vessels are capillaries, consisting of a lumen with an inner diameter of 4-10 
µm, and a surrouding wall of endothelial cells (Ko et al. 2007). Capillaries 
are the main site of gas and nutrient exchange (Rivron et al. 2008). The 
difference between capillaries and arterioles is the appearance of smooth 
muscle cells in arterioles. Arterioles have a diameter of 10-300µm, and they 
contain 1-2 layers of smooth muscle cells in addition to the endothelial cell 
layer. Post-capillary venules lack smooth muscle cells, but differ from 
capillaries with the inner diameter of a lumen, that is 10-50 µm for the 
post-capillary venules. Larger venules are called collecting venules, with an 
inner diameter of 50-300 µm. (Ko et al. 2007) 
Blood vessel formation 
Blood vessels are formed of endothelial cells, extracellular matrix (ECM) 
and mural cells. Endothelial cells form a permeable tubule layer connected 
with tight junctions. Tubules are surrounded by mural cells, i.e. either 
pericytes in capillaries, or pericytes and smooth muscle cells in arterioles 
and arteries. Pericytes stabilize endothelial cells by releasing factors such 
as VEGF and Ang-1. (Rivron et al. 2008) The adult cells also contain oxygen 
sensors prolylhydroxylase and hypoxia-inducible factors (HIF-2Ʉ). They 
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allow the vessels to adjust to changes in human body and to optimize the 
blood flow. (Carmeliet and Jain 2011) 
Normal blood vessel formation can occur by three different processes: 
vasculogenesis, angiogenesis and arteriogenesis. Vasculogenesis appears in 
the embryonic development, when mesodermal cells differentiate into 
angioblasts or hemangioblasts. These endothelial precursor cells 
differentiate into endothelial cells which then organize into primary 
capillary plexuses and further into vascular networks. (Moon and West 
2008; Papetti and Herman 2002; Risau 1997) Angiogenesis is the formation 
of new capillary sprouts from the pre-existing blood vessels (Carmeliet and 
Jain 2011; Risau 1997). Angiogenesis is mainly driven by tissue hypoxia 
signals and occurs under conditions that belong to normal life cycle and 
retain normal body homeostasis such as menstrual cycle (folliculogenesis 
and ovulation), pregnancy, fracture repair and wound healing. 
Angiogenesis also occurs in pathological disease conditions such as in 
tumor growth and metastasis, in rheumatoid arthritis, in ischemic 
diseases, in neonatal hemangiomas, in hypertrophic scars or keloids, in 
atherosclerosis and in retinopathies (Beer et al. 1998; Buschmann and 
Schaper 1999; Carmeliet and Jain 2011; McHoney 2010). Arteriogenesis 
occurs after occlusion of a major artery, and is defined as a rapid 
proliferation of pre-existing arteries. It allows the pre-existing arteries to 
bypass the occlusion site. (Buschmann and Schaper 1999) Arteriogenesis 
and angiogenesis share many properties such as growth factor induction, 
but arteriogenesis is dependent on inflammation, not on hypoxia, as 
angiogenesis is. (Buschmann and Schaper 1999) 
Tumors can use also additional processes for abnormal blood vessel 
formation, such as vascular mimicry, where tumor vessels form abnormal 
vascular-like structures themselves, or vessel co-option, where tumor 
blood vessels incorporate into normal tissue capillaries.  Tumor stem cells 
themselves have also ability to differentiate into abnormal endothelial 
cells. (Carmeliet and Jain 2011)  
This review will focus on physiological angiogenesis and its regulation, 
and on angiogenesis in adipose tissue.  
Angiogenesis 
In adults, new blood vessels arise mainly by sprouting from the existing 
vasculature (Carmeliet 2005). In sprouting angiogenesis, proliferative 
endothelial cells retain their basal-luminal polarity (Paku et al. 2011) 
Angiogenesis can also occur by intussusceptive growth of existing vessels 
(Carmeliet 2005; Rivron et al. 2008).  Intussusceptive angiogenesis is rapid 
and is mainly characterized by the insertion of endothelial cell bridges and 
connective tissue columns across the capillary lumen (Paku et al. 2011). The 
pre-existing vessels therefore partition into daughter vessels which results 
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in an increase in the capillary density (Carmeliet and Jain 2011; Paku et al. 
2011).  
Endothelial cell migration 
After receiving angiogenic signal such as VEGF, VEGF-C, Ang-2 or FGFs 
from a hypoxic, inflammatory or tumor cell, pericytes detach from the 
vessel wall. The basement membrane and ECM are degraded by matrix 
metalloproteases (MMPs) and by suppression of protease inhibitors (tissue 
inhibitor of matrix metalloproteases, TIMPs). VEGF increases the 
permeability of the endothelial cell layer and loosens the endothelial tight 
junctions. The vessel is then dilated by nitric oxide synthase. (Carmeliet 
and Jain 2011) Plasma proteins are leaked from loosened vessels and they 
provide a provisional ECM to the developing vessels (Jain 2003). 
Endothelial cells lose contact with basement membrane laminin and 
become exposed to collagen I, which activates cytoskeleton reorganization 
and endothelial sprouting (Davis and Senger 2005; Rhodes and Simons 
2007). In a healthy adult, quiescent endothelial cells have half-lives of 
thousands of days (Carmeliet and Jain 2011; Fan et al. 1995). However, in 
angiogenesis, activated endothelial cells have a half-life of only a few days 
(Fan et al. 1995). Endothelial cells become motile and align into chords. 
One endothelial cell is differentiated to be the leading cell, a tip cell. The 
tip cell starts to migrate towards the VEGF stimulation signal from 
extracellular matrix. The VEGF gradient induces tip cell’s neighbors, the 
stalk cells, to proliferate and elongate the vessel sprout and to form the 
lumen. (Carmeliet and Jain 2011; Gerhardt et al. 2003; Ruhrberg et al. 2002)  
VEGF induces expression of delta-like ligand (DLL-4) in tip cells. DLL-4 
binds to its receptors Notch 1 and Notch 4 in stalk cells. (Carmeliet and 
Jain 2011) This contact downregulates VEGFR-2 expression in stalk cells 
and they become less responsive to VEGF. This ensures that only one cell, 
the tip cell, leads the tubule formation, that vessel is orderly developed and 
the excess angiogenesis is prevented. (Carmeliet and Jain 2011; Chung et al. 
2010) The tip cell expresses membrane type 1 matrix metalloprotease (MT1-
MMP) that opens up the matrix for the endothelial sprout. MT1-MMP is 
later down-regulated when stalk cells come into contact with pericytes. 
(Chung et al. 2010) Endothelial cells are sealed with tight cell-cell junctions 
and adherens junctions. VE-cadherin is an important component of 
endothelial cell-to-cell junctions, neural (N) –cadherin facilitates 
endothelial cell-mural cell communication and gap junctions exist 
between endothelial cells and endothelial cells and pericytes. (Jain 2003)  
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Pericytes and maturation of the vessels 
Vessels are stabilized by recruiting mural cells to the vessel wall and 
generating ECM. Mature capillaries are partially covered by mural cells 
called pericytes and larger vessels are covered by vascular smooth muscle 
cells and pericytes (Gerhardt and Betsholtz 2003). Pericytes are cells that 
are located in between the endothelium and the surrounding tissue and 
make contacts with the endothelium (Armulik et al. 2005). Pericytes are 
important regulators of vascular maturation, stabilization and remodeling 
(Armulik et al. 2005). Pericytes are morphologically diverse cells 
depending on the tissue and the stage of development. Some of the 
markers that pericytes express are smooth muscle Ʉ-actin (Ʉ-SMA), 
desmin, platelet derived growth factor receptor-Ʌ (PDGFR-Ʌ), 
proteoglycan NG-2, aminopeptidases A and N, RGS5 and XlacZ4 gene 
(Gerhardt and Betsholtz 2003), however, these markers are not specific to, 
nor recognize, all pericytes (Armulik et al. 2005). Pericyte recruitment to 
the vessel wall is essential for the maturation, stability and functionality of 
vessels (Benjamin et al. 1998). Pericytes stimulate endothelial cell 
basement membrane formation (Stratman et al. 2009) and control 
perfusion (Carmeliet and Jain 2011). Mural cells can be derived from bone 
marrow (Carmeliet 2000), adipose tissue stroma (Traktuev et al. 2008; 
Wang et al. 2010), and from fibroblasts that can differentiate into 
myofibroblasts and further into vascular smooth muscle cells (Chambers et 
al. 2003).  
Four pathways are involved in vascular wall maturation: i) PDGF-B – 
PDGFRɅ. PDGF-B secretion by endothelial cells induces recruitment of 
PDGFRɅ expressing mural cells. ii) sphingosine -1-phosphate-1 (SIP -1) – 
endothelial differentiation sphingolipid G-protein-coupled receptor -1 
(EDG1). SIP-1 induces the recruitment of EDG1 expressing mural cells. iii) 
Ang-1 - tyrosine kinase (T) with Ig (I) and epidermal (E) growth factor 
homology domain 2 (Tie-2) pathway. Pericytes and vascular smooth 
muscle cells express Ang-1, and they bind tightly to the their receptor Tie-2 
on the surface of endothelial cells. This interaction mediates blood vessel 
stabilization. iv) TGF-Ʌ. Ang-1/Tie-2 contact induces activation of TGF-Ʌ, 
which further induces basement membrane formation. (Carmeliet and Jain 
2011; Holderfield and Hughes 2008; Jain 2003) 
The re-established contact between endothelial cells and pericytes 
induces expression of TIMP-2 in endothelial cells and TIMP-3 in pericytes, 
which switches off the proteolytic phenotype of endothelial cells (Saunders 
et al. 2006). TIMPs and plasminogen activator inhibitor 1 (PAI-1) induce 
the deposition of basement membrane (Carmeliet and Jain 2011). The 
basement membrane is built up of laminins, collagen IV (COL IV), 
perlecan, nidogens and COL XVIII (Davis and Senger 2005). Basement 
membrane keeps endothelial cells apart from COL I, which is needed in 
order to prevent the activation of endothelial cells. The adult endothelial 
cells are therefore stable mainly due to basement membrane. After 
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establishment of blood flow, the local oxygen levels increase which leads to 
the decrease in VEGF levels and the end of angiogenesis. (Darland and 
D'Amore 1999) 
Maturation of the vascular network involves optimal patterning of the 
network by branching, expanding and pruning (Jain 2003). Some of the 
capillaries remain, while some of the capillaries differentiate into arteries 
or veins (Risau 1997). Increase in shear stress and pressure induces 
recruitment of smooth muscle cells into capillaries, leading to 
differentiation into arteries or veins (Buschmann and Schaper 1999). 
Expansion of larger arteries and veins aquires several layers of mural cells 
in addition to ECM and elastic laminae. This is essential to obtain 
viscoelastic properties and neural control for the blood vessels. (Jain 2003) 
Endothelial cells, mural cells and matrix undergo also organ-specific 
specialization.  
Role of extracellular matrix in angiogenesis  
ECM provides support for existing and developing vasculature and 
guidance for the new forming capillaries. ECM stores biologically active 
molecules such as angiogenesis inducers and inhibitors. (Carmeliet and 
Jain 2011) Many ECM proteins such as COL I, III and XV, collagen receptor 
integrins Ʉ͝Ʌ1, Ʉ͞Ʌ1, laminin-1 and -8, fibronectin, fibronectin receptor 
integrin Ʉ͡Ʌ1 as well as perlecan have angiogenic properties (Jain 2003). 
Moreover, several angiogenic factors are bound in heparin sulphate in the 
ECM (e.g. VEGF, bFGF and TGFɅ) (Rundhaug 2003). ECM components 
thrombospondin 1 and 2 (Tsp-1 and Tsp-2, respectively) inhibit 
angiogenesis (Jain 2003). Many other angiogenesis inhibitors such as 
endostatin (derived from COL XVIII) (O'Reilly et al. 1997), angiostatin 
(derived from plasminogen) (Dong et al. 1997), as well as tumstatin 
(derived  from  COL  IV)  (Hamano  et  al.  2003),  are  also  stored  in  ECM  as  
fragments within larger matrix molecules.  
The balance in protease activity and interactions of proteases with ECM 
regulate angiogenesis (Christiaens and Lijnen 2010). During angiogenesis 
and vessel remodeling, the proteolytic modification of ECM allows 
endothelial cells to migrate and converts the basement membrane into a 
proangiogenic environment (Carmeliet and Jain 2011; Lamalice et al. 2007). 
Three classes of proteases; serine proteases, cystein proteases, and 
metalloproteases participate in the ECM remodeling (Christiaens and 
Lijnen 2010). These proteases generate angiogenic and anti-angiogenic 
factors from ECM proteins and modify growth factors and receptors (van 
Hinsbergh et al. 2006). MMPs promote angiogenesis by degrading 
basement membrane and by regulating endothelial cell attachment, 
proliferation and migration as well as by releasing growth factors from 
ECM (Stetler-Stevenson 1999). One such MMP, cathepsin B, having both 
angiogenic and anti-angiogenic effects, is suggested to be the “angiogenic 
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switch” of endothelial cells (Christiaens and Lijnen 2010; Im et al. 2005). If 
no blood flow is created, the capillaries are repressed by MMPs 
(Buschmann and Schaper 1999; Davis and Saunders 2006).  
The fibrinolytic system also participates in angiogenesis, in wound 
healing and in tissue remodeling (Christiaens and Lijnen 2010). 
Plasminogen is an inactive proenzyme that, when converted into the active 
enzyme, plasmin, degrades fibrin (Christiaens and Lijnen 2010). Plasmin 
activates and releases MMPs, elastase and growth factors such as VEGF, 
bFGF, HGF, TGFb and PDGF (Tkachuk et al. 2009). Two plasminogen 
activators are tissue-type plasminogen activator (t-PA) and urokinase-type 
plasminogen activator (u-PA) (Christiaens and Lijnen 2010). uPA 
stimulates endothelial cell tubule formation (Christiaens and Lijnen 2010; 
Tkachuk et al. 2009). Plasminogen activator inhibitor 1 (PAI-1) is the 
principal inhibitor of uPA and tPA, and has a significant role in the 
regulation of ECM remodeling (Christiaens and Lijnen 2010). ECM 
associated proteases PAI-1 and uPA are activated by VEGF (Pepper 2001).  
Molecular regulation of angiogenesis 
Angiogenesis is tightly regulated by several positive and negative 
regulators; cells, soluble factors and extracellular matrix components (Fan 
et al. 1995). Some of the most important factors are next discussed in 
detail.   
The Vascular Endothelial Growth Factor family 
The VEGF protein family contains VEGF (VEGF-A), VEGF-B, VEGF-C, 
VEGF-D and placental growth factor (PlGF) (Christiaens and Lijnen 2010). 
VEGF is the predominant and most potent inducer of angiogenesis, 
inducing endothelial cell proliferation, sprouting and tubule formation 
(Otrock et al. 2007), both in normal and in tumor angiogenesis (Carmeliet 
and Jain 2011). Three forms of VEGF are produced in alternative splicing 
(VEGF-A121, VEGF-A165, VEGF-A189) (Christiaens and Lijnen 2010). 
Paracrine VEGF, secreted by tumor, myeloid or other stromal cells 
increases vessel enlargement and branching (Stockmann et al. 2008) 
whereas autocrine VEGF, released by endothelial cells, maintains vessel 
homeostasis (Lee et al. 2007). Soluble VEGF isoforms enlarge vessels, 
whereas membrane-bound VEGF induces vessel branching (Iruela-Arispe 
and Davis 2009).   
All the members of VEGF family signal through three transmembrane 
tyrosine kinase receptors, VEGF receptor-1 (VEGFR-1, also known as Flt-1), 
VEGFR-2 (also known as Flk-1) and VEGFR-3 (Ferrara 2004). VEGF 
interacts through VEGFR-1 (Christiaens and Lijnen 2010) and VEGFR-2 
(Ferrara 2009; Nagy et al. 2007). VEGF-B and PlGF bind to VEGFR-1 
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(Hagberg et al. 2010). VEGF-C acts through VEGFR-2 and VEGFR-3 
(Tvorogov et al. 2010) and VEGF-D through VEGFR-3 (Stacker et al. 2001). 
VEGFR-1 and VEGFR-2 mediate angiogenesis, whereas VEGFR-3 is known 
to be important in embryogenesis and adult lymphangiogenesis (Tammela 
and Alitalo 2010; Veikkola et al. 2001).  
VEGF-B is 43% identical to VEGF-A165 (Christiaens and Lijnen 2010). 
VEGF-B has restricted angiogenic activity in certain tissues, such as heart 
(Hagberg et al. 2010). VEGF-B also participates in ECM degradation 
(Olofsson et al. 1998). VEGF-C that activates tip cells (Tvorogov et al. 
2010),  is 30% identical to VEGF-A165 (Christiaens and Lijnen 2010). VEGF-
D is 48% identical to VEGF-C (Christiaens and Lijnen 2010). It promotes 
lymphangiogenesis (Stacker et al. 2001). PlGF is 43% identical to VEGF-
A165 (Christiaens and Lijnen 2010). PlGF is not relevant for developmental 
angiogenesis, but has a role as an angiogenic factor in pathological 
conditions (Carmeliet et al. 2001; Christiaens and Lijnen 2010). PlGF has 
been shown to increase revascularization in ischemic tissue, in wounded 
skin and in tumors (Carmeliet and Jain 2011).  
Platelet Derived Growth Factor-ɴ 
PDGF-Ʌ induces proliferation of smooth muscle cells and fibroblasts in 
vitro (Kiritsy et al. 1993). PDGF is a homodimer of two polypeptides B 
(PDGF-BB). PDGF polypeptides can also assemble into other hetero- or 
homodimers (PDGF-AA, -CC, -DD, or PDGF-AB). PDGF receptors 
(PDGFR) are also assembled into dimers, PDGFR-ɄɄ, PDGFR-ɅɅ and 
PDGFR-ɄɅ. PDGF-Ʌ is the only PDGF isoform that can bind all these 
receptor dimers. (Wang et al. 2012) Angiogenic endothelial cells release 
PDGF-B to chemoattract PDGFR-Ʌ expressing pericytes (Hellberg et al. 
2010). The interaction between PDGF-Ʌ and PDGFR-Ʌ is the key for the 
pericyte recruitment and the development of functional vasculature 
(Hellstrom et al. 1999). PDGF has also an important role in wound healing 
(Kiritsy et al. 1993). 
The Ang/Tie signaling  
Ang/Tie signaling provides a maintenance and adjustment system for 
normal healthy vessels (Carmeliet and Jain 2011). The signaling system 
consists of two receptors, Tie-1 and Tie-2, expressed by endothelial cells 
and three  ligands,  Ang-1,  Ang-2  and Ang-3  (Christiaens  and Lijnen 2010).  
Ang-1 is expressed by mural and tumor cells, whereas Ang-2 is expressed 
by angiogenic tip cells (Christiaens and Lijnen 2010; Jain 2003). Tie-2 binds 
both Ang-1 and Ang-2, but the ligands of Tie-1 are less well-known 
(Christiaens and Lijnen 2010). Ang-2 either activates or blocks Tie-2, 
depending on cells, whereas Ang-1 constantly activates Tie-2 (Davis et al. 
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1996). Ang-1 tightens vessels by recruiting pericytes and promoting 
interaction between endothelial cells and mural cells (Carlson et al. 2001). 
Ang-1 is also reported to inhibit inflammation under normal physiological 
conditions (Thurston et al. 1999). Ang-2 stimulates vessel growth by 
destabilizing endothelial cell-pericyte interactions, dissociating pericytes 
from vessels and by degrading ECM (Cao et al. 2007; Morange et al. 2002). 
Transforming Growth Factor-ɴ 
TGF-Ʌ is a multifunctional cytokine that regulates growth and 
differentiation and is produced by a variety of cells (Christiaens and Lijnen 
2010). Ang-1/Tie-2 contact induces secretion of TGF-Ʌ (Holderfield and 
Hughes 2008). TGF-Ʌ is secreted by macrophages and other stromal 
vascular fraction cells in adipose tissue (Bourlier et al. 2008). It has both 
pro- and antiangiogenic properties. At low levels it upregulates angiogenic 
factors and ECM degrading proteases, whereas at high levels it inhibits 
endothelial proliferation and promotes tubule maturation by inducing 
basement membrane formation and differentiation of mesenchymal cells 
into mural cells (Holderfield and Hughes 2008; Pardali et al. 2010).  
basic Fibroblast Growth Factor 
bFGF belongs to a superfamily of FGFs, the widely expressed mitogens that 
control a number of biological functions (Beenken and Mohammadi 2009). 
FGFs are needed to maintain vascular integrity (Murakami et al. 2008). 
FGFs also indirectly stimulate angiogenesis by activating other angiogenic 
factors like interleukin 6 (IL-6) (Beenken and Mohammadi 2009; Okamura 
et al. 1991). bFGF was one of the first angiogenic factors discovered 
(Carmeliet and Jain 2011). bFGF stimulates endothelial cell proliferation, 
migration and differentiation by activating its receptor on endothelial cells 
(Kawaguchi et al. 1998). When bFGF is bound to its tyrosine kinase 
receptors FGFR1 and FGFR2, it activates downstream MAPK signaling and 
induces cell proliferation (Cross and Claesson-Welsh 2001). bFGF also 
stimulates the synthesis of proteases, such as collagenase, during 
angiogenesis (Okamura et al. 1991). 
 
A schematic drawing of angiogenesis and its regulators is seen in Figure 1. 
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Figure 1. Angiogenesis and its main regulators. Angiogenesis is first 
initiated by growth factor secretion (e.g. Ang-2, FGFs, VEGF) from hypoxic cells, 
inflammatory cells or tumor cells. Growth factors are attached to their receptors 
in endothelium, which activates the endothelial cells and induces the degradation 
of  basement  membrane  and  ECM  by  MMPs.  Endothelial  tip  cell  then  migrates  
towards the VEGF gradient. Tip cell secretes MT1-MMP, which degrades ECM, 
and DLL-4, which binds to its receptor Notch in stalk cells. After tube formation 
and elongation, PDGFRɅ expressing pericytes are recruited by PDGF-B expressing 
endothelial cells. Ang-1 expressing pericytes bind tightly to their receptor Tie-2, 
which induces TGFɅ production from endothelial cells. After basement 
membrane deposition, endothelial cells become surrounded by COL IV and 
obtain their quiescent state. Image modified from Klagsbrun and Moses (1999). 
 
Angiogenesis in tissue repair 
Neovascularization is a critical step in tissue repair such as in wound 
healing. Tissue injury causes disruption of blood vessels and the release of 
blood constituents into wound site. During the early phase of wound 
repair, granulation tissue appears. At first, neutrophils cleanse the wound 
from foreign particles and bacteria. Activated platelets stimulate the 
formation of hemostatic plug, as well as the release of growth factors such 
as PDGF, that then attract and activate macrophages and fibroblasts. 
Hypoxia induces secretion of VEGF. (Epstein 1999; Tonnesen et al. 2000) 
Macrophages and the secreted factors are essentially needed for the new 
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tissue formation (Epstein 1999). Peripheral blood monocytes are recruited 
into the injury site by ECM fragments as well as by TGFɅ and monocyte 
chemotactic protein-1 (MCP-1). Monocytes are then activated into 
macrophages which ensure the continous synthesis and secretion of 
growth factors (e.g. PDGF and VEGF) for the formation of granulation 
tissue. (Epstein 1999; Tonnesen et al. 2000) Macrophages also secrete CSF-
1, TNFɄ, TGFɄ, TGFɅ, IL-1, and IGF-1 (Rappolee et al. 1988). Chemotactic 
factors can also be secreted by parenchymal cells. They may trigger release 
of bFGF and aFGF during the first three days of wound healing. This is the 
initiation stimulus of angiogenesis in wound healing. (Tonnesen et al. 
2000) bFGF stimulates endothelial cells to release plasminogen activator 
and procollagenase (Magnatti et al. 1989). Plasminogen activator converts 
plasminogen into active plasmin and procollagense into active collagense 
that then degrade basement membrane allowing endothelial sprouting. 
Endothelial cells migrate in response to the angiogenic factors such as 
VEGF. Integrin ɄɅ3 is suggested to be critical for wound repair 
angiogenesis. The tips of sprouting endothelial cells express ɄɅ3, which is 
needed to the endothelial cell migration into fibrin/fibronectin-rich 
provisional ECM in the wound clot. The provisional matrix is later replaced 
by collagen-rich scar tissue, and majority of the neovasculature undergoes 
apoptosis. (Tonnesen et al. 2000)  
Perfusion independent role of endothelial cells  
Endothelial cells and endothelial cell secreted factors have an important 
perfusion independent role in tissue development and remodeling. In 
embryogenesis, the endothelial cell migration into developing organs 
provides inductive signals to promote organogenesis. This does not require 
blood flow or conduits for oxygen delivery, but instead, the cells produce 
stimulating factors, so called angiocrine factors, that affect paracrinically 
organogenesis and tissue remodeling. (Butler et al. 2010; Ding et al. 2010) 
Angiocrine factors are, for example, growth factors, cytokines or adhesion 
molecules like bFGF, VEGF-A, Ang-2, PDGF-B, bone morphogenic protein-
2 and -4 (BMP-2 and -4, respectively), MCP-1, intercellular adhesion 
molecule 1 (ICAM1), vascular cell adhesion molecule 1 (VCAM1), IL-6 and 
IL-8 that can enhance angiogenesis and tissue repair (Butler et al. 2010). 
During development, endothelial cells secrete inductive sigmals that 
promote organ development, even in the absence of blood flow (Butler et 
al. 2010; Lammert et al. 2001). Endothelial cells can therefore support the 
maintenance and induction of tissue stem and progenitor cells (Butler et 
al. 2010). 
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Adipose tissue 
The human body has two main types of adipose tissue, brown and white 
adipose tissue (Choi et al. 2010). Brown adipose tissue is a major type of 
adipose tissue in prenatal period (Bucky and Percec 2008). In adult, brown 
adipose tissue is mainly found in neck, mediastinum and supraclavicular 
areas   (Nedergaard  et  al.  2007).  Brown  adipose  tissue  is  mainly  used  for  
heat generation from triglycerides (Bucky and Percec 2008), and it is 
activated during cold exposure (Nedergaard et al. 2007).  
White adipose tissue is a primary energy storage site in the body. It is 
distributed as depots in hypodermis (subcutaneous fat), around internal 
organs (visceral fat) and in other sites such as in bone marrow, in 
pericardium and in breast (REF). Adipose tissue stores energy as 
triglycerides in adipocytes, and rapidly releases them when needed (Rosen 
and Spiegelman 2006). Adipose tissue is a unique organ, as it has a 
capacity to undergo continuous expansion and regression throughout 
adult life (Sun et al. 2011; Poulos et al. 2010). Subcutaneous adipose tissue 
deposits are the main adipose tissue depots in humans (Harrington et al. 
2004). Visceral adipose tissue i.e. internal adipose tissue deposits are 
known to be more active metabolically than subcutaneous adipose tissue 
(Fain et al. 2004).  
Adipose tissue is composed of mature adipocytes surrounded by 
stromal-vascular fraction (SVF) cells. SVF is a heterogenous population of 
cells containing fibroblasts, mast cells, macrophages, leukocytes, 
endothelial cells, pericytes, adipose stem cells and ECM components 
(Astori et al. 2007; Karastergiou and Mohamed-Ali 2010; Poulos et al. 2010). 
50% of adipose tissue cells are mature adipocytes, 10% resident 
macrophages and the rest comprises of other stromal vascular cells 
(Karasterigou and Mohamed-Ali 2010). Adipose tissue is very rich in blood 
vessels, at least one capillary surrounding each adipocyte (Lijnen 2008), 
and also innervated by sympathetic nervous system (Bartness and 
Bamshad 1998). ECM interconnects adipocytes and forms the fat lobules in 
adipose tissue (Bucky and Percec 2008).  
Adipocytes 
Adipocytes are specialized connective tissue cells that have a basic 
function to store energy as triglycerides in lipogenesis and to release them 
as fatty acids in lipolysis. Adipocytes release a wide number of proteins and 
peptides that act in endocrine, paracrine or autocrine manner. They are 
implicated as adipokines. The most abundant adipokines released by 
adipocytes are leptin and adiponectin. (Galic et al. 2010; Karastergiou and 
Mohamed-Ali 2010) 
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Adipose stromal cells 
Multiple cells in adipose tissue share a common progenitor, adipose 
stromal cell (ASC), also widely known as adipose stem cell. Adipose 
stromal cell is a name suggested by the Mesenchymal and Tissue Stem Cell 
Committee of the International Society for Cellular Therapy to be used of 
these plastic-adherent stromal vascular fraction cells, rather than stem 
cells (Dominici et al. 2006). 
ASC are defined as a population of cells in SVF that differentiate into 
adipocytes, chondroblasts and osteoblasts in vitro (Dominici et al. 2006). 
Moreover, ASC express cell surface markers CD105 (endoglin), CD90 (Thy-
1) and CD73 (Dominici et al. 2006). ASC also typically express CD13 
(aminopeptidase N), CD29 (integrinɅ1), CD44 (hyaluronate), CD71 and CD 
10 (CALLA/neutral endopeptidase) (Lindroos et al. 2010; Lindroos et al. 
2009; Zuk et al.  2002) as well  as CD34 (Lindroos et al.  2010; Zimmerlin et 
al. 2010). 
ASC are known to have developmental plasticity both in vitro and in 
vivo (Planat-Benard et al. 2004; Rehman et al. 2004). They have capacity to 
differentiate into multiple cell phenotypes such as adipose tissue cells 
(Gimble and Guilak 2003; Zuk et al. 2001), contractile smooth muscle cells 
(Traktuev et al. 2008), skeletal muscle cells (Di Rocco et al. 2006; Zuk et al. 
2001), cartilage (Awad et al. 2004), bone (Zuk et al. 2001) endothelial cells 
(Miranville et al. 2004; Oswald et al. 2004; Pittenger et al. 1999; Planat-
Benard et al. 2004; Wosnitza et al. 2007; Wu et al. 2007) and neuronal cells 
(Ning et al. 2006). ASC are known to promote vessel growth, maturation 
and stabilization in vivo (Amos et al. 2008; Cai et al. 2009; Covas et al. 
2008; Traktuev et al. 2008; Zannettino et al. 2007) by secreting angiogenic 
factors such as VEGF, HGF, TGFɅ, IL-6, IL-8 and by differentiating into 
vessel lining cells with pericytic properties (Amos et al. 2008; Kilroy et al. 
2007; Merfeld-Clauss et al. 2010; Miranville et al. 2004; Traktuev et al. 
2008).  
The determination of ASC phenotype is strongly regulated by the tissue 
microenvironment (Balwierz et al. 2008; Stacey et al. 2009). ASC are 
reported to play a role in host defense (Saillan-Barreau et al. 2003) and 
they are able to modulate the inflammatory profile of macrophages in vitro 
into anti-inflammatory phenotype (Hanson et al. 2011) and to suppress 
inflammatory response (Gonzalez-Rey et al. 2010). 
In adipose tissue, a subpopulation of perivascular cells serves as 
adipocyte progenitor cells (Traktuev et al. 2008; Zannettino et al. 2007). 
These specific cells contribute to vessel maturation by co-operating with 
endothelium during blood vessel formation (Traktuev et al. 2008) and as 
pericytes in blood vessel wall of adipose tissue (Cai et al. 2011; Tang et al. 
2008). It suggested that ASC are resided within the pericytic population 
surrounding the blood vessels in adipose tissue and that these cells contain 
pluripotent adipose stem cells (Cai et al. 2011). However, only a limited 
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number of pericytes and adipose tissue stroma are adipose stem cells (Cai 
et al. 2011; Zannettino et al. 2008).  
Adipogenesis 
Adipogenesis begins with the appearance of several fat clusters called 
primitive organs. These are vascular structures with few or no fat cells. 
(Christiaens and Lijnen 2010) The adipocyte differentiation procedes with 
mesodermal cell differentiation into adipoblasts and further into ASC, then 
into committed preadipocytes and finally into mature lipid-synthesizing 
and sorting adipocytes (Bucky and Percec 2008). Adipose tissue can be 
expanded by adipocyte hypertrophy, where the existing cells grow in size, 
or by hyperplasia, increase in adipocyte number, which requires progenitor 
cells to differentiate into adipocytes (Spalding et al. 2008). 
Glucose and free fatty acids are the main molecules that lead to the 
synthesis of triglycerides (Bederman et al. 2009). Growth arrest of the 
preadipocyte is required for the adipocyte differentiation. In the early 
phase of adipogenesis, the ASC change shape from fibroblast-like shape 
into more spherical shape. (Gregoire 2001) Simultaneously ECM is 
degraded and cytoskeletal components are modified (Gregoire et al. 1998; 
Selvarajan et al. 2001). ECM modifications are required for the key gene 
activation and lipid accumulation into cells (Selvarajan et al. 2001; Gregoire 
2001). The number of mitochondria is also largely increased during 
adipogenesis (Wilson-Fritch et al. 2003) as a response to the increased 
metabolic demand (Wilson-Fritch et al. 2004). 
To obtain the mature adipocyte, activation of over 2000 genes is 
required (Guo and Liao 2000). The most important transcriptional factors 
involved in adipogenesis are CCAAT/enhancer binding proteins (C/EBP) Ʉ, 
Ʌ and Ɉ and peroxisome proliferator activated receptor ɇ (PPARɇ), that is 
activated by C/EBPs (Farmer 2006; Rosen and Spiegelman 2000). PPARɇ, 
the main regulator of adipogenesis, is activated early in adipogenesis 
(specifically PPARɇ2 in adipose tissue) by C/EBPɅ and C/EBPɈ (Rosen and 
Spiegelman 2000; Gregoire 2001). Activation of PPARɇ is the key switch for 
adipocyte differentiation (Bucky and Percec 2008; Daquinag et al. 2011; 
Lowe et al. 2011). C/EBPɅ increases expression of another key inducer of 
angiogenesis, C/EBPɄ (Wu et al. 1996). PPARɇ also further activates 
C/EBPɄ by positive feedback signal to maintain the differentiated state 
(Daquinag et al. 2011). In addition, cyclic adenosine monophosphate 
(cAMP) responsive element binding protein (CREB) is activated and 
expressed prior to and during adipogenesis (Gregoire 2001). Lipoprotein 
lipase (LPL), Kruppel-like transcription factor 5 (KLF5) (Oishi et al. 2005), 
early growth response 2 (Krox20) (Chen et al. 2005) early B-cell (O/E-1) 
factor (Akerblad et al. 2002), glucocorticoids, prostacyclin (PGI2) as well as 
activation of the MEK/ERK and the p38 MAPK signalling pathways are 
required for adipogenesis (Engelman et al. 1999; Prusty et al. 2002). 
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C/EBPɅ and C/EBPɈ activate KLF5 and they in concert then activate 
PPARɇ2 (Oishi et al. 2005). PGI2, released from preadipocytes, activates 
the protein kinase A (PKA) pathway (Vassaux et al. 1992) and upregulates 
C/EBPɅ and C/EBPɈ (Belmonte et al. 2001). Insulin and insulin-like growth 
factor -1 (IGF-1) are also required for adipocyte differentiation (Bucky and 
Percec 2008). Insulin and lipids activate sterol-regulatory element binding 
protein 1c (SREBP1c) that also induces PPARɇ (Daquinag et al. 2011). 
SREBP1c further activates a variety of genes, that along with PPARɇ and 
C/EBPɄ activate late adipogenesis marker proteins such as fatty acid 
synthetase (FAS), insulin-regulated glucose transporter 4 (GLUT4), 
adipsin, angiotensinogen II, acyl-coenzyme A – binding protein (ACBP), 
fatty acid binding protein (aP2), keratinocyte lipid-binding protein (KLBP), 
lipoprotein lipase (LPL), sn-1-acylglycerol-3-phosphate acyltransferase2 
(AGPAT2) and perilipin (Bucky and Percec 2008; Daquinag 2011; Lowe et 
al. 2011). At the terminal phase of differentiation, enzymes of triacylglycerol 
synthesis and degradation are activated. Glucose transporters, insulin 
receptors and insulin sensitivity are also increased. Synthesis of adipocyte-
secreted products including leptin, adipsin, resistin, and adipocyte-
complement-related protein (Acrp30, adiponectin) begin. (Gregoire 2001) 
Mature adipocytes secrete also COL IV, laminin, entactin and 
glycosaminoglycans (Bucky and Percec 2008). 
Several inflammatory cytokines, including tumour necrosis factor-Ʉ 
(TNF-Ʉ), TGF-Ʌ, IL-1, IL-6, IL-11, leukaemia inhibitory factor (LIF), 
interferon-ɇ, oncostatin M and ciliary neurotrophic factor (CNTF), can 
inhibit stem cell differentiation (Gimble et al. 1989; Gimble et al. 1994) or 
even induce stem cell dedifferentiation (Ron et al. 1992). However, LIF has 
also reported to have stimulating or diverse effects on angiogenesis (Hogan 
and Stephens 2005). The activity of PPARɇ is regulated by TNF-Ʉ (Ye 
2008). Growth hormone (GH) represses adipogenesis by inhibiting C/EBPɄ 
and PPAR-ɇ (Ross et al. 2000). GATA-binding transcription factors GATA-2 
and -3 as well as preadipocyte factor -1 (Pref-1) expressions are high in ASC, 
and their downregulation is required for adipogenesis (Bucky and Percec 
2008; Feve 2005; Gregoire 2001). 
A schematic drawing of adipogenesis and its main transcriptional 
regulators is shown in Figure 2. 
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Figure  2.  Adipogenesis  and  its  main  regulators.  Glucose and free fatty 
acids are the main triggers for adipogenesis. During the first steps of adipogenesis, 
expression of Pref-1 is decreased in ASC. The main transcriptional factors are 
C/EBPs and PPARɇ2, which is activated by C/EBPs. PPARɇ activates C/EBPɄ by 
positive feedback signaling. Glucocorticoids, FGFs, LIF, insulin, IGF-I and PGI2 
induce adipogenesis. SREBP1c activates several genes that along with PPARɇ and 
C/EBPɄ activate  late  adipogenesis  markers  such  as  ACBP  and  aP2.  Synthesis  of  
adipocyte secreted products, such as leptin and adiponectin, and basement 
membrane components such as COL IV, begin. 
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Adipose tissue angiogenesis 
Blood vessel growth is essential for every organ, including the orderly 
development of adipose tissue. In developing embryo, the vascular system 
differentiation is developed prior to the adipogenesis (Hausman and 
Richardson 2004; Crandall et al. 1997).  
During adipogenesis, angiogenic vessels contribute to adipose tissue 
expansion by supplying nutrients and oxygen to tissue and by removing 
waste (Cao 2007; Cao 2010). Importantly, vessels supply the tissue with 
growth factors and cytokines as well as with circulating stem/progenitor 
cells which have the capacity to differentiate into adipose tissue cells (Tang 
et al. 2008). Also monocytes and neutrophils are infiltrated from bone 
marrow into adipose tissue through vasculature (Tang et al. 2008; Cao 
2010).  
Adipose tissue expansion and function require parallel growth and 
remodeling of the capillary network (Christiaens and Lijnen 2010). 
Expansion of adipose tissue can be promoted by either neovascularization 
or by dilation and remodeling of the existing capillaries (Hausman and 
Kaufmann 1986). The regulation of angiogenesis in adipose tissue is 
dependent on the local balance between pro- and antiangiogenic growth 
factors and cytokines (Christiaens and Lijnen 2010; Cao 2010). Activated 
endothelial cells communicate with adipocytes and secrete growth factors 
and cytokines, and vice versa (Cao 2007; Cao 2010). Many of the inductive 
angiogenic factors are derived from adipose tissue cells (Crandall et al. 
1997; Hausman and Richardson 2004; Planat-Benard et al. 2004; Saiki et al. 
2006). Vessels determine both the local and systemic effects of the adipose 
tissue secreted factors (Cao 2010). The adipose tissue secretory products 
and their functions in angiogenesis induction are next explained in detail. 
Adipose tissue secretory products 
Adipose tissue is a major source of growth and differentiation promoting 
factors in body (Kershaw and Flier 2004; Kilroy et al. 2007; Rehman et al. 
2003; Rehman et al. 2004; Traktuev et al. 2008; Trayhurn 2005; Trayhurn 
and Beattie 2001). Mature adipose tissue secretes numerous hormones, 
growth factors, matrix proteins, enzymes, proinflammatory and anti-
inflammatory cytokines as well as coagulation and complement factors 
(Kershaw and Flier, 2004; Kilroy et al., 2007; Poulos et al. 2010; Rehman et 
al., 2003; Rehman et al., 2004; Traktuev et al., 2008; Trayhurn, 2005; 
Trayhurn and Beattie, 2001). The secreted factors participate in the 
regulation of adipocyte differentiation, fat mass accumulation and 
remodeling, in the development of vasculature and blood flow as well as 
function of immune system (Poulos et al. 2010). The major organ systems 
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affected by adipose tissue derived factors are vasculature, liver, muscle, 
pancreas Ʌcells, brain and reproductive tract (Scherer 2006). There are 
detailed studies where the adipose tissue secreted factors have been 
characterized (Alvarez-Llamas et al. 2007; Fain et al. 2004). Most of the 
adipose tissue secereted factors are derived from stromal vascular cells. 
Visceral adipose tissue is known to secrete more factors than subcutaneous 
tissue, for example, 400% greater amount of VEGF is released from visceral 
adipose tissue than from subcutaneous adipose tissue. (Fain et al. 2004)  
The main endogenous factors released from adipose tissue and their 
effect on adipogenesis and angiogenesis as reported in the main references 
are summarized in Table I. Some of the important factors are also 
discussed in detail below. A few of the secretory products of adipose tissue 
related to angiogenesis induction (VEGF, PDGF-BB, TGF-Ʌ, bFGF, 
Angiopoietins) are discussed in detail earlier in chapter “Molecular 
regulation of angiogenesis”. In addition to the ones presented here, 
adipose tissue secretes and synthesizes other factors and adhesion 
molecules as well as plasma membrane and nuclear receptors. 
Adipokines 
The most abundant endocrine hormones released by adipocytes are leptin 
and adiponectin. Leptin and adiponectin have opposite functions in 
hypothalamus, and they regulate the balance between energy storage and 
uptake (Galic et al. 2010). 
Leptin 
Leptin is one of the major adipogenic and angiogenic hormone 
(Karastergiou and Mohamed-Ali 2010; Galic et al. 2010; Christiaens and 
Lijnen 2010). Leptin is produced by mature adipocytes, mainly from 
subcutaneous adipose tissue (Christiaens and Lijnen 2010). Leptin is also 
secreted from stomach (Cinti et al. 2000), placenta and fetal tissues 
(Cervero et al. 2006). Leptin has a key role in regulating energy balance. It 
functions as a signal of negative energy balance and low energy stores. In 
lean (or normal) people, high leptin levels reduce food intake and fat 
storage, however, although leptin levels are elevated in obese individuals 
(Wang et al. 2008), obese persons are resistant to leptin and continue to 
maintain high levels of body fat (Galic et al. 2010). Leptin stimulates 
angiogenesis by inducing migration of endothelial cells and by promoting 
the expression of VEGF and VEGFR-2 (Suganami et al. 2004). Leptin also 
possibly induces cytokine-related signaling pathways e.g. IL-6, CNTF and 
LIF pathways (Ailhaud 2006). Leptin signals through receptor LR (also 
called as obR). Alternative splicing of the leptin gene results in at least six 
receptor isoforms (LRa - LRf) (Sweeney 2002) that can be divided into 
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three classes: long, shot and secreted (soluble) isoforms (Bates and Myers 
Jr 2003). The long isoform LRb is expressed mainly in hypothalamus and 
regulates body weight and feeding (Ahima and Flier 2000; Tartaglia 1997). 
The long isoform is assumed to mediate most of the leptin signaling 
(Sweeney 2002). In fact, the lack of leptin signaling, especially the long 
isoform, results in obesity in such individuals (Lee et al. 1996). Leptin has 
receptor isoforms in almost all other tissues as well, such as in heart, 
placenta, lung, liver, kidney, small intestine, ovary, pancreas, spleen and 
skeletal muscle (Ahima and Flier 2000; Dulloo et al. 2002; Kielar et al. 1998; 
Tartaglia et al. 1995). The short isoforms are suggested to mediate leptin 
transport through blood-brain barrier and regulate leptin degration (Banks 
et al. 1996). The secreted isoform regulates concentration of free leptin in 
blood (Ge et al. 2002). 
Adiponectin 
Adiponectin, (also known as an adipocyte complement-related protein 30, 
Arcp 30) a major adipogenic hormone, is an abundant circulating plasma 
protein (Christiaens and Lijnen 2010; Hu et al. 1996). Adiponectin is 
exclusively secreted by mature adipocytes (Hu et al. 1996; Wang et al. 
2008). It is mainly known as an inhibitor of angiogenesis (Brakenhielm et 
al. 2004). However, it is reported to have a dual role and act also as a 
stimulator of angiogenesis (Ouchi et al. 2004; Shibata et al. 2004). 
Adiponectin is highly expressed in lean people, but obesity reduces 
adiponectin levels (Matsubara et al. 2002; Ouchi et al. 1999). Adiponectin 
improves insulin sensitivity and inhibits glucose secretion from liver 
(Combs et al. 2001; Ouchi et al. 2001). PPARɇ ligands have shown to 
increase adiponectin expression and plasma concentration in vitro and in 
vivo (Maeda et al. 2001). 
Cytokines 
Cytokines are peptides that are bioactive at very low levels and play an 
integral role in the regulation of inflammation, cell proliferation and 
maturation. Over 100 cytokines have been described and classified as 
interleukins, interferons, chemokines, haematopoietic factors and growth 
factors. (Thalmann and Meier 2007) Chemokines are small secreted basic 
proteins that are implicated in the chemoattraction of inflammatory cells 
(Juge-Aubry et al. 2005). 
Adipose tissue secretes a wide number of cytokines such as TNFD, IL-
1E, IL-6, IL-8, IL-10, IL-11, LIF, interferon-ɇ, oncostatin M, CNTF, CC-
chemokine 5 (CCL5), MCP-1, visfatin, vaspin and omentin. The majority of 
interleukins and other inflammatory cytokines in human adipose tissue are 
released from SVF cells (Fain 2006; Weisberg et al. 2003). IL-6 plasma 
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levels are increased in type 2 diabetes and obesity (Lazar 2005). TNF-Ʉ is a 
multifunctional cytokine with several immunological functions. It is 
mainly secreted from macrophages and it promotes endothelial cell tubule 
formation (Papetti and Herman 2002). It also promotes obesity-induced 
insulin resistance (Christiaens and Lijnen 2010; Galic et al. 2010). The 
increased expression of TNF-Ʉ in obesity is due to infiltration of circulating 
macrophages (Weisberg et al. 2003).  
Angiogenin induces angiogenesis by activating vessel endothelial and 
smooth muscle cells and triggering a number of biological processes, 
including cell migration, invasion, proliferation, and formation of tubular 
structures. Angiogenin is secreted by mature adipocytes and stromal 
vascular fraction cells. (Gao and Xu 2008) 
Growth factors 
The two main angiogenic growth factors secreted by adipose tissue are 
VEGF and hepatocyte growth factor (HGF). Adipose tissue secretes also 
several other growth factors such as bFGF, FGF-1, FGF-9, insulin-like 
growth factor I (IGF-I), VEGF-B, VEGF-C, PlGF, PDGF-Ʌ, Ang-1 and Ang-2. 
(Cao 2007; Wang et al. 2008; Cao 2010) 
VEGF is expressed by stromal vascular cells and mature adipocytes 
(Ledoux et al. 2008; Voros et al. 2005). VEGF is highly expressed in adipose 
tissue and the expression is enhanced during adipocyte differentiation 
(Claffey et al. 1992). VEGF is thought to be responsible for the most of the 
angiogenic capacity of adipose tissue (Zhang et al. 1997). The VEGF 
functions in angiogenesis are discussed in detail earlier.  HGF is a molecule 
with multifunctions, derived from mesenchymal cells (Christiaens and 
Lijnen 2010) such as fibroblasts, hepatic cells or adipose stromal cells 
(Traktuev et al. 2008). HGF promotes tubule formation of HUVEC (Saiki et 
al. 2006) and has a central role in regulating angiogenesis in developing 
adipose tissue (Bell et al. 2008). HGF concentrations are elevated in obese 
individuals (Rehman et al. 2003). bFGF is a multifunctional proliferative 
growth factor which functionsd are discussed in detail earlier. bFGF 
promotes angiogenesis and induces adipocyte differentiation in vivo 
(Kawaguchi et al. 1998). bFGF also induces HGF secretion in ASC (Kilroy et 
al. 2007). Macrophage derived PDGF stimulates angiogenesis during 
expansion of adipose tissue (Pang et al. 2008). 
Extracellular matrix components and proteases 
ECM components and ECM proteolytic remodelling by proteases have also 
an important role in adipose tissue remodelling (Lijnen and Juhan-Vague 
2002; Mariman and Wang 2010). Each adipocyte is surrounded by a 
basement membrane in vivo (Wang et al. 2008). Extracellular matrix 
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components, especially COL I, III, IV and VI are synthesized in adipose 
tissue at high levels (Maeda et al. 1997). ECM protein processing enzymes 
such as MMPs, ADAMTS (a disintegrin and metalloproteinase with 
thrombospondin motifs), PAI-1 and vaspin are important in maintating the 
adipocyte ECM (Mariman and Wang 2010). During adipocyte formation, 
remodeling of ECM and increased basement membrane synthesis occur by 
secretion MMPs such as MMP-2 and MMP-9 (Alexander et al. 2001; Brown 
et al. 1997; Mannello 2006). In fact, the assembly of ECM is suggested to be 
the rate-limiting step in adipogenesis (Alexander et al. 2001). MMP activity 
regulators TIMPs (Visse and Nagase 2003), are released from connective 
tissue cells and macrophages in adipose tissue (Fain 2006).  
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Excess adipogenesis and cytokine release 
Obesity is characterized by an increase in adipocyte size and number, 
changes in the levels of adipocytokine secretion, and recruitment of 
macrophages that release the pro-inflammatory cytokines. Excess 
adipogenesis leads to chronic inflammation and obesity that is related to 
various diseases such as type 2 diabetes, hypertension, dyslipidemia and 
cardiovascular disease. Obesity is also related to diseases such as certain 
cancers and depression. Obesity is defined as a body mass index (BMI) of 
30kg/m2 or more. (Daquinag et al. 2011) Obesity is a major health problem 
in the world. According to World Health Organization (WHO), 1.6 billion 
adults are overweight, and at least 400 million are obese. (Wang et al. 
2008; WHO, 2011) Highly metabolically active visceral adipose tissue is 
known to be in a predominant role in the development of obesity related 
diseases (Fain et al. 2004; Fain 2006), and visceral fat accumulation is 
therefore a risk factor for cardiovascular disease, cerebrovascular disease, 
hypertension and type 2 diabetes (Carr et al. 2004; Chudek and Wiecek 
2006). 
The excess intake of lipids induces adipocytes to produce more pro-
inflammatory cytokines and chemoattractant molecules. Indeed, the 
chronic inflammation is characterized by a strong increase in the release of 
inflammation markers such as TNFa, IL-1Ʌ, IL-6, IL-8, IL-10, MCP-1, PAI-1, 
colony stimulating factor (CSF) and iNOS. (Fain et al. 2004; Feghali and 
Wright 1997; Neels and Olefsky 2006; Wang et al. 2008) Several angiogenic 
factors, e.g. VEGF-C, VEGF-D, Ang-2, angiogenin and endostatin are also 
significantly elevated in overweight subjects (Christiaens and Lijnen 2010). 
In obesity, in addition to the macrophage number, the number of 
neutrophils and T lymphocytes are also increased (Elgazar-Carmon et al. 
2008;  Ohmura  et  al.  2010;  Weisberg  et  al.  2003).  The  induction  of  
inflammatory changes is due to endoplasmic reticulum stress, hypoxia and 
oxidative stress (Furukawa et al. 2004; Hosogai et al. 2007; Ozcan et al. 
2004). The tissue hypoxia induces apoptosis and necrosis of adipocytes in 
obese (Strissel et al. 2007) which further induce macrophage recruitment 
into tissue and inhibit ASC differentiation into adipocytes by suppressing 
e.g. PPARɇ activity, but favor ASC differentiation into endothelial cells (Ye 
and Gimble 2011). Local inflammation induces angiogenesis through 
induction of angiogenic factors and therefore improves the tissue blood 
supply (Pang et al. 2008; Ye and Gimble 2011). On the other hand, to 
maintain the tissue volume, preadipocytes and adipose stem cells pursue 
to replace the dead cells by differentiating into adipocytes. Therefore, 
there is competition between adipogenesis and endothelial cell 
differentiation of ASC. Meanwhile, the remaining adipocytes maintain the 
tissue volume by storing triglyserides and increasing in size. (Ye and 
Gimble 2011)  
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Adipose tissue macrophages 
Lean adipose tissue has resident macrophages that express e.g. IL-10 
(Lumeng et al. 2007). These cells have increased capacity to contribute to 
tissue repair and angiogenesis (Galic et al. 2010). Macrophages secrete 
several angiogenic factors and cytokines e.g. VEGF-A, IL-6, IL-8, TNF and 
chemokines (Hotamisligil 2006; Wang et al. 2008), resistin (Patel et al. 
2003)  and  are  a  main  source  of  PDGF-B  in  tissue  (Mornex  et  al.  1986;  
Shimokado et al. 1985). 
Macrophages have an essential role in in adipose tissue remodeling,  
obesity and metabolic syndrome (Suganami and Ogawa 2010). During 
tissue stress such as adipose tissue expansion during obesity or tissue 
response to implantion of grafts, cytokines and endothelial cells recruit 
monocytes from bone marrow to adipose tissue, that then differentiate 
into macrophages (Shoelson et al. 2006). As adipocyte necrosis is 3-times 
higher with obese than lean people, infiltrating macrophages are suspected 
to be recruited to tissue to destroy the necrotic adipocytes (Cinti 2006; 
Wang et al. 2008). Macrophages undergo phenotypic transformation in 
obese adipose tissue from M2 anti-inflammatory phenotype into activated 
M1 proinflammatory phenotype macrophages (Hibino et al. 2011; Lumeng 
et al. 2007; Suganami and Ogawa 2010; Weisberg et al. 2003; Wellen and 
Hotamisligil 2003) that have increased expression of pro-inflammatory 
cytokines such as interleukins, TNFɄ and iNOS (Lumeng et al. 2007). 
Infiltrated macrophages are mainly responsible for the chronic 
inflammation and increased production of cytokines in obesity (Fain 2006; 
Odegaard and Chawla 2008; Weisberg et al. 2003). 
Angiogenic macrophages are activated through hypoxia-dependent 
VEGF-A signaling system (Cho et al. 2007). MCP-1 and chemokine (C-C 
motif) receptor 2 (CCR2) induce the macrophage recruitment into adipose 
tissue (Ito et al. 2008; Kanda et al. 2006). Macrophages are localized to 
dead adipocytes where they fuse to form multinucleate giant cells, a sign of 
chronic inflammation, in order to scavenge the dead cells and lipids (Cinti 
et al. 2005). Macrophages are known to stimulate angiogenesis in obese 
adipose tissue (Pang et al. 2008) and suppress the formation of mature 
adipocytes and to increase the inflammatory factor production in 
preadipocytes (Lacasa et al. 2007; Suganami and Ogawa 2010). They 
therefore may also limit adipose tissue expansion (Lacasa et al. 2007).  
 
A schematic drawing of adipose tissue expansion and the development of 
obesity is seen in Figure 3. 
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Figure 3. Adipose tissue expansion and development of obesity. 
During adipose tissue formation, adipogenesis and angiogenesis occur 
simultaneously,  leading  to  formation  of  normal  lean  adipose  tissue.  Due  to  e.g.  
excess dietary intake, abnormal adipose tissue expansion begins. This leads to 
endoplasmic reticulum (ER) stress, oxidative stress, hypoxia and adipocyte death, 
that leads to increased proinflammatory cytokine production. These phenomena 
induce macrophage migration into adipose tissue and transformation into 
proinflammatory phenotype, which leads to further increased cytokine 
production and chronic inflammatory stage. 
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Soft tissue engineering 
Clinical need for soft tissue engineering 
Soft tissue consists of structures supporting the body such as muscles, 
connective tissue, adipose tissue and blood vessels. Soft tissue engineering 
seeks to fabricate replacement parts for soft tissue defects (burns, scars 
and chronic wounds), surgical resections, and congenital malformations. 
Particularly congenital or trauma related facial defects are a challenge to 
soft tissue surgery. Cosmetic use, such as rejuvenation (filling of facial 
wrinkles) and breast augmentation are also important applications of 
reconstituted soft tissue. (Choi et al. 2010; Masuda et al. 2004a; Patrick 
2001; Schaffler and Buchler 2007)   
Soft tissue engineering is a prominent research area, and soft tissue 
defects and chronic wounds are a medical and economic challenge to the 
health care system with the demand for the treatment of soft tissue defects 
increasing every year (Ferreira et al. 2006; Levin and Condit 1996). The 
major causes for chronic wounds are diabetic neuropathy and obstruction 
of main blood vessels (Ferreira et al. 2006). The foot ulcers, pressure ulcers 
and active venous ulcers affect altogether 650 000 patients only in United 
Kingdom, with a cost of even £3 billion a year (Bennett et al. 2004; Simon 
et al. 2004). In the United States, there are 5 million wound patients that 
generate annual costs in excess of $20 billion for health care and the 
numbers are growing 10% annually (Levin and Condit 1996). Moreover, 13.8 
million cosmetic plastic surgery procedures (both surgical and minimally-
invasive) and 5.5 million reconstructive plastic surgery procedures (of 
which 4.2. million are tumor removals) were performed in the United 
States in 2011. According to ASPS, cosmetic procedures have experienced 
growth of nearly 600 percent in the last decade. (ASPS, 2011) Soft tissue 
defects often also impair function and affect the patients emotionally 
(Patrick 2001). For all of these reasons, there is an urgent clinical need for 
adipose tissue substitutes. 
Despite the progress in soft tissue engineering during recent years, 
tissue-engineered adipose tissue is still a great challenge, and the current 
applications have shown only modest success e.g. some vascularization but 
hardly any adipose tissue formation (Neels et al. 2004). Solely the 
revascularization of ischemic tissues would benefit millions of people, but 
therapeutic angiogenesis and the optimal application for the 
reconstruction of soft tissue remain an unmet clinical need (Carmeliet and 
Jain 2011; Torio-Padron et al. 2007; Vermette et al. 2007).  
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Key requirements for soft tissue replacement 
Biocompatibility, bioactivity and sustainability are the main goals for the 
optimal soft tissue implant. The ideal soft tissue replacement should first 
rapidly induce functional vascularization and induce adipogenesis with 
permanent effect. (Choi et al. 2010) Moreover,  the regenerated adipose 
tissue should mimic endogenous tissue both in function and in structure 
(Hausman et al. 2001). Therefore, the metabolic and endocrine activity of 
adipose tissue should also be taken into account (Giorgino et al. 2005). The 
degradation properties of the selected biomaterial are also important to 
consider, as especially natural biomaterials are typically easily degraded by 
tissue proteases (Lavik and Langer 2004). Moreover, the implanted 
construct should not induce immunorejection in host (Levenberg and 
Langer 2004). Minimal donor-site morbidity is also a prerequisite (Choi et 
al. 201o). 
Present clinical methods for soft tissue repair 
Current therapeutic procedures for soft tissue replacement include filling 
the defects with synthetic or natural biomaterials, often with injectable 
systems. Also autologous fat grafts as well as stem cell therapy, where stem 
cells are usually incorporated into biomaterial, are common. (Badylak 
2002; Choi et al. 2010; Gomillion and Burg 2006; Hanson et al. 2011; 
Hemmrich et al. 2005; Patrick 2001) 
Clinically, the mostly used soft tissue augmentation procedures are 
breast reconstructions (Patrick 2001). Current surgical breast tissue 
therapies include autologous vascularized flaps or synthetic 
nonvascularized approaches. Autologous vascularized flaps consist of 
adipose tissue which is transplanted with its blood supply (Tachi and 
Yamada 2005). These flaps may also contain muscle and fascia tissue 
(Butterwick et al. 2007). However, with the current methods, significant 
donor-site morbidity occurs (Tachi and Yamada 2005, Wu et al. 2008) and 
recipient-site morbidity is also common (Wu et al. 2008). Nonvascular 
alternatives for breast reconstruction include silicone implants, known to 
represent difficult long-term complications such implant rupture that 
leads to severe foreign body reactions (Beahm and Walton, 2009).  
ASC, known to secrete a wide number of inductive factors and have an 
ability to induce adipogenesis (Zuk et al. 2001), angiogenesis (Rehman et 
al. 2004) and wound healing (Altman et al. 2009), have currently become 
the most popular choice for adipose tissue engineering (Choi et al. 2010). 
Adipose tissue is an attractive and advanced source for soft tissue repair as 
it is abundant and easy to obtain with minimal invasive methods 
(Christiaens  and  Lijnen  2010;  Strem  and  Hedrick  2005;  Traktuev  et  al.  
2008). Furthermore, the methods for adipose stromal cell isolation and 
differentiation are well described in the literature (Bunnell et al. 2008; 
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Gimble and Guilak 2003; Zuk et al. 2001). As natural components of 
adipose tissue, ASC are also the most natural source for adipose tissue 
engineering, and compared to e.g. bone marrow stem cells, ASC have 
advantages such as low donor-site morbidity (Miranville et al. 2004).  
De novo soft tissue formation  
Inductive adipogenesis/angiogenesis (de novo adipogenesis/angiogenesis) 
is defined as the use of cellular tissue engineering devices, where stimulus 
is applied in vivo as inductive growth factors. The inductive 
microenvironment enhances migration of adipose stromal cells in the 
surrounding tissue and induces the cells to differentiate into mature 
adipocytes. (Kim et al. 2012) 
The adequate induction of angiogenesis is a prerequisite for successful 
adipose tissue reconstruction (Kim et al. 2012; Rivron et al. 2008; 
Verseijden et al. 2009). Neovascularization is required for the developing 
adipose tissue for providing nutrients and essential differentiation factors 
and therefore to avoid necrosis and scar formation (cao 2010). Acellular 
soft tissue substitute that would induce its own replacement, would be 
advantageous to soft tissue engineering (Kelly et al. 2006; Marra et al. 
2008; Neels et al. 2004). Inductive adipogenesis would not require stem 
cell harvest from the patient and acellular alternative would likely have 
less immune reactions and therefore the alloplastic use of the implant 
could be possible. (Kelly et al. 2006; Kimura et al. 2002; Masuda et al. 
2004a; Masuda et al. 2004b; Patrick et al. 2002; Tabata et al. 2000; Vashi et 
al. 2006; Yuksel et al. 2000a) 
The neovasculature in tissue engineered vascular grafts has been 
reported to be derived from the host cells, via vascular remodeling, instead 
of the implanted cells (Neels et al. 2004; Roh et al. 2010). The inductive key 
molecules are therefore suggested to be sufficient for the induction of 
vascular development (Roh et al. 2010). Indeed, several studies have been 
performed to provide a suitable microenvironment for blood vessel and 
adipose tissue induction. This has been tried by incorporating growth 
factors or extracellular matrix proteins into biomaterials (Kawaguchi et al. 
1998; Kelly et al. 2006; Masuda et al. 2004a; Neels et al. 2004; Nillesen et al. 
2007; Yuksel et al. 2000b; Yuksel et al. 2000c). Induction of adipogenesis 
has been studied with gelatin based microspheres with incorporation of 
bFGF, insulin and IGF-1 (Tabata et al. 2004). Matrigel with bFGF has also 
been used (Marra et al. 2008). Epidermal growth factor (EGF), TGF-Ʌ and 
PDGF have also been shown to induce adipogenesis (Gomillion and Burg 
2006). The controlled release of multiple angiogenic factors is therefore 
beneficial for tissue regeneration. (Neels et al. 2004; Rehman et al. 2004; 
Semenza 2003) However, finding the optimal cocktail of molecules and to 
deliver them in the most optimal way for inductive angiogenesis and 
adipogenesis is still difficult, especially in long-term (Patrick 2001).  
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Biomaterials for soft tissue engineering 
To regenerate functional tissue, cells and inductive factors are most often 
cultured with an artificial extra cellular matrix, a biomaterial scaffold that 
will aid in the cell attachment, proliferation and differentiation. Scaffolds 
are divided in to two different types, synthetic polymer scaffolds and 
natural scaffolds.  The prerequisites for scaffolds used in vascular 
engineering or soft tissue engineering are biocompatibility, 
biodegradability, and structure that allows cell interaction (Choi et al. 
2010). The structure (rigidity and pore size) of the scaffold plays a 
significant role in differentiation induction. (Choi et al. 2010; Stacey et al. 
2009)  
Synthetic polymers 
Synthetic polymers are widely used in adipose tissue engineering, as their 
mechanical and chemical properties and degradation rate are easily 
modified (Lavik and Langer 2004). The most commonly used synthetic 
polymers are biodegradable polymers poly(lactic acid) (PLA), poly(glycolic 
acid) (PGA) or their co-polymer poly(lactic-co-glycolic acid) (PLGA) (Cho 
et al. 2005; Choi et al. 2010). Silicone, a non-degradable synthetic material, 
is commonly commercially used for breast tissue augmentations (Patrick 
2001). However, synthetic materials have brawbacks such as unwanted 
allergic or foreign body reactions, resorption of transplants or poor 
adipogenesis and angiogenesis induction (Gomillion and Burg 2006).  
Natural polymers 
Natural polymers are components of extracellular matrix or materials 
generated by biological systems (Lavik and Langer 2004). Natural polymers 
provide rapid interaction with host cells, induce host cell migration to 
graft and deposition of additional ECM (Laschke et al. 2005). Overall, they 
have advantanges such as good biocompatibility and biological properties 
that match to the host tissue (Choi et al. 2010). Naturally occurring 
hydrogels are usually non-toxic and less severe foreign body reactions 
occur, but they also have certain limitations in their use. Natural 
biomaterials are often structurally rigid, degrade easily in tissue and have 
poor mechanical properties (Hemmrich et al. 2008; Ko et al. 2007). 
Moreover, in some cases, naturally derived materials may trigger severe 
immune responses in patients (Schmidt and Baier 2000). 
Several ECM components such as COL I, fibronectin, gelatin, 
hyaluronan, fibrin, decellularized human placenta, amnion membrane, 
adipose derived hydrogels, Matrigel, silk, small intestinal submucosa, 
acellular dermis and amniotic membrane have been used for adipose tissue 
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engineering (Patrick 2001; Laschke et al. 2005; Choi et al. 2010). Probably 
the most widely used natural material is COL I. It is homologous between 
species and a major structural component in the body (Brown et al. 2000) 
and therefore biocompatible (Vashi et al. 2006). Matrigel, a collagen-based 
growth factor rich gel matrix from mouse sarcoma, promotes adipogenesis 
and  angiogenesis  (Cronin  et  al.  2007).  However,  the  use  of  Matrigel  is  
problematic as it is a tumor-derived and xenogenic material and moreover, 
not thought to be very inductive material, rather only conductive (Chiu et 
al. 2011). Therefore, other potential adipogenic and angiogenic materials 
are needed and searched for clinical use (Kelly et al. 2006). Recently, 
autologous and allogenic injectable hydrogel fillers, especially hyaluronic 
acid-based materials, have become an especially attractive option for soft 
tissue engineering due to the minimal invasive procedures  needed (Bucky 
and Percec 2008; Rohrich et al. 2007). 
Hyaluronic acid  
Hyaluronic acid (HA) is a glycosaminoglycan that consists of a basic unit 
of two sugars, glucuronic acid and N-acetylglucosamine, that are 
polymerized into large macromolecules (Badylak 2002).  HA is a common 
natural component of ECM among many organisms and present in 
connective tissues of skin, cartilage, bone and synovial fluid. HA is 
structurally conserved regardless of the source and therefore it is 
considered nonallergenic. (Rohrich et al. 2007; Badylak 2002). It is unique 
as it is natively present in the intracellular matrix of the dermis (Laurent 
1987). HA takes part in binding growth factors and cytokines (Badylak 
2002). HA is known to modulate inflammation and tissue reparation 
(Hanson et al. 2011) and to promote angiogenesis (Hemmrich et al. 2008; 
Ventura et al. 2007) and is therefore considered a very potential material 
for  soft  tissue  engineering.  (Hanson  et  al.  2011)  HA  has  been  used  for  
inducing bone and cartilage (Yuksel et al. 2000), as dermal filler (Rohrich 
et al. 2007), in vocal fold regeneration (Sahiner et al. 2008) and in soft 
tissue induction (Patrick 2001; Wu et al. 2007). The degradation products 
of HA are thought to be able to also modulate wound healing (Rohrich et 
al. 2007).  
Natural HA is rapidly degraded in the liver to carbon dioxide and water 
(DeVore et al. 1994) and therefore it lacks potential utility for adipose 
tissue engineering (Hemmrich et al. 2008). Therefore, the commercial HAs 
currently used are mainly crosslinked. Restylane® (Q-Med) and Juvederm® 
(Allergan Inc.) are partially cross-linked HA derivatives obtained with 
bacterial fermentation. This crosslinking results in viscoelastic transparent 
gel (Rohrich et al. 2007).  Hylaform™ (Genzyme Corporation), another 
comeercial HA, is derived from avian proteins (Rohrich et al. 2007). Several 
FDA approved injectable hyaluronan hydrogel materials are already in 
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clinical use and the adverse reactions of HA fillers have been minimal and 
mainly injection-related (Friedman et al. 2002; Rohrich et al. 2007).  
The popularity of HA has increased dramatically since 2004, when 
approximately 45 000 treatments were administered by ASPS member 
surgeons as a filler for cutaneous lines and wrinkles. By the year 2011 the 
number of these minimally invasive procedures with HA increased almost 
30-fold, being more than 1.3 million procedures in a year. According to 
ASPS, soft tissue fillers like hyaluronic acid (Restylane®, Juvederm Ultra®) 
and fat injections experienced some of the largest growth in the minimally-
invasive market during 2011 (increase in 2011 vs. 2010 for HA fillers 9%, fat 
injections 19%), whereas collagen injections had decreased at 2011 55% 
from 2010. Moreover, HA fillers are the far most popular treatment for soft 
tissue filling. (ASPS, 2011) 
In vitro vascular analogues 
Due to complex interactions during angiogenesis, the evaluation of factors 
that affect angiogenesis would optimally be studied in vivo. The most 
commonly used in vivo angiogenesis assays include chick chorioallantoic 
membrane (CAM) assay, Matrigel plug assay, zebrafish embryo system, 
corneal micropocket assay, rat/mouse hindlimb ischemia model, rat aortic 
ring assay, intradermal angiogenesis assays and Xenopus tadpole assay. 
(Auerbach et al. 2003). These in vivo assays are used to measure new blood 
vessel formation by pro- and anti-angiogenic compounds (Akhtar et al. 
2002; Auerbach et al. 2003; Ishikane et al. 2008; Norrby 2006; Ziche and 
Morbidelli 2009), to study tumor angiogenesis (Auerbach et al. 2003; 
Norrby 2006) or embryonic and organogenic angiogenesis (Norrby 2006). 
Although animal assays do not reflect the effect in human body and disease 
as regards both efficacy and relevance and are difficult to interpret 
(Ishikane et al. 2008; Norrby 2006), they are widely used as they are 
considered to provide more information on complex cellular and molecular 
interactions compared to in vitro models (Norrby 2006).  
In vitro angiogenesis assays are regarded as useful tools for screening 
compounds, their toxicity and effective concentrations in the initial stage 
of safety testing of chemicals, but due to complex interactions during 
angiogenesis, they often need to be followed by in vivo studies (Auerbach 
et al. 2003) and do not allow the complete replacement, but reduction of 
animal testing (Balls et al. 1995). An ideal in vitro assay should contain all 
the relevant steps of human angiogenesis including vessel maturation 
(Vailhe et al. 2001), it should measure both stimulation and inhibition 
(Bishop et al. 1999; Norrby 2006), provide easy quantitative measurement 
of the tubule formation (Norrby 2006), and cost-effective, fast, 
reproducible and reliable routine assay (Jain et al. 1997; Vailhe et al. 2001). 
The first capillary-like structures developed in vitro were endothelial cells 
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grown on plastic (Folkman and Haudenschild 1980) and on collagen gels 
(Montesano et al. 1983). Capillary-like structures have later been developed 
by co-culturing endothelial cells with dermal fibroblasts and keratinocytes 
(Black et al. 1998) and with mouse myoblasts and embryonic fibroblasts 
(Levenberg et al. 2005). In addition to microvascular EC (Folkman and 
Haudenschild, 1980) and HUVEC (Black et al. 1998; Levenberg et al. 2005), 
endothelial progenitor cells have also been used (Shepherd et al. 2006).  
The current in vitro assays can be divided into two categories, two-
dimensional and three-dimensional assays. In two dimensional assays, 
endothelial cells form tubules in the presence of e.g. collagen I, III or IV/V, 
Matrigel, fibronectin or gelatin. The two-dimensional assays do not reflect 
all the steps of angiogenesis, but are considered convenient for screening 
of angiogenic molecules. In three-dimensional assays, endothelial cells 
form tubular structures in gelified substrates (e.g. collagen, Matrigel, 
fibrin). (Vailhe et al. 2001)  
The disadvantages of the current in vitro assays are the lack of 
metabolism and rare use of normal human primary cell based assays 
(Auerbach et al. 2003). Most of the current angiogenesis assays have also 
dramatic variability or the methods lack quantification and clinical 
relevance (Auerbach et al. 2000). Most cell culture assays (e.g. tubule 
formation assays in collagen or Matrigel, cell motility assays, trans-
membrane assays or cell proliferation assays) only reflect one single step of 
angiogenesis and critical cell-cell or cell-matrix interactions are limited 
(Auerbach et al. 2003). Although tubule formation in vitro does not cover 
the whole angiogenesis process, it effectively mimics the key steps, i.e. 
migration and differentiation of endothelial cells (Donovan et al. 2001).  
Co-culture assays that have been used in several studies (Bishop et al. 1999; 
Donovan et al. 2001; Friis et al. 2005; Friis et al. 2003; Merfeld-Clauss et al. 
2010; Montesano et al. 1993; Nicosia and Ottinetti 1990) provide a useful 
method for studying angiogenesis in controlled conditions in vitro, with 
the advantage of being able to replicate some tissue-derived signaling 
(Rubina et al. 2009).  
Validation of in vitro assays 
One of the most critical technical problems is the accurate interpretation 
of highly variable results from different in vitro (angiogenesis) assays 
(Folkman et al. 2001; Jain et al. 1997). Methods vary dramatically in what 
they measure, are limited in the relevance to human and often lack 
quantitative measurements (Auerbach et al. 2000). An important goal 
would be to standardize the current in vitro assays and to develop assays 
that reflect the in vivo situation (Vailhe et al. 2001). A valid in vitro assay 
should give similar results in different laboratories, and therefore 
standardization between laboratories is essential (Piersma 2004). 
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Good Laboratory Practice (GLP) is a quality system under which the 
non-clinical health and environmental safety studies are planned, 
performed, monitored, recorded, archived and reported. The principles of 
GLP should be applied to the non-clinical safety testing of test items 
including pharmaceuticals, pesticides, cosmetics, veterinary drugs, food 
additives and industrial chemicals. (OECD, 1998) The GLP system is 
traditionally designed for safety studies, but the principles of GLP can be 
applied to all in vitro studies (OECD, 2004), including efficacy studies. The 
important requirements of GLP are trained and qualified personnel; 
adequate laboratory facilities, equipment and materials; accurate 
recordings of the qualifications, training and experience and establishment 
of Standard Operating Procedures for the laboratory (Balls et al. 1995; 
Gimble et al. 2011). For each study, a study plan must be written and 
followed, and changes need to be documented with amendments to the 
original protocol. The responsibilities of the personnel for each study must 
be addressed. Importantly, the origin of the biological system, such as 
cells, must be well defined and characterized and the stability must be 
assured (Balls et al. 1995).  
The establishment of a routine test method contains three stages, 
method development, method optimization and method validation 
(FICAM 2010). The test development phase defines the scientific base of 
the method as well as the need of the method and method optimization 
defines the detailed protocol for the method (Balls et al. 1995). The method 
validation is a process, where the reliability and relevance of a test system 
is established (Balls 1990) and it is generally described in and guided by the 
OECD regulatory Guidance Document No 34 (OECD 2005). For in vitro 
method validation, the overall responsibility of the final validation process 
is with an official authority, which in European Union (EU) is The 
European Reference Laboratory on Alternatives to Animal Testing (EURL 
ECVAM) that was founded by the European Commission to coordinate the 
validation of alternative methods in the European Union (Curren et al. 
1995).  EURL ECVAM action is directed by EU Directive 2010/63/EU (EC 
2010). The EURL ECVAM validation process consists of several stages: test 
development, intra-laboratory validation (called as pre-validation in the 
process), inter-laboratory validation, independent assessment and 
progression towards regulatory acceptance. During intra-laboratory 
validation the protocol is standardized. (Balls et al. 1995) The intra-
laboratory validation phase defines the robustness and reproducibility of 
the test method and how well it predicts the specific in vivo end-points 
(Curren et al. 1995). The main purpose of the validation is to conduct an 
inter-laboratory blind trial of the methods. The formal validation study 
contains a preliminary phase, transfer phase and a definitive validation 
phase. After validation, the results of the blinded study are considered by 
independent assessment panels and finally the validated method will 
progress towards regulatory acceptance for OECD guidelines. (Balls et al. 
1995) Only formally inter-laboratory validated methods can be accepted by 
the regulatory authorites. 
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Importantly, the validation of the in vitro test system includes the 
comparison of the responses obtained in the specific in vitro test with 
known in vivo responses. The extrapolation of the in vitro effects  is  
challenging and mathematical modeling can be used to predict the results. 
(Piersma 2004)  
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Aims of the study 
The specific aims of the present study were: 
 
1. To extract adipogenic and angiogenic factors from mature adipose 
tissue and to characterize the extract (I) 
 
2. To study the angiogenic and adipogenic properties of the adipose 
tissue extract in respective in vitro assays (I) 
 
3. To study the potential of the adipose tissue extract to induce 
capillary proliferation and soft tissue formation in vivo, especially in 
long-term (II) 
 
4. To study the biocompatibility of the adipose tissue extract in vivo 
(II) 
 
5. To study hASC potential in angiogenesis induction in vitro and to 
develop hASC angiogenesis in vitro assays (III)  
 
6. To create a routine in vitro angiogenesis test method for drug and 
chemical screening by optimizing and validating a scientific 
research assay (IV)  
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Materials and methods 
Ethical approvals (I-IV) 
The use of human tissue in this study was conducted in accordance with 
the Ethics Committee of the Pirkanmaa Hospital District, Tampere, 
Finland (ethical approval R03058 for adipose tissue and R08028 for 
umbilical cords). The animal experiments were performed according to the 
Finnish animal protection laws and approved by the Department for Social 
Welfare and Health Services of State Provincial Office of Western Finland. 
Cells and tissue samples (I-IV) 
The subcutaneous adipose tissue samples were obtained from surgical 
operations from female (n=33)  and  male  donors  (n=4) and the human 
umbilical cords from scheduled caesarean sections (n=19) with informed 
consents at the Tampere University Hospital, Tampere, Finland. The BJ 
human foreskin fibroblast cell line was purchased from American Type 
Culture Collection (ATCC). 
Reagents, equipment and computer programs (I-IV) 
Oligonucleotides for platelet/endothelial cell adhesion molecule-1 
(PECAM), Ang-1, Caldesmon, and ribosomal protein large P0 (RPLP0) were 
purchased from Oligomer Oy, Helsinki, Finland. Lentiviral construct 
pLKO-MISSION-Bright-GFP was purchased from Biomedicum Genomics, 
Biomedicum Helsinki, Helsinki, Finland. anti-CD3 (Clone SP7) rabbit 
monoclonal antibody, DAKO EnVision™+ System, HRP kit, DAKO REAL™  
Peroxidase-Blocking Solution and DAKOCytomation Liquid DAB Substrate 
Chromogen System were from DakoCytomation Glostrup, Denmark. Milk 
powder was obtained from Valio Oy, Helsinki, Finland.  
Mouse  on  Rat  HRP  Polymer  Kit  and  Rodent  Block  R  were  from  
Biocare Medical, Concord, CA, USA. Monoclonal mouse anti rat CD68 and 
mouse anti human Cd79a were from AbD Serotec, MorphoSys AG, 
Martinsried, Germany. TRIzol® and Collagenase I were purchased from 
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Invitrogen, Carlsbad, CA, USA. Dulbecco’s Modified Eagle’s Medium 
Nutrient Mixture F-12 (DMEM/F12), Minimal Essential Medium with 
Earle´s salts w/o L-Glutamine (MEM), antibiotic-antimycotic mixture 
(AB/AM), non-essential amino acids (NEAA), foetal bovine serum (FBS), L-
glutamine and TrypLE Express were from Gibco, purchased from 
Invitrogen. Histostain Plus Broad Spectrum Detection Kit, DAB Substrate 
Kit and Digest-AllTM 2 kit were from Zymed Laboratories Inc, purchased 
from Invitrogen. EGM-2 bullet kit Medium, Endothelial Basal Medium 
(EBM), EGM-2 SingleQuots–supplements, MycoAlert® Mycoplasma 
Detection Kit, Gentamicin Sulfate 50 mg/ml and Amphotericin B 250 
µg/ml were obtained from Lonza Group Ltd., Basel, Switzerland. Non-
animal derived partially cross-linked hyaluronic acid Restylane was from 
Q-Med, Uppsala, Sweden. Erlotinib was a kind gift from Roche Diagnostics 
GmbH, Mannheim, Germany. 
CD144-PE, CD202b, VEGFR2, Recombinant human bFGF (for study IV), 
recombinant human VEGF as well as Quantikine Human VEGF 
Immunoassay, Quantikine Human FGF basic Immunoassay and 
Quantikine Human IGF-I Immunoassay were obtained from R&D Systems, 
Abingdon, UK. Bovine Serum Albumin (BSA) Fraction V (for study IV) was 
from Roche, Indianapolis, IN, USA. Human serum was from Cambrex, East 
Rutherford, NJ, USA. Human basic Fibroblast Growth Factor (study I and 
III), biotin, pantothenate, insulin, dexamethasone, isobutyl-
methylxanthine (IBMX), anti-von Willebrand Factor (vWf) primary 
antibody produced in rabbit, monoclonal anti alfa smooth muscle actin 
ȋɄSMA) clone 1A4, anti-smooth muscle myosin heavy chain (SMMHC), 
anti-calponin, anti-platelet derived growth factor receptor-Ʌ (PDGFRɅ), 
BSA (for study II),  polyclonal anti- rabbit IgG TRITC, polyclonal anti- 
mouse IgG FITC, anti-neurofilament 68 (NF-68) produced in mouse, 
casein, Neutral Red Solution, anti-vascular endothelial growth factor, 
thalidomide, levamisole (tetramisole hydrochloride), 2-methoxyestradiol, 
acetyl salicylic acid, hexadimethrine bromide and paraformaldehyde were 
purchased from Sigma Aldrich, Manassas, VA, USA. Polyclonal antibody to 
rabbit IgG FITC was from Acris Antibodies GMbH, Herford, Germany. BCA 
protein Assay Kit was from Pierce Biotechnology, Rockford, IL, USA. 
RayBio® Human Cytokine Antibody Array C Series 1000 was purchased 
from RayBioTech, Inc., Norcross, GA, USA.  ABI Prism 7000 sequence 
detector, SYBR Green PCR Master Mix kit and High-Capacity cDNA 
Reverse Transcriptase Kit were from Applied Biosystems, Foster City, CA, 
USA. Biotinylated Anti-Rabbit IgG (H+L) made in goat, and Vectastain 
Elite ABC Kit were purchased from Vector laboratories Inc, Burlingame, 
CA, USA. Triton X-100 was from JT Baker, Phillipsburg, NJ, USA. Xylene 
was from VWR International, LLC, PA, USA and hydrogen peroxide and 
methanol were from Mallinckrodt Baker Inc., Deventer, The Netherlands. 
Papanicolauslösung 1a Harris’ Hämatoxylinlösung, Entellan and 
isopropanol were from Merck KGaA, Darmstadt, Germany. Pertex was 
from HistoLab Products Ab, Gothenburg, Sweden.  
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The antibodies for flow cytometric analysis; CD13-PE was from BD 
Biosciences, Erembodegem, Belgium; CD31-FITC, CD34-APC and CD44-
FITC were from Immunotools GmbH Friesoythe, Germany; CD117-APC and 
CD 133-PE from Miltenyi Biotech, Bergisch Gladbach, Germany; and CD63-
PE and anti-vWF (for study III) from Abcam, Cambridge, UK. IgG-PE was 
obtained from CalTag Laboratories, CA, USA.  
The 48-well plate inserts were obtained from Scaffdex Oy, Tampere, 
Finland. 50 ml tubes, 75 cm2 flasks (Nunc EasyFlask™) and 48-well plates 
(Nunclon™ Multidish) were from Nunc, Roskilde Denmark. IbiTreat 8-well 
cell culture slides were from Ibidi Gmbh, Martinsried, Germany. 100 µm, 
40  µm  and  0.22  µm  filters  were  obtained  from  Sarstedt,  Nümbrecht,  
Germany, 96-well optical reaction plates from Applied Biosystems and 1 ml 
syringes and 27 gauge needles from Terumo Europe, Leuven, Belgium. 
Bürker Chamber was from Menzel-Gläser, Braunschweig, Germany. 
Domitor (medetomidin hydrochloride) was purchased from Orion 
Pharma, Espoo, Finland and Ketalar (ketamin hydrochloride) from Pfizer, 
Espoo, Finland. 
Leica DM 2000 microscope and Leica DM2000 microtome were from 
Leica Instruments GmbH, Germany and microtome Microm HM 430 from 
Microm GmbH, Waldorf, Germany.  Sony DXC-S500 camera control unit 
and Sony Twain Driver Software 1.0 were from Sony Europe Limited, 
Weybridge, Surrey, UK. The chemiluminesence reader FluorChem™ 8800 
imaging system and FluorChem™ software v. 3.1. were from Alpha 
Innotech, San Leandro, CA, USA. Fluorescence activated cell sorter 
FACSAria was from BD Biosciences, Erembodegem, Belgium. Varioskan 
Flash Spectral Scanning Multimode Reader was from Thermo Fisher 
Scientific Inc. Waltham, MA, USA. Nikon Microphot FXA microscope, 
Nikon Eclipse TS-100 microscope, Nikon DS Camera Control Unit DS L-1 
and Nikon Eclipse Ti-S microscope were from Nikon, Tokyo, Japan. 
Confocal laser scanning microscope Zeiss LSM 700 (Zeiss LSM 700 on the 
Axio Observer) and Zen2009 confocal imaging software were from Carl 
Zeiss Microimaging GmbH, Jena, Germany. Canon Photo Stitch 3.1 was 
from Canon, Tokyo, Japan, Adobe Photoshop softwares 7.0 and CS3 were 
purchased from Adobe Systems, San Jose, CA, USA, Corel Draw software 
10.0 from Corel Corporation, Ottawa, ON, Canada and GraphPadPrism 5.0 
from GraphPad Software, Inc., San Diego, CA, USA.  
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Adipose tissue extract preparation 
Human adipose tissue extract preparation for cell culture and 
animal studies (I,II) 
Human adipose tissue specimens were minced into small (approximately 
1mm2)  pieces.  Tissue  pieces  were  transferred  into  50  ml  tubes.  Equal  
amount (1:1) of DMEM/F12 medium or alternatively, phosphate buffered 
saline (PBS) was added into each tube and the tubes were left for growth 
factor extraction at 37°C in a 5%CO2 incubator. A few of the samples were 
incubated in room temperature. The tubes were gently shaken a few times 
during incubation. The extract was then collected at several time points (15 
min, 30 min, 1hr,  2hr, 3hr, 4hr, 5hr, 6hr or 24 hr).   After incubation time, 
the  tube  contents  were  sentrifuged  at  1000  rpm  for  3-5  min,  and  the  
floating adipose tissue layer was removed with Pasteur pipette. The liquid 
extract was then removed from the tube, filtered through a 40 µm filter 
into another tube and centrifuged at 12 000 rpm for 5 min. The obtained 
supernatant was sterile filtered through 0.22 µm filter and stored in 
aliquots at -20°C.  
Rat adipose tissue extract (rATE) preparation for animal studies (II) 
Fat tissue from sacrificed rats was minced into small (approximately 1mm2) 
pieces  and  transferred  to  a  50  ml  tube.  Equal  amount  (1:1)  DMEM/F12  
medium or phosphate buffered saline (PBS) was added into tube and left 
for growth factor extraction at 37°C in a 5%CO2 incubator for 24 hours. The 
extract was then removed from the tube, filtered through a 40 µm filter 
into another tube and centrifuged at 12 000 rpm for 5 min. The obtained 
supernatant was sterile filtered through 0.22 µm filter and stored in 
aliquots at -20°C.  
Adipose tissue extract characterization 
Protein measurement (I,II) 
ATE samples, from different patients or from animals and/or from 
different time points (n=80), were analyzed for the total protein 
concentration with BCA protein Assay Kit according to the manufacturer’s 
instructions.  
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Growth factor measurement (I) 
The concentrations of VEGF, bFGF and IGF-1 were measured from human 
adipose tissue extract samples (n=26-58) with Quantikine Human VEGF 
Immunoassay, Quantikine Human FGF basic Immunoassay or Quantikine 
Human IGF-I Immunoassay according to the manufacturer’s instructions.  
Cytokine array (I) 
Altogether 120 cytokines were tested from six different extract samples at 
two different time points (1 hr and 24 hrs) with RayBio® Human Cytokine 
Antibody Array C Series 1000 according to the manufacturer’s instructions. 
The chemiluminescence was detected with FluorChem™ 8800 imaging 
system and the chemiluminescent signals were measured with 
FluorChem™ software 3.1. and analyzed qualitatively and 
semiquantitatively. 
Cell isolation and culture 
The  cells  were  maintained  at  37°C  under  a  5%  CO2 air atmosphere at a 
constant humidity and medium was changed every two to three days. A 
complete list of the cell culture and differentiation media used throughout 
the study is shown in Table II.  
 
Table II. A complete list of the cell culture and differentiation media 
used for cell culture studies.  
 
Culture condition/medium Basal 
medium 
Serum Supplements Study 
Fibroblast proliferation medium MEM 10% 
FBS 
NEAA, 1% L-glutamine, 1% 
GA 
I, IV 
HUVEC proliferation medium 
(EGM-2 BulletKit medium) 
EBM-2 2% 
FBS 
Single Quots –supplements 
(0,1% GA-1000, IGF-I, EGF, 
VEGF, FGF-2, ascorbic acid, 
hydrocortisone, heparin)  
I,III,IV 
human ASC (hASC) proliferation 
medium (Adipogenesis negative 
control medium) 
DMEM/F12 15% 
HS 
1mM L-glut, 1% AB/AM, 15% 
HS 
I,II,III 
Angiogenesis negative control 
medium (basic test medium) 
EBM-2 2% 
FBS 
0,1% GA-1000(#), 1% L-glut I,III, 
IV 
Standard adipogenic medium DMEM/F12 10% 
FBS 
1% AB/AM, 1% L-glut, 33 µM 
biotin (Sigma Aldrich, 
Manassas, VA, USA), 17 µM 
pantothenate, 100 nM 
insulin, 1  µM 
dexamethasone, 0.25 mM 
IBMX(*) 
I 
ATE adipogenesis induction 
medium I 
DMEM/F12 15% 
HS 
1mM L-glut, 1% P/S, 350 
µg/ml of ATE 
I 
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ATE adipogenesis induction 
medium II 
DMEM/F12 15% 
HS 
1mM L-glut, 1% P/S, 700 
µg/ml of ATE 
I 
ATE adipogenesis induction 
medium III 
DMEM/F12 15% 
HS 
1mM L-glut, 1% P/S, 950 
µg/ml of ATE 
I 
ATE adipogenesis induction 
medium IV 
DMEM/F12 15% 
HS 
1mM L-glut, 1% P/S, 1200 
µg/ml of ATE 
I 
ATE angiogenesis induction 
medium II  
EBM-2 2% 
FBS 
0,1% GA-1000#, 1%  L-glut, 
900 µg/ml of ATE 
I 
ATE angiogenesis induction 
medium III  
EBM-2 2% 
FBS 
0,1% GA-1000#, 1%  L-glut, 
1300 µg/ml of ATE 
I 
Angiogenesis induction medium 
I for hASC and HUVEC 
angiogenesis assay(¤) (EGM-2 
BulletKit medium) 
EBM-2 2% 
FBS 
Single Quots –supplements 
(0,1% GA-1000, IGF-I, EGF, 
VEGF, FGF-2, ascorbic acid, 
hydrocortisone, heparin) 
I,III,IV 
Angiogenesis induction medium 
II for  hASC and HUVEC 
angiogenesis assay (EGM-2 
BulletKit medium with human 
serum) 
EBM-2 2% HS Single Quots –supplements 
(0,1% GA-1000, IGF-I, EGF, 
VEGF, FGF-2, ascorbic acid, 
hydrocortisone, heparin) 
I,III,IV 
Angiogenesis induction medium 
III for hASC and HUVEC 
angiogenesis assay (EGM-2 
BulletKit medium w/o serum) 
EBM-2 serum 
free 
Single Quots –supplements 
(0,1% GA-1000, IGF-I, EGF, 
VEGF, FGF-2, ascorbic acid, 
hydrocortisone, heparin) 
I,III,IV 
Angiogenesis induction medium 
I for BJ+HUVEC angiogenesis 
assay($)   
EBM-2 2% 
FBS 
2% FBS, 0,1% GA-1000, 1% L-
glut, 1.0 ng/ml VEGF, 0.1 
ng/ml bFGF 
I, IV 
Angiogenesis induction medium 
II for   BJ+HUVEC angiogenesis 
assay($) 
EBM-2 2% 
FBS 
2% FBS, 0,1% GA-1000, 1% L-
glut, 2.5 ng/ml VEGF, 0.25 
ng/ml bFGF 
I, IV 
Angiogenesis induction medium 
III for  BJ+HUVEC angiogenesis 
assay($) 
EBM-2 2% 
FBS 
2% FBS, 0,1% GA-1000, 1% L-
glut, 5 ng/ml VEGF, 0.5 
ng/ml bFGF 
I, IV 
Angiogenesis induction medium 
IV for BJ+HUVEC  angiogenesis 
assay($) 
EBM-2 2% 
FBS 
2% FBS, 0,1% GA-1000, 1% L-
glut, 7.5 ng/ml VEGF, 0.75 
ng/ml bFGF 
 IV 
Angiogenesis induction medium 
V for BJ+HUVEC  angiogenesis 
assay($) 
EBM-2 2% 
FBS 
2% FBS, 0,1% GA-1000, 1% L-
glut, 10 ng/ml VEGF, 1 ng/ml 
bFGF 
IV 
Angiogenesis induction medium 
VI for BJ+HUVEC  angiogenesis 
assay($) = Positive control 
medium, stimulation medium 
EBM-2 2% 
FBS 
2% FBS, 0,1% GA-1000, 1% L-
glut, 25 ng/ml VEGF, 2.5 
ng/ml bFGF 
I, IV 
Angiogenesis induction medium 
VII for BJ+HUVEC  angiogenesis 
assay ($) 
EBM-2 2% 
FBS 
2% FBS, 0,1% GA-1000, 1% L-
glut, 50 ng/ml VEGF, 5 
ng/ml bFGF 
 IV 
Angiogenesis induction medium 
VIII for BJ+HUVEC  angiogenesis 
assay($) 
EBM-2 2% 
FBS 
2% FBS, 0,1% GA-1000, 1% L-
glut, 75 ng/ml VEGF, 7.5 
ng/ml bFGF 
IV 
(*)IBMX  removed  from  culture  after  24  hours,  (#)From  EGM-2  BulletKit  Single  Quots  –
supplements, ($)BJ fibroblast and HUVEC angiogenesis assay 
BJ fibroblast culture (I,IV) 
Human BJ neonatal foreskin fibroblasts were cultured in fibroblast 
proliferation medium as shown in detail in Table II. When cells were 
grown to confluency, they were subcultured in a ratio of 1:4 to 1:9. The cells 
were cryopreserved in liquid nitrogen 500 000 cells per vial. 
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Isolation and culture of human umbilical vein endothelial cells (I,III, 
IV) 
The isolation of umbilical vein endothelial cells (HUVEC) from human 
umbilical cord veins was performed as described by Jaffe (Jaffe et al. 1973) 
but the process was further optimized. The umbilical cord was separated 
from the placenta and the umbilical vein was cannulated with a 20G 
needle. The needle was secured by clamping the cord over the needle with 
a surgical clamp. The vein was perfused with Umbilical cord Buffer 
Solution (UBS; 0.1M phosphate buffer solution containing 0.14M NaCl, 
0.004M KCl and 0.011 M glucose) to wash out blood after which the other 
end of the umbilical vein was clamped with a surgical clamp. The vein was 
infused with 0.05% collagenase I. The umbilical cord was incubated in a 
water bath at 37oC for up to 20 min. After incubation, the collagenase 
solution containing HUVEC was flushed from the cord by infusing the vein 
with UBS. The suspension was flushed out into a 50 ml polypropylene 
tube.  The  cells  were  centrifuged  at  250  x  g  for  10  min,  resuspended  in  
HUVEC proliferation medium and seeded into 75 cm2 filtered cell culture 
flasks. HUVEC were subcultured at primary culture (p0) in the ratio of 1:2 
to 1:4 and at passages 1 (p1) upwards in a ratio of 1:3 to 1:5. Cells were 
cryopreserved in liquid nitrogen mainly at passage 2 (p2), 500 000 cells per 
vial.  
Isolation and culture of human adipose stromal cells (I,II,III) 
Human adipose tissue specimens were cut into small pieces and 
enzymatically digested with 0,05% collagenase I in plain DMEM/F12 for 60 
min at 37qC in a gyratory water bath. The digested tissue was centrifuged 
at 600 x g for 10 min in room temperature. The digested tissue was filtered 
through a 100 µm filter, centrifuged and filtered through a 40 µm filter. 
Cells were seeded into 75 cm2 flasks in hASC prolifieration medium. Cells 
were subcultured 1:2-1:4 when 70-80% confluent and used for cell 
differentiation studies or frozen in liquid nitrogen for storage, 106 cells per 
vial. 
Detection of mycoplasma (IV)  
BJ fibroblasts and HUVEC were quality-controlled prior to liquid nitrogen 
storage. The cells were tested for mycoplasma contamination with 
MycoAlert® Mycoplasma Detection Kit according to manufacturer’s 
instructions.  
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Determining the cell viability (IV) 
The viability of BJ fibroblasts and HUVEC was tested prior to liquid 
nitrogen storage. Cells were stained with TrypanBlue and the viability was 
calculated manually with a Burker Chamber under Nikon Ts-100 
microscope. 
Adipogenic induction in vitro (I,II) 
To initiate adipogenic differentiation, hASC were plated at early passages 
(p1-p5) at a density of 10 000 cells/cm2 into hASC proliferation medium. 
The next day, six different induction media were applied to hASC. Cells 
were cultured in the hASC proliferation medium, in the standard 
adipogenic medium, and in ATE adipogenesis induction media I-IV 
containing either 350 µg/ml, 700 µg/ml, 950 µg/ml or 1200 µg/ml of ATE. 
The cell culture media and ATE adipogenesis induction media 
formulations are shown in detail in Table II. Cells were cultured for 1, 2 or 
for 4 weeks and examined for lipid accumulation by Oil-Red-O (ORO) 
staining or used for detecting adipogenic genes with quantitative real-time 
RT-PCR.  
Angiogenic induction in vitro 
 BJ fibroblast and HUVEC angiogenesis assay (I,IV) 
The assay was modified from Bishop et al. (1999) and Friis et al. (2003) and 
optimized. BJ fibroblasts were seeded in fibroblast proliferation medium at 
a density of 20 000 cells/cm2 into 48-well plates and grown for 3 days. 
Next, HUVECs were seeded on top of fibroblast cultures at a density of 
4000 cells/cm2 in HUVEC proliferation medium.  
ATE angiogenesis test (I) 
The day after plating the HUVEC, the different induction media were 
applied. Cells were cultured in the angiogenesis negative control medium, 
in angiogenesis induction media I-VIII and in ATE angiogenesis induction 
media I-III containing approximately 300 µg/ml, 600 µg/ml or 950 µg/ml 
of ATE. The cell culture media and ATE angiogenesis induction media 
formulations used are shown in detail in Table II. The treatments were 
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applied twice to cells during culture and cells were cultured for six to seven 
days prior to immunocytochemical analysis.  
Optimization of the human umbilical vein endothelial cell passage (IV) 
The isolated HUVEC were tested for their tubule formation capacity in the 
angiogenesis assay from passages 2-10. The BJ fibroblast angiogenesis assay 
was performed as described above. The day after seeding HUVEC (p2-p10) 
Angiogenesis induction medium VI for BJ+HUVEC angiogenesis assay i.e. 
positive control medium, was applied to cells. The cells were cultured for 
six days prior to DAB-staining.  
Linearity and cell batch variation test (IV)  
The sensitivity of the BJ fibroblast and HUVEC angiogenesis assay was 
evaluated by studying linearity and determining the upper and lower limits 
of detection. Eight different angiogenesis induction media I-VIII for   
BJ+HUVEC angiogenesis assay (see Table II) were applied to cells. Each 
induction media was tested in six parallels and the media were applied 
twice to cells that were cultured for 6 days prior to DAB-staining.  
The batch to batch variation between different HUVEC batches was 
performed to confirm that each of the Master cell bank batches set up in 
our laboratory gives comparable results. This was done by using different 
HUVEC cell batches in the linearity test.  
Reference chemical test (IV) 
The six reference chemicals and their concentrations used for validation of 
an in vitro angiogenesis assay are shown in Table III. The initial 
concentration range for each chemical was based on our previous studies 
(data not shown). The selection criteria for the concentrations were: to be 
in the effective angiogenic range, soluble in the test system, and not to 
exceed the maximum concentration (0.5%) of dimethyl sulphoxide 
(DMSO) in the test system. All reference chemicals were prepared in 
Angiogenesis induction medium IV for BJ fibroblasts and HUVEC 
angiogenesis assay (positive control, stimulation medium, see Table II).  
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Table III. The reference chemicals used for intra-laboratory 
validation of the in vitro angiogenesis assay.  
 
hASC monoculture angiogenesis assay (III) 
hASC (up to passage 7) were seeded in HUVEC proliferation medium into 
48-well plates (Nunclon™ Multidishes) at a density of 20 000 cells/cm2. 
Cells were cultured for either 3 or 6 days in EGM-2 BulletKit medium or in 
DMEM/F-12 medium supplemented with 15% HS, 1mM L-glut and 1% 
AB/AM. The cell culture media and ATE adipogenic induction media 
formulations used are shown in detail in Table II. The treatments were 
applied once to cells cultured for 3 days and twice to cells cultured for 6 
days. 
hASC and HUVEC angiogenesis assay (III) 
hASC (passages 1 to 7) were seeded in HUVEC proliferation medium  into 
48-well plates (Nunclon™ Multidishes) or for confocal imaging into 8-well 
slides (IbiTreat) at a density of 20 000 cells/cm2. HUVEC, cultured as 
above  (up  to  passage  4),  were  immediately  seeded  on  top  of  hASC  at  a  
density of 4000 cells/cm2 in HUVEC proliferation medium. The day after 
plating, the differentiation treatments were applied to hASC-HUVEC 
culture. Treatments were angiogenesis negative control medium, 
angiogenesis induction media I-III for hASC+HUVEC angiogenesis assay. 
The media formulations used are shown in detail in Table II. Cells were 
cultured for either 3 or 6 days prior to immunocytochemistry or 
quantitative real-time RT-PCR. The treatments were applied once to cells 
cultured for 3 days and twice to cells cultured for 6 days.  
Reference 
chemical/ 
(Tradename) 
Mechanism of 
action 
Use Concentration range 
used in the study 
Solute 
Levamisole 
(Ergamisol) 
phosphatase 
inhibitor 
drug against 
parasitic worm 
infections 
0.01, 0.1, 1, 10, 50, 100, 
250, 500,  
750, 1000 and 2000 µM 
DMSO 
Acetyl salicylic acid 
(Aspirin) 
non-selective 
cyclo-oxygenase 
inhibitor 
anti-
inflammatory 
drug (painkiller) 
10, 100, 500, 1000, 1500 
and 2000 µM 
medium 
Thalidomide 
(Thalomid) 
TNF-Ʉ inhibitor anti-cancer drug 10, 100, 200, 300, 400 and 
500 µM 
DMSO 
Erlotinib (Tarceva) EGFR tyrosine 
kinase inhibitor 
anti-cancer drug 0.0005, 0.001, 0.01, 0.1, 1, 
10, 25 and 50 µM 
medium 
Anti-VEGF (Avastin) VEGF inhibitor anti-cancer drug 0.5, 1, 2.5, 5, 7.5, 10, 25 
and 50 µg/ml 
medium 
2-methoxyestradiol 
(Panzem) 
microtubule 
inhibitor, HIF-1a 
pathway inhibitor 
anti-cancer drug 0.01, 0.1, 0.2, 0.4, 0.6, 0.8, 
1 and 2 µM 
DMSO 
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Lentiviral infection (III) 
The lentiviral pLKO-MISSION-Bright-GFP infection was carried out with 
HUVEC at passages 2-4 with 300 µl of pLKO-MISSION-Bright-GFP in 1 ml 
HUVEC proliferation medium (1 U/ml). Viral infection was accelerated 
with 8 µg/ml hexadimethrine bromide. After 24 hours of incubation, 
medium was replaced with fresh medium. Highly fluorescent clones were 
selected with cloning rings and further with dilution cloning to obtain 
pure GFP-HUVEC-cultures.  After expanding the infected HUVEC, they 
were used for hASC and HUVEC angiogenesis assay as described above. 
Flow cytometric analysis (III) 
The HUVECs at passage 3 were analyzed with a fluorescence activated cell 
sorter (FACS). The list of the surface markers used is shown in Table IV. 
10,000 cells were analyzed per sample and the positive expression was 
defined as the level of fluorescence greater than 99 % of the corresponding 
unstained cell sample. 
 
Table IV. List of surface markers used in flow cytometric analysis 
 
Surface 
marker  
Description 
CD13 PE-conjugated monoclonal antibody against human CD13/Aminopeptidase N 
CD31 FITC-conjugated monoclonal antibody against human CD31/PECAM 
CD 34 APC-conjugated monoclonal antibody against human CD34 
CD44 FITC-conjugated monoclonal antibody against human CD44/hyaluronate, HCAM 
CD117 APC-conjugated monoclonal antibody against human CD117/c-kit, SCFR 
CD 133 PE-conjugated monoclonal antibody against human CD 133/AC133 
CD144 PE-conjugated monoclonal antibody against human CD144/VE-Cadherin 
CD202b monoclonal antibody against human Tie-2/TEK 
VEGFR2 monoclonal antibody against human VEGF receptor 2 
CD63 PE-conjugated monoclonal antibody against human CD63/Tetraspanin 
vWF/factor 
VIII 
monoclonal antibody against human von Willebrand factor 
 
Cytotoxicity test (IV) 
The cytotoxicity test was performed prior to reference chemical study for 
BJ fibroblast and HUVEC in vitro angiogenesis assay to assure that only 
non-toxic concentrations of chemicals were used in chemical exposure. 
The cell viability was tested with the Neutral Red Uptake (NRU) assay. 24 
hours after the establishment of fibroblast and HUVEC angiogenesis assay, 
the cells were treated with chemical exposure for 24 hours. After chemical 
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exposure (see Table III for chemical exposure details), the cells were 
washed with preheated Phosphate Buffered Saline (PBS). 250 µl Neutral 
Red (NR) medium (25 mg NR/1ml medium) was added into the wells and 
incubated for 2 hours at 37°C. After incubation, the cells were washed with 
PBS. After that, 100 µl NR-desorption medium (50% EtOH, 1% acetic acid 
in  H2O)  was  added  into  the  wells  and  incubated  in  a  shaker  for  20  min,  
protected from light. After shaking, the cells were allowed to settle down 
for 5 min. The absorbance was measured at 540 nm with Thermo Scientific 
Varioskan Flash Spectral Scanning Multimode Reader. 
Quantitative RT-PCR (I,III) 
Primers used for angiogenesis and blood vessel maturation or adipogenesis 
are shown in Table V. The total RNAs from hASC monoculture 
angiogenesis assay or from hASC and HUVEC angiogenesis assay were 
extracted from 3 days or 6 days differentiated confluent cultures using 
TRIzol® following the manufacturer’s protocol. Alternatively, total RNA 
was extracted from hASC adipogenesis culture at 7 days and at 28 days. 
cDNA was synthesized using High-Capacity cDNA Reverse Transcriptase 
Kit according to manufacturer’s instructions. Quantitative RT-PCR analysis 
was performed in a 96-well optical reaction plate using an ABI Prism 7000 
sequence detector. The RPLP0 gene was used as reference gene for data 
normalization. Reactions were performed using SYBR Green PCR Master 
Mix kit, 50 ng cDNA sample and 10 ɑM primers.  The PCR conditions were: 
10 min at 95 ºC, followed by 40-45 cycles of 15 seconds at 95 ºC and 60 
seconds at 60 ºC. RNA expression was calculated in comparison to RPLP0 
RNA expression for cell culture experiments using the Pfaffl method (Pfaffl 
2001):   
 
ratio of relative expression =  
(Etarget) ȥCP target (control-sample)  / (Eref) ȥCP ref (control-sample) 
 
Table V The list of primers used for quantitative RT-PCR  
 
Primer Forward Reverse Study 
RPLP0 5’-AATCTCCAGGGGCACCATT-3’ 5’-CGCTGGCTCCCACTTTGT-3’ I, III 
PPARɇ2 5’ -CAGTGTGAATTACAGCAAACC-3’ 5’ -ACAGTGTATCAGTGAAGGAAT-3’ I 
ACBP 5’-GCAACTGTGGGCGACATAAA-3’ 5’-GGCCTTGCCCGTGAAGT-3’ I 
CD31/ 
PECAM 
5´-TCATTTCTGGGATCCATATGCA-3´ 5´-TGGGTGTAGAGAAGGATTCCGT-3´ III 
Ang-1 5´-AGCTACCACCAACAACAGTG-3´ 5´-CAAAGATTGACAAGGTTGTGG-3´ III 
Caldesmon 5´-AAGAATCCTTGGGACAGGTGAC-3´ 5´-GTGGTGGTTGTCTTGGCCTC-3´ III 
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Implantation studies (II) 
Preparation of implants 
The adipose tissue extract, either from 1) human (hATE) or from 2) rat 
(rATE) was mixed with hyaluronan hydrogel in a ratio that the implant 
contained 57% ATE and 43% HA hydrogel. As a control implant, HA with 
incorporated plain PBS was used, with corresponding volumes of PBS 
(57%) and HA (43%). The final ATE concentration in the hATE implant 
was 1.48 mg/ml of hydrogel (148 µg in each implant) and in the rATE 
implant was 0.75 mg/ml of hydrogel (75 µg in each implant).  
Protein release from implants 
The protein release from the implants was tested by incubating the 
implants in PBS at 37°C up to three weeks. The 48-well plate inserts were 
filled with HA-ATE hydrogels and put on top of PBS filled 48-well plate 
culture wells. Aliquots of PBS were collected and analyzed for total protein 
concentration with BCA protein Assay.  
Adipose stromal cell differentiation in the presence of ATE-
hyaluronic acid hydrogel 
To study the adipogenic effect of bioactive implants in cell culture, the 
adipose stromal cells were plated at 48-well plates early passages (p1-p3) at 
a density of 10 000 cells/cm2.  Cells were seeded and cultured in the hASC 
proliferation medium. The 48-well plate inserts were filled with HA-ATE 
hydrogels and put on top of PBS filled 48-well plate culture wells. The 
medium was changed twice during the study. Cells were cultured for 6 
days and examined for lipid accumulation with ORO staining. 
Animal model of acellular soft tissue induction 
26 male Sprague-Dawley rats (weight 325±75 g, average age of 8 weeks) 
were housed per 2,  12 hours light and 12 hours darkness, fed pelleted diet 
and water ad libitum. Rats were anesthesized with a mixture of Domitor 
(0.5 mg/kg) and Ketalar (75 mg/kg). Three different types of hyaluronic 
acid implants, each incorporated with different substances, were created as 
described above. 100 µl of the resulting gel mixture was injected with a 1 ml 
syringe and 27 gauge needle into dorsal subcutis of rat Implants were 
injected in between the upper subcutis and muscle layer into rat dorsal 
subcutis. Three constructs per rat were implanted for three rat per time 
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point (n=3 in each time point). The places of implants were varied in 
different time points. Implants were left under subcutis for 1, 4, 12, 20 or 40 
weeks after which animals were sacrificed. The remaining implant and its 
surrounding tissue was carefully cut from the implant site and further 
processed for histological analysis.  
Cytological stainings  
Oil-red-O staining (I)  
Lipid accumulation was assessed at six days after the onset of the 
differentiation experiment by using ORO staining. hASC were fixed with 
4% paraformaldehyde for 20 min and rinsed several times with PBS. 0.5% 
ORO stock solution was prepared in 100% isopropanol and for staining 
diluted  3:2  in  distilled  water,  left  at  RT  for  10  min  and  filtered  through  
standard filter paper. hASC were incubated with 60% isopropanol for 2 to 5 
min,  incubated  with  the  ORO  staining  solution  for  5  min  and  rinsed  
several times with PBS. Phase contrast micrographs of the stained cells 
were taken with Nikon Eclipse TS-100 microscope equipped with Nikon DS 
Camera Control Unit DS L-1. The images were processed with Adobe 
Photoshop 7.0 and Corel Draw 10.0.  
Immunofluorescence staining (I,III) 
The complete list of antibodies used is shown in Table VI. The tubule 
formation was visualized with endothelial cell specific antibody anti-von 
Willebrand Factor (anti-vWf). For study I, cells were washed three times 
with PBS, fixed with ice-cold 70% ethanol for 20 min, permeabilized with 
0,5% Triton X-100 for 15 min and blocked for unspecific staining with 10% 
BSA for 30 min. After blocking, cells were incubated with the primary 
antibody 4°C overnight. Cells were washed three times with PBS, 
incubated 30 min with secondary antibody (polyclonal antibody to rabbit 
IgGFITC, 1:500). Fluorescence was visualized with Nikon Eclipse Ti-S 
microscope and the images were processed with Adobe Photoshop 7.0 and 
Corel Draw 10.0. 
For study III, to evaluate human adipose stromal cell differentiation, 
immunofluoresence staining procedure was performed as in study I, except 
that parallel double immunofluorescence staining with Ʉ-vWf was 
performed.  Primary antibody against either common pericytic marker Ʉ-
smooth muscle actin (ɄSMA), vascular smooth muscle cell marker smooth 
muscle myosin heavy chain (anti-SMMHC), contractile smooth muscle cell 
marker calponin (anti-calponin), pericytic and smooth muscle cell 
progenitor marker platelet derived growth factor receptor-Ʌ (anti-
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PDGFRɅ) or basement membrane marker collagen IV (anti-COLIV) was 
combined with anti-vWf. Secondary antibodies used were polyclonal anti- 
rabbit IgG TRITC (1:100) for anti-vWf and polyclonal anti- mouse IgG FITC 
(1:100) for anti-ɄSMA, anti-COLIV, anti- PDGFR-Ʌ and anti-SMMHC. 
Fluorescence was visualized with Nikon Eclipse Ti-S microscope or for 
confocal laser scanning microscope Zeiss LSM 700 and the images were 
processed with Zen2009 and with Adobe Photoshop 7.0 or CS3 and Corel 
Draw 10.0. 
 
Table VI The complete list of antibodies used in studies  
 
Primary 
antibody 
Detection/ 
Marker 
Dilution 
rate 
Origin Secondary antibody  Study 
calponin smooth muscle 
cells 
1:800 mouse IgG-FITC III 
CD79a B-cells 1:500 mouse Mouse on RAT HRP Polymer Kit II 
CD68 macrophages 1:100 mouse Mouse on RAT HRP Polymer Kit II 
CD3 T-cells 1:100 rabbit Dako EnVisionTM+ System, HRP Kit II 
COLIV basement 
membrane 
1:500 mouse IgG-FITC III 
NF-68 neurofilaments 1:500 mouse Histostain Plus Broad Spectrum 
Detection Kit 
II 
ɄSMA pericytes 1:200 mouse IgG-FITC III 
SMMHC smooth muscle 
cells 
1:800 mouse IgG-FITC III 
vWf endothelial cells 1:500 rabbit IgG-FITC I 
vWf endothelial cells 1:100 rabbit IgG-TRITC  III 
vWf endothelial cells 1:5000 rabbit Biotinylated IgG IV 
vWf endothelial cells 1:5000 rabbit Histostain Plus Broad Spectrum 
Detection Kit 
II 
 
DAB –staining (IV) 
The media were removed and the cells were washed three times with PBS, 
fixed with ice-cold 70% ethanol for 20 min, permeabilized with 0,5% 
Triton X-100 for 15 min and blocked for unspecific staining with 10% BSA 
for 30 min. After blocking, the cells were incubated with primary antibody 
(1:5000)  at  4°C overnight  or  for  1-2  hours  in  RT.  Cells  were  washed three  
times with PBS, incubated for 30 min with the secondary antibody 
(Biotinylated Anti-Rabbit IgG, H+L made in goat) and washed again three 
times with PBS. The cells were then incubated with enzyme conjugate 
solution (Vectastain Elite ABC Kit) for 30 min, after which substrate was 
added (DAB Substrate Kit). The color development was followed under 
microscope for 5 to 10 min and the reaction was stopped with 0.5 M Tris 
buffer. After staining, 500 µl of Tris buffer was pipetted into each cell 
culture well and the plates were sealed with parafilm for storage at 4°C 
until microscopic analysis for tubule formation.  
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Histological stainings 
 Hematoxylin Eosin staining (II) 
The histological specimens were cut into 1 mm2 pieces  and  fixed  in  4%  
paraformaldehyde overnight, dehydrated with a graded ethanol series and 
embedded  in  paraffin.  Specimens  were  cut  into  5  µM  thick  slices  with  
microtome and stained with hematoxylin-eosinfor histology. Briefly, 
samples were deparafinized by treating them three times for 5 min each 
with xylene and after that with graded ethanol series. The samples were 
stained for 10 min with Mayer Hematoxylin or Papanicolauslösung 1a 
Harris’ Hämatoxylinlösung, rinsed with tap water 10 min and with distilled 
water  2  min,  then  stained  with  1%  Eosin  for  15  seconds,   rinsed  with  tap  
water and further with distilled water. The samples were then dehydrated 
with 94% and 100% ethanol, treated 3 x 5 min with xylene and mounted 
with Entellan for storage.  
Immunohistochemical staining (II) 
The complete list of antibodies used is shown in Table VI. The histological 
specimens were  cut  into  1  mm2 pieces and fixed in 4% paraformaldehyde 
overnight, dehydrated with a graded ethanol series and embedded in 
paraffin. Specimens were cut into 3 or 5 µM thick slices with microtome 
(Leica DM2000, or Microm HM 430, respectively). Samples were 
deparafinized with xylene 3 x 5 min each, rehydrated with graded ethanol 
series and washed with distilled water.  
For anti-von Willebrand Factor and for anti-Neurofilament-68 staining 
(anti –vWF produced in rabbit, 1:5000 and anti-NF-68, 1:500, respectively, 
both 4ºC overnight), tissue samples were treated 15 min with 0,5% 
hydrogen peroxide in methanol, microwave oven -treated 10 min in 
preboiled 0.01 M sodiumcitrate buffer pH 6.0, samples cooled 20 min in 
sodiumcitrate buffer and treated with Histostain Plus Broad Spectrum 
Detection Kit. The color was developed with DAB Substrate kit for 5 min. 
The samples were counterstained for 5 sec with Mayer Hematoxylin and 
mounted with Entellan.  
For anti-CD3 staining (CD3 (Clone SP7) rabbit monoclonal antibody, 
1:100, 90 min at RT), the samples were microwave oven treated 2 x 7 min in 
10mM TRIS-HCl 1mM EDTA pH 9.0., cooled for 20 min in TRIS-EDTA 
buffer and then treated with DAKO EnVision™+ System, HRP kit. For anti-
CD79a staining (mouse anti human Cd79a, 1:500, 4 C overnight) and for 
anti-CD68 staining (monoclonal mouse anti rat CD68, 1:100, in 0.1%BSA in 
TBS,  4ºC  overnight),  samples  were  treated  with  Mouse  on  Rat  HRP  
Polymer Kit. The color was developed with DAKOCytomation Liquid DAB 
Substrate Chromogen System, samples were counterstained with 
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Papanicolauslösung 1a Harris’ Hämatoxylinlösung and mounted with 
Pertex. 
The results were analyzed with Leica DM 2000 microscope from five 
different fields from three animals per each time point. Images were taken 
with Nikon Microphot FXA microscope connected to a Sony DXC-S500 
camera control unit and Sony Twain Driver Software 1.0 and processed 
with Adobe Photoshop software CS3, Corel Draw software 10.0 and Canon 
Photo Stitch 2.0. 
Microscopic analysis of tubule formation (III,IV) 
After immunocytochemical staining, the tubules were analyzed with Nikon 
Eclipse TS100 microscope from 48-well plate wells with 40x magnification. 
The extent of tubules in different cultures was quantified visually by using 
semi-quantitative grading scale from 0 to 10. The analysis and grading was 
based on tubule formation, the length and the branches of tubules. The 
tubule formation in different cultures was compared to positive control 
(Angiogenesis induction medium VI for BJ+HUVEC angiogenesis assay, see 
Table II).  
Analyses of transplanted implant (II) 
Determining the capillary density 
The number of formed capillaries was calculated microscopically from 
three animals per time point (each containing three different types of 
implants), and from five different random high power field (hpf, 400x) in 
each implant at the implant-tissue interface with Leica DM 2000 
microscope. The capillaries were confirmed to be stained positive for vWf, 
and the capillaries needed to have lumen that was visible in hpf (400x 
magnification). Both capillary proliferation and larger arteriole- like and 
venule-like vessels were counted. 
  
Automated quantitative analysis of the adipose tissue formation  
In order to quantitate the adipose tissue formation in rat subcutis, an 
automated computer assisted analysis tool was earlier developed for fat 
deposit detection. The applicability of the analysis tool for quantification 
of fat and to evaluating the differences in the fat accumulation between 
time has been previously described (Ruusuvuori et al. 2009). Briefly, prior 
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to analysis, the samples were stained as described above in Hematoxylin-
Eosin staining. Hematoxylin-eosin stained slides were photographed with 
Nikon Microphot FXA microscope connected to a Sony DXC-S500 camera 
control unit and Sony Twain Driver Software 1.0 and analyzed with the 
analysis tool without any preprocessing to the images. The analysis tool 
estimates the area of fat coverage by segmenting the hue component of the 
image with dual thresholding. Size constraints were applied in order to 
remove small, fractioned areas and excessively large areas, which typically 
belong to background. Finally, the user was allowed to modify the 
segmentation result by removing any possible false detections and by 
adding missing areas. Adding of new areas was implemented using seeded 
region growing where the user gives the seed point and the area grows 
around this point (Ruusuvuori et al. 2009).  
Evaluation of the local immunological effects of implantation  
The local biological effects were quantitatively scored after 
immunohistochemical staining as described previously (Kotzar et al. 2002; 
Lehle et al. 2004)  and according to the International Organization of 
Standardization (ISO) Standard ISO-10993:6-2007 (ISO, 2007) when 
applicable. The response was evaluated (hpf, 400x) from five (5) different 
fields and from three different animals per time point. The inflammation 
score criteria were (as modified from ISO 10993-6:2007): 0= no cell type 
detected, 1= rare, 1-5/hpf (except for giant cells, 1-2/hpf), 2 = 5-10/hpf 
(except for giant cells, 3-5/hpf), 3 = heavy infiltrate, 4 = packed. The final 
average irritating ranking (as described in ISO 10993-6:2007) was obtained 
from the average of overall scores that were multiplied by two for the final 
irritation ranking. Finally, the results of ATE-implants were subtracted 
from the results of the control implant to obtain the final score. Final 
scoring was: non-irritant (0,0 – 2,9), slight irritant (3,0 – 8,9), moderate 
irritant (9,0 – 15,0), severe irritant (>15). 
Validation criteria for angiogenesis in vitro assay (IV) 
Criteria for Master cell banks 
Quality controlled liquid nitrogen Master cell banks were created from 
HUVEC and BJ fibroblasts. Quality control (QC) criteria for setting up the 
Master cell banks were as follows: i) cell cultures had high proliferation 
capacity, cells were typical and pure in morphology (when microscopically 
observed prior to Master cell bank establishment) and iii) contained no 
mycoplasma. No antibiotics were used in cell culture. ii) Cell viability was 
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over  90%.  The  BJ  fibroblasts  were  never  passaged  over  10  times  and  the  
passaging of HUVEC was investigated and optimized.  
Criteria for the intra-laboratory validation 
The technical criteria and validation criteria for the intra-laboratory 
validation study are shown in Table VII. 
 
Table VII The criteria for intra-laboratory validation  
 
Technical criteria Accepted value 
Positive control value score 6-7 from 3 different wells, score 5 from one well1 
Negative control value always negative (score 0) 
Reference chemicals only one well out of two parallels could be discarded 
Validation criteria Accepted value 
Sensitivity of 
detection 
Growth factor curve of each HUVEC batch tested in the BJ firbolast HUVEC 
angiogenesis assay must follow linearity, and criteria for the upper and lower limits 
of detection 
HUVEC batch to batch 
variation 
each cell line must follow the criteria for the sensitivity of detection 
Precision total coefficient of variation (CV) ϐ15% in the positive control value2 
Reliability the positive control criteria must be met, 
reference chemicals must give comparable values in each test time (repeatability), 
the effect of each reference chemical had to be same regardless of the person 
(reproducibility) 
1The calculated minimum value for positive control 5.75, 2Total variation in the test had to be ϐ15% 
when analyzed statistically with coefficient of variation (CV). 
Performance  
The overall performance of the assay was tested by repeating the identical 
protocol in a Reference Chemical Test three times by two technicians. The 
results were analyzed by two different microscopic analysts.  
Statistical analyses (I-IV) 
Statistical analyses were performed and graphs were processed with 
GraphPadPrism 5.0. The results were reported as mean ± SD and 
differences were considered significant when p<0.05*, p<0.01** and 
p<0.001***. 
 
Study I. Protein concentrations of different ATE samples were subjected to 
one-way analysis of variance (ANOVA) followed by Tukey’s multiple 
comparison test and growth factor concentration measurements to 
nonparametric Mann-Whitney test. RT-PCR results were subjected to one-
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way ANOVA with Tukey’s multiple comparisons test. The variation in ATE 
–induced adipogenesis was analyzed with unpaired t-test.  
 
Study II. Samples were subjected to one-way ANOVA followed by 
appropriate post-tests. For the capillary formation and adipose tissue 
formation Tukey´s and Dunnett´s post tests and for tissue thicknesses 
Tukey’s post test were used.  
 
Study III. Analysis of tubule formation and RT-PCR results were subjected 
to One-way ANOVA followed by Dunnett’s and Bonferroni’s post-tests.  
 
Study IV. One-way analysis of variance with Dunnett’s post test was used 
for the statistical analysis of the reference chemical results. The linearity of 
tubule formation was tested with linear regression and precision with 
coefficient of variation (CV). The day to day variation of technicians was 
tested with one-way analysis of variance, person to person variation 
between technicians with unpaired t-test and person to person variation 
between analysts with paired t-test.  
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Results 
Protein, growth factor and cytokine content of adipose 
tissue extract (I) 
The protein concentration, the cytokine profile and the concentrations of 
VEGF, bFGF and IGF-I of ATE were analyzed. The protein concentration of 
ATE was mainly dependent on incubation time as well as on the ratio of 
minced fat and extraction solution. The extraction solution (PBS or basal 
DMEM/F12) or the incubation temperature (room temperature compared 
to 37°C) did not have effect on protein concentration. The variation in 
protein concentration did not seen to markedly have impact on the 
cytokine composition. It was possible to collect aliquots at different time 
points from one sample, instead of using only one incubation time per 
sample. In that case, the protein concentration was generally highest at 1 
and 2 hours, after which the protein concentration was seen to decrease 
with time. If one sample was incubated for a prolonged period of time (e.g. 
24 to 48 hours), high concentrations of different cytokine compositions 
could be obtained. The selected total protein concentrations for further 
analyses (determined with calculated mean) were 1 hr 2.017 mg/ml, 
(SD=0.5222),  2  hrs  1.783  mg/ml,  (SD=0.1516)  and  24  hrs  1.120  mg/ml  
(SD=0.1917).  
The concentrations of IGF-I, bFGF and VEGF were measured with 
enzyme-linked immunosorbent assay (ELISA) at 1 hour (hr) and 24 hours 
(hrs). The results are shown in Figure in Original Publication I. The IGF-I 
concentration (pg/ml of protein) was significantly higher at 1 hr than at 24 
hrs (1 hr median=709.6, 24 hr median=126.2, p<0.0148). The bFGF 
concentrations (pg/ml of protein) did not vary significantly between time 
points (1 hr median=217.0, 24 hr median=522.2, p<0.1031). The VEGF 
concentrations (pg/ml of protein) were significantly elevated at 24 hrs 
compared to 1hr (1 hr median=6.020, 24 hr median=72.36, p<0.0001).  
In addition, a selection of 120 growth factors and cytokines, known to 
have effect on angiogenesis, were semiquantitatively analyzed from six 
different extract samples at two different time points (1 hr and 24 hrs) with 
RayBioTech Angiogenesis Cytokine Array 1000. In the analysis of the 
chemiluminescent signals, the protein array results were compared to the 
negative control in the assay, and the original values were adjusted to the 
scale from 0-4 (<1=no detectable expression compared to control, 1<1,5 low, 
1,5 <2,5 moderate, 2,5 high, 3,5 very high). At 24 hrs, the overall number 
of cytokines was higher compared to 1 hr time point. Very high at 1 hour 
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were adiponectin and angiogenin, and at 24 hours adiponectin and IL-6.  
All of the highly expressed cytokines at 1hr; angiogenin, adiponectin, Ang-
2, insulin-like growth factor binding protein 3 (IGFBP-3), TIMP-2 and 
Fibroblast-associated/Tumour necrosis factor receptor superfamily 
member 6 (Fas/TNFRSF6), macrophage migration inhibitory factor (MIF), 
growth regulated oncogene (GRO), were high also at 24 hr. IL-6, leptin, 
CC-chemokine ligand 5 (CCL5 e.g. RANTES), Ang-2, bFGF, FGF-9, IGFBP-
6, TIMP-2, VEGF-D, MIP-1Ʉ, IL-8, tumor necrosis factor related apoptosis 
inducing ligand receptor 4 (TRAIL R4), IL-12 p40 and macrophage 
stimulating protein (MSP-Ʉ) expressions were mostly increased over time 
and were very high or high at 24 hrs. Neutrophil activating protein 2 (NAP-
2) and angiogenin were quite highly expressed in all samples, but had 
donor dependent variations in the expression levels between time points. 
NAP-2 was occasionally were seen to mildly decrease by 24 hours, 
however, occasionally, vice versa. Angiogenin was high, but sometimes 
seen to decrease by 24 hrs. Donor dependent variability in the levels of 
angiopoietin-2, PDGF-B, TIMP-1, leptin, MCP-1 and IGFBP-6 were also 
found. The only cytokine that had significant increase by 24 hours in the 
Cytokine Array was IL-6 (p<0.001), as tested with one-way ANOVA after 
semiquantitative analysis of chemiluminesence signals. Moderate or low 
levels of numerous other cytokines, especially at 24 hrs, were released, as 
shown in Table VIII. However, cytokines with expression of <1 are 
considered not to be present at detectable levels in the array. The factors 
that were quantitatively detected with ELISA: VEGF, bFGF and IGF-1, were 
detected at low (VEGF), moderate (bFGF) or no expression (IGF-1) in the 
cytokine array. This indicates that the lowest concentrations of the factors 
detected in cytokine array were at ng level per mg of total protein. 
Moreover, no increase in the level of VEGF was detected in the cytokine 
array.  
 
Table VIII. Cytokines measured with Raybiotech Cytokine Array 1000 
and average factor expression by adipose tissue extract at 1 hr and at 
24 hrs.  
 
Cytokine 1h 24h Cytokine 1h 24h Cytokine 1h 24h 
Adiponectin 4,00* 4,0 I-309 0,25 0,8 MIP-3Ʌ 1,00 1,0 
AgRP 2,00 2,0 ICAM-1 1,50 2,0 MSP-Ʉ 1,75 1,8 
Angiogenin 3,50 2,5 ICAM-3 0,75 1,0 MCP-1 0,50 1,0 
Angiopoietin-2 2,75 3,0 IFN-ɇ 0,75 1,0 MCP-2 0,25 0,3 
Amphiregulin 1,00 1,0 IGFBP-1 1,25 1,3 MCP-3 0,25 0,3 
Axl 1,00 1,0 IGFBP-2 1,00 1,5 MCP-4 0,25 0,5 
BDNF 1,00 1,3 IGFBP-4 0,75 0,5 M-CSF 0,75 1,8 
BLC 0,5 0,5 IGF-I 0,25 0,0 MDC 0,50 0,8 
BMP-4 1,75 2,0 IGFBP-3 3,0 3,0 MIG 0,25 0,5 
BMP-6 1,50 1,8 IGFBP-6 2,0 2,3 MIP-1ä 0,50 0,8 
BTC 1,50 1,3 IGF-I SR 1,00 1,0 MIP-3Ʉ 0,0 0,5 
CCL-28 0,75 1,0 IL-1 R4/ST2 1,25 1,3 b-NGF 0,75 1,0 
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CK Ʌ8-1 1,50 1,8 IL-1 RI 1,00 1,0 NAP-2 3,25 2,5 
CNTF 1,00 0,8 IL-11 1,00 1,0 NT-3 1,25 1,0 
CTACK 1,00 1,0 IL-12 p40 2,25 2,0 NT-4 1,00 1,0 
Dtk 1,00 1,0 IL-12 p70 1,75 1,0 Osteoprotegerin 1,25 1,0 
EGF 1,00 1,3 IL-17 1,00 1,0 Oncostatin M 1,25 1,0 
EGF-R 1,50 2,0 IL-2 R alpha 1,00 1,0 PARC 1,75 1,0 
ENA-78 1,00 1,0 IL-6 R 1,75 2,0 PIGF 1,25 1,0 
Eotaxin 0,75 0,5 IL-8 1,00 1,3 PDGF-BB 0,5 0,8 
Eotaxin-2 1,00 1,3 IL-10 1,00 1,3 RANTES 2,25 2,3 
Eotaxin-3 1,00 1,0 IL-13 0,01 0,0 SCF 1,50 1,5 
Fas/TNFRSF6 3,0 3,0 IL-15 0,0 0,0 SDF-1 0,0 0,3 
bFGF 2,0 2,3 IL-16 0,75 1,0 sgp130 1,50 1,3 
FGF-4 2,0 1,8 IL-1Ʉ 0,5 1,0 TARC 0,0 0,3 
FGF-6 1,0 0,8 IL-1Ʌ 0,25 0,8 TGF-Ʌ1 0,0 0,0 
FGF-7 0,5 0,5 IL-1ra 0,75 1,0 TGF-Ʌ3 0,0 0,0 
FGF-9 2,25 2,3 IL-2 0,01 0,3 TNF-Ʉ 0,75 1,0 
Flt-3 Ligand 0,25 0,3 IL-3 0,5 0,8 TNF-Ʌ 1,50 2,3 
Fractalkine 0,0 0,8 IL-4 0,5 0,8 sTNF RII 1,25 1,0 
GCSF 1,00 1,0 IL-5 0,25 0,8 sTNF-RI 1,50 1,3 
GCP-2 0,01 0,5 IL-6 0,75 4,0 TECK 0,75 1,0 
GDNF 1,00 1,5 IL-7 0,25 0,0 TIMP-1 1,75 2,0 
GM-CSF 0,25 0,8 I-TAC 0,75 1,0 TIMP-2 2,5 3,0 
GITR-Ligand 2,00 1,8 Leptin 2,00 2,3 Thrombopoietin 1,50 1,8 
GITR 2,25 1,8 LIGHT 1,00 1,0 TRAIL R3 1,50 1,5 
GRO 2,75 3,0 Lymphotactin 1,75 2,0 TRAIL R4 1,50 2,0 
GRO-Ʉ 2,00 2,0 MIF 2,50 2,5 uPAR 1,25 1,0 
HCC-4 1,00 1,0 MIP-1Ʉ 2,00 2,0 VEGF 1,50 1,3 
HGF 1,50 2,0 MIP-1Ʌ 1,00 1,0 VEGF-D 2,25 2,3 
Abbreviations: AgRP, agouti-related protein; BDNF, brain-derived nerve factor, BLC, B-lymphocyte 
chemoattractant;  BTC,  betacellulin;  CCL-28,  C-C  motif  chemokine  28;  CK  Ʌ8-1  chemokine  Ʌ8-1;  CTACK,  
cutaneous T cell-attracting chemokine; Dtk, growth factor receptor tyrosine kinase; EGF-R, epidermal growth 
factor receptor; ENA-78, epithelial neutrophil activating peptide-78; Flt-3 ligand, Fms-like tyrosine kinase-3 
ligand; GCSF, granulocyte colony-stimulating factor; GCP-2, granulocyte chemotacitc protein 2; GDNF glial-
derived neurotrophic factor; GM-CSF, granulocyte macrophage colony stimulating factor; GITR-ligand, 
glucocorticoid-induced TNFR-related protein ligand; GITR, glucocorticoid-induced TNFR-related protein; GRO, 
growth related oncogene; HCC-4 hemofiltrate C-C chemokine;  I-309, T-lympocyte secereted protein I-309; ICAM-
1, intercellular adhesion molecule 1; ICAM-3, intercellular adhesion molecule 3; IFN-ɇ, interferon-ɇ; I-TAC, 
Interferon-inducible T-cell alpha chemoattractant; LIGHT; M-CSF, macrophage colony stimulating factor; MDC, 
C-C motif chemokine 22; MIG, monokine induced by interferon gamma; NT-3, neurotrophin 3; NT-4, 
neurotrophin 4; PARC, C-C motif chemokine 18; SCF stem cell factor; SDF-1, stromal cell derived factor-1; sgp130, 
sialoglycoprotein 130; TARC, thymus and activation -regulated chemokine; TECK, thymus-expressed chemokine; 
TRAIL R3, tumor necrosis factor related apoptosis-inducing ligand receptor 3; TRAIL R4; tumor necrosis factor 
related apoptosis-inducing ligand receptor 4; uPAR, urokinase plasminogen activator surface receptor;  NT-4, 
neurotrophin 4. 
*bold/gray indicates high and/or changed expression level of factor 
Differentiation potential of adipose tissue extract in 
vitro (I) 
The adipogenic potential of ATE was studied in cell culture assay and with 
qRT-PCR. ATE induced differentiation of hASC towards mature 
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adipocytes. The adipogenic conversion was homogenously seen in hASC 
from 3 days onwards in vitro. Mild adipogenic effect was seen at 125 µg/ml 
upwards with ATE. The effect increased with longer culture time and 
higher concentrations of ATE (up to 2000 µg/ml was tested). The variation 
in adipogenic ability between donors was quantified with ORO extraction 
after ORO staining of triglyserides. ATE samples containing 1000 µg/ml of 
ATE  (n=32) induced 1.5 to 4.1 fold (median 2.28, SD=0.57, CV=24.7%) 
triglyseride accumulation compared to a standard adipogenic induction 
medium (Gregoire 2001; Scott et al. 2011).  No significant difference in 
adipogenesis induction was found between ATE samples at 1 hr (n=17) and 
24 hr (n=15) (p=0.878, SD=0.3507 and CV=9.84%).   
The adipogenesis markers were also studied with qRT-PCR. The key 
switch of adipogenesis, PPARɇ, was induced between 1 and 4 weeks almost 
7-fold with 1200-1500 µg/ml of ATE (p<0.001). The expression of late 
adipogenesis  marker  ACBP  was  low  in  a  week  (1.7  –fold),  but  induced  3-
fold at four weeks. See Figure 2 in the Original Publication I. 
The angiogenic potential of ATE was studied in an in vitro 
angiogenesis assay. The ATE induced time- and dose-dependent induction 
of endothelial cell tubule formation in an angiogenesis in vitro assay. The 
tubules were developed from day 4 onwards. 7 days after ATE induction, 
tubule formation was observed at 450 µg/ml or higher concentrations of 
ATE.  900  µg/ml  and  1300  µg/ml  of  ATE  induced  moderate  to  strong  
induction of tubule formation. The endothelial cell tubule formation at 
1300 µg/ml of ATE resembled the tubule induction of angiogenic positive 
control  (see  Table  II)  with  10  ng/ml  of  VEGF  and  1  ng/ml  of  FGF-2.  See  
Figure 3 in the Original Publication I. However, donor-dependent and 
time-dependent differences existed. 24 hr time point was occasionally 
more favourable to angiogenesis than 1 hr time point. Moreover, the effect 
was not always dose-dependent. 
Soft tissue induction with ATE in vivo (II) 
The ability of ATE to induce angiogenesis and adipogenesis in tissue was 
studied by incorporating ATE into hyaluronan hydrogel and implanting 
the constructs in rat subcutis for 1 to 40 weeks. The implants were initially 
implanted  for  1,  2,  3,  4,  6,  8,  12,  20  and  40  weeks,  from  which  the  time  
points  (1,  4,  12,  20,  40  weeks)  that  presented  the  most  relevant  tissue  
changes, were chosen for further studies.  
Induction of capillary proliferation 
Capillary induction was evaluated microscopically from histological 
samples of implants at 1, 4, 12, 20 and 40 weeks and manually quantified 
 83 
 
 
from 5 different microscopic hpf (400x magnification) at 1 and 4 weeks, i.e. 
prior to adipose tissue accumulation. Both capillary proliferation and 
larger arteriole- like and venule-like vessels were counted from 
hematoxylin-eosin -stained histological slides.  The histology of capillary 
proliferation at the implantation site are seen in Figure 4A and 4B. 
Capillary proliferation with small newly formed capillaries was extensively 
present  at  one  and  four  weeks  in  the  implant-  tissue  interface  in  ATE  -
implants. In rATE, also larger arteriole-like and venule-like vessels were 
seen next to the implant. Control implant did not have any relevant tissue 
changes. At 12, 20 and 40 weeks, few larger vessels were seen in the control 
HA implant. However, in ATE- implants at 12, 20 and 40 weeks, especially 
in rATE-implant, well vascularized, dense, large fat pads, were seen. 
Capillaries were evenly distributed throughout the fat tissue.  
When the capillary count was statistically evaluated, the control 
implant blood vessel number did not differ between 1 and 4 weeks. hATE-
HA –implant induced significantly higher capillary proliferation at 1 week 
(p<0.05) and at 4 weeks (p<0.001) compared to the respective control 
implants. Also, increase in capillary number in rATE-HA –implant 
compared to control implant was seen, however, the result was not 
significant. See also Figure 3 in Original Publication II. 
Adipose tissue accumulation  
The adipose tissue accumulation was visually evaluated from hematoxylin-
eosin -stained samples. At week 1 and week 4, cell penetration into all of 
the implants was seen. Small adipose tissue deposits, indicating 
triglyceride accumulation, were seen at week 1. Control implant did not 
show any relevant tissue changes. At 12 and 20 weeks, well vascularized, 
dense  fat  pads  were  seen  in  rATE  and  hATE  implants.  At  12,  20  and  40  
weeks, rATE-HA implants had induced large fat pad formations, seen as 
several  layers  of  fat  in  tissue  (result  shown  in  Figure  4C).  At  12  and  20  
weeks, modest angiogenesis and fat tissue formation was seen in the 
control HA implant (see Figure 4D), whereas control tissue had fairly 
slight fat accumulation (Figure 4F).  
The adipose tissue accumulation was quantified with a specific 
automated computer assisted analysis tool designed for the purpose 
(Ruusuvuori et al. 2009). The results are seen in Figure 4G. The amount of 
adipose tissue (% from randomly imaged microscopic field, 40x 
magnification) was increased during time, however, at 1 and 4 weeks, there 
was no significant increase in adipose tissue accumulation. At 12 weeks, 
however, rATE-HA -implant contained significantly more adipose tissue 
than the same implant at one week (p<0.05). At 20 weeks, all implants had 
more adipose tissue than respective implants at one week (control implant 
p<0.05, rATE implant p<0.001 and hATE implant p<0.001). Moreover, at 20 
weeks, rATE-HA implant and hATE-HA implant had induced more 
adipose tissue accumulation than control tissue (p<0.05 and p<0.01, 
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respectively). At 40 weeks, all implants, as well as control tissue, contained 
more adipose tissue than respective implants at one week (all significant 
compared to their respective samples at one week, p<0.001). However, at 
40 weeks, rATE-HA and hATE-HA implants had induced more adipose 
tissue accumulation than control implant (both significant, p<0.001) or 
what was seen in control tissue (p<0.001 and p<0.01, respectively).  
Other histological features of the implant 
Nerve bundles, immunostained with anti-neurofilament-68, were detected 
at 12, 20 and 40 weeks, but seldom at the earlier time points. Fibroblast 
proliferation and loose connective tissue formation were observed, 
accompanied with capillary proliferation. This was seen as expanded loose 
connective tissue formation contributing to the increased tissue thickness. 
When microscopically observed, control implants had more connective 
tissue formation and less adipose tissue formation than ATE-implants. 
The change in tissue thickness was evaluated by measuring the 
thickness of the subcutis manually microscopically from histological 
samples at 40 weeks. The results are shown in Fig. 4E. When statistically 
evaluated, all implants had induced significant increase in tissue thickness 
at 40 weeks compared to control tissue (control implant p<0.01, hATE-
implant p<0.001, rATE-implant p<0.001). At 40 weeks, the tissue thickness 
was significantly higher in rATE-implant and hATE-implant (both 
p<0.001), compared to control implant.  
The degradation of control implant was faster than rATE-HA and 
hATE-HA -implants. At 20 weeks, all implants were equally and partly 
degraded  but  still  present  in  tissue.  However,  at  40  weeks,  the  control  
implants were completely degraded. Two of the rATE-HA -implants (out of 
three animals) were degraded completely, but some implant was still 
present in one animal. hATE-HA -implant degradation rate was slower 
than that of other implants, as all of the  hATE-HA -implants were still 
partly present at 40 weeks.   
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Figure 4. Soft tissue induction with adipose tissue extract in vivo (A) 
Capillary formation in hATE –implant at 4 weeks, (B) Capillary formation in 
hATE –implant at 4 weeks, Adipose tissue accumulation at 20 weeks in (C) rATE 
implant, (D) in control implant and (F) in control tissue. (E) The tissue 
thicknesses in implants at 40 weeks and (G) adipose tissue accumulation during 
time. The statistical analysis was performed in 4E and 4G between different 
implants (significancy shown in Fig. 4E and 4F as asterisks), as well as in 4G also 
by comparing each implant to their one week control (significancy shown in Fig. 
4G as hash signs). Scale bar 200 µm in each image. Image modified from Original 
Publication II. 
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The biocompatibility of the adipose tissue extract (II) 
The biocompatibility of the implants was evaluated at 1, 20 and 40 weeks. 
Implants were seen to be often surrounded by a narrow band of 
fibroblasts, but after implant was degraded, no signs of fibrous bands were 
seen. No serious adverse tissue effects occurred. No granuloma, fibrous 
capsule formation, giant cells or necrosis were seen in any of the samples.  
The evaluation of immunological effects of implantation was modified 
from the International Standardization Organization (ISO) ISO-10993:6-
2007 (International Standardization Organization 2007). To be able to 
perform irritating ranking as described in ISO 10993-6:2007, the active 
inflammatory changes were multiplied by two, as similarly also described 
previously (Kotzar et al. 2002; Lehle et al. 2004). The irritation ranking was 
evaluated solely by immunological effects, not with induction of 
vascularization or fatty infiltrate, as these were the desired effects of 
implants. Mild inflammatory cell infiltration was seen in earlier time 
points. At one week, moderate B-cell (CD79a) and mild macrophage 
(CD68) infiltration was seen in control implant, as well as mild infiltration 
of B-cells (CD79a), T-cells (CD3) and macrophages (CD68) in rATE-HA 
and hATE-HA -implants. The polymorphonuclear cell (evaluated from 
hematoxylin-eosin staining) infiltration was low throughout the study.  
When statistically evaluated, none of the implants were found to be more 
irritating than others. The results are seen in Figure 5. CD3 (T-cell) positive 
cell count was significantly higher in rATE-HA implant at 1 week than with 
any other implant and in two later time points (p<0.001) as well as in 
hATE-HA implant at 1 week compared to implants at 20 weeks (p<0.05) 
and 40 weeks (p<0.01).  The CD68 (macrophage) positive cell infiltration 
was significantly higher in control implant at 1 week and at 20 weeks 
compared to control implant at 40 weeks (p<0.01 and p<0.001, 
respectively). Moreover, rATE-HA and hATE-HA implants had 
significantly more macrophage infiltration at 1 week compared to the 
respective implants at 40 weeks (p<0.05 and p<0.01, respectively). Control 
implant had significantly more CD79a positive cells at 1 week than at 20 
weeks of 40 weeks (p<0.05 and p<0.01, respectively), whereas rATE-HA or 
hATE-HA implants did not. During time, the number of inflammatory cells 
was overall decreased and they were completely disappeared at 40 weeks 
from the animals with control implant, when also the implant itself had 
degraded completely. rATE-HA and hATE-HA implants were both present 
at 40 weeks, hATE-HA in each sample and rATE-HA occasionally, and 
some inflammatory cell infiltration was seen (mild CD79a and mild CD68). 
No giant cells of necrosis were detected. The total response (shown in 
Figure  5  as  “result”)  was  evaluated by  summing up the scores  from all  of  
the cells detected. Then the results of rATE and hATE implants were 
subtracted from the control implant. The implants were found to be non-
irritating compared to control implant as evaluated according to ISO (ISO, 
2007). 
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Figure 5. The local effects of implantation. The results are shown as average 
scores  (scale  0=  no  cell  type  detected,  1=  rare,  1-5/hpf  2  =  5-10/hpf  3  =  heavy  
infiltrate, 4 = packed) from 5 different hpf (400x) and from three different 
animals per time point. (A) CD3 score, (B) CD79a score, (C) CD68 score (D) 
polymorphonuclear cell score. The statistical analysis was performed between 
different implants and by comparing each implant at week 1, 20 and 40. The total 
response was evaluated by summing up the individual cell scores and finally the 
results of rATE and hATE implants were subtracted from the result of control 
implant. The implants were found non-irritating as evaluated according to 
ISO(2007). 
Creation of in vitro assays for angiogenesis (I,III,IV) 
Three different angiogenesis in vitro assays were studied. The BJ fibroblast 
and HUVEC angiogenesis assay was optimized and validated to be used as 
a routine method in drug and chemical screening. Two different hASC 
assays, hASC monoculture assay and hASC and HUVEC angiogenesis assay 
Response* 1 week 20 weeks 
 
40 weeks 
 ctrl 
 
rATE-
HA 
 
hATE-
HA 
 
ctrl 
 
rATE-HA 
 
hATE-
HA 
 
ctrl rATE- 
HA 
hATE-
HA 
 
TOTAL SUM 
OF SCORES 8 7,9 7,6 6,3 5,3 5,1 3,4 3,9 4,4 
TOTAL x 2 16 15,8 15,2 12,5 10,5 10,1 6,8 7,87 8,8 
RESULT 
(test-
control) 
 
-- 
0 0 -- 0 0 -- 1,07 2 
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were developed to be used for in vitro tissue models and for tissue 
engineering applications. The morphology of the three in vitro assays 
developed in this study are shown in Figure 6. 
 
 
 
 
Figure 6. The in vitro angiogenesis assays developed in the studies. 
(A) hASC and HUVEC angiogenesis assay, anti-vWf staining, 1:500 (B) hASC 
monoculture  assay,  anti-vWf  staining,  1:500  (C)  BJ  fibroblast  and  HUVEC  
angiogenesis assay, anti-vWf staining, 1:5000. Scale bar 500 µm in each image. 
Optimization of the cell banks used in the in vitro assays (III,IV) 
The isolated HUVEC were tested for their tubule formation capacity in the 
BJ fibroblast and HUVEC angiogenesis assay up to passage ten. The tubule 
formation potency of HUVEC was passage dependent. During cultivation, 
when the passage number increased, the tubule formation decreased. Up 
to passage 4 the tubule formation remained constant and at adequate 
level. The passage number of HUVEC to be routinely used in the BJ 
fibroblast and HUVEC angiogenesis assay was therefore chosen to be 
passage 4 (p4) resulting to the passage of 2 (p2) for liquid nitrogen storage. 
The batch to batch variation of HUVEC was tested with the Linearity and 
Cell Batch Variation Test. All different HUVEC batches had same lower 
and upper limits of detection and the technical quality control criteria 
were accepted with all batches. The variation between the batches was 
small (CV=1.72%). The flowcytometrically identified surface marker 
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expression of HUVEC is seen in Table I in the original article III. The 
surface marker expression profile of HUVEC was mainly corresponding 
with previous reports (Fukasawa et al. 2006; Ichikawa et al. 2006; Korbling 
et al. 2006; Schmidt et al. 2006) and expression of e.g. CD13 (99.4%) CD31 
(94,5%), CD44 (44,5%), vWf (14,5%) and CD202b (31.9%) were detected.  
hASC angiogenesis assays (III) 
We induced the tubule network formation in hASC and HUVEC 
angiogenesis assay or in hASC monoculture angiogenesis assay with 
naturally occurring angiogenic growth factors; EGF, VEGF, bFGF and IGF-I 
(Mehta and Besner 2007). 
In hASC monoculture, the induction towards angiogenesis was not 
reproducible between different experiments. hASC monoculture had high 
passage and donor dependent differentiation capacity towards endothelial-
like cells. hASC formed often short cords in culture, but only occasionally 
tubule network formation. However, vessel supporting pericytic and 
smooth muscle cell markers were seen quite often, despite the lack of 
capillary formation at the area.  
However, when hASC were combined with HUVEC (hASC and 
HUVEC angiogenesis assay) and cultured in HUVEC proliferation medium, 
a remarkable enhancement in cell proliferation, capillary formation and 
induction of maturation were seen in both cells. hASC and HUVEC formed 
reproducibly intensive three-dimensional tubular network. The relative 
mRNA expression of vessel maturation genes PECAM-1, Angiopoietin 1 and 
Caldesmon were studied in both hASC angiogenesis assays. The results of 
the relative expression levels are shown in Figure 3 in the Original 
Publication III. Angiopoietin 1, a molecule regulating blood vessel 
stabilization (Nishishita and Lin 2004) and indicating late stages of tubule 
maturation and stabilization as well as Caldesmon, a smooth muscle cell 
contraction regulator indicating higher differentiation of smooth muscle 
cells (Frid et al. 1992), were significantly expressed in both hASC and hASC 
and HUVEC at day 6. However, Angiopoietin 1 expression was significantly 
increased by day 6 in both hASC monoculture angiogenesis assays and in 
hASC and HUVEC angiogenesis assay (both p<0.05) when compared to 
control. The PECAM-1 expression was significantly increased between day 3 
and 6 in hASC monoculture angiogenesis assay (p<0.05).  PECAM-1 
expression was also increased with hASC+HUVEC, but was not statistically 
significant. Caldesmon expression was increased already at day 3 with both 
hASC monoculture angiogenesis assays and in hASC and HUVEC 
angiogenesis assay (p<0.05) and even more by day 6 (both assays p<0.001).  
In immunofluoresence staining, COLIV, showing the development of 
basement membrane, was widely expressed in hASC and HUVEC 
angiogenesis assay. The expression was co-localized with the developing 
tubules, covering the tubules. In other treatments, basement membrane 
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formation was incomplete. PDGFRɅ, an important receptor in pericytic cell 
recruitment to developing tubules (Nishishita and Lin 2004), was 
extensively seen already at 3 days as dot-like structures in hASC and 
HUVEC, localizing at the areas of developing tubules. Ʉ-SMA, SMMHC 
and calponin immunostainings confirmed that the tubules were 
maturating.  The cell coverage with Ʉ-SMA, SMMHC and calponin was 
partial, often located in the tubule branch points. The confocal laser 
scanning microscopy of basement membrane (COL IV) and tubule 
network (vWf) staining in Figure 7 shows the three-dimensionality (7A) 
and multilayered (7B) nature of the tubule network, showing close to 200 
µm thick tubule network with tubules overlaying each other.  
 
 
 
 
Figure  7.  The  multilayered  tubule  network  formation  in  hASC  and  
HUVEC angiogenesis assay. (A) The 3D projection obtained with confocal 
microscopy  showing  196  µm  thick  tubule  network.  (B)  The  tubule  network  
showing multilayered nature of the network. Tubules crossing each other are 
pointed out with arrows. Tubule network stained with anti-vWF (1:100) and anti-
COL IV (1:100). Image reproduced from Original Publication III. 
 
hASC and GFP-infected HUVEC angiogenesis assay was developed in order 
to evaluate which cells were responsible for the massive tubule network 
formation in hASC and HUVEC angiogenesis assay. The anti-von 
Willebrand factor –stained co-cultures mostly consisted of a mosaic and 
two different populations of vWf-positive cells, approximately half of the 
cells in the assay being GFP-positive, and the other half of the anti-von 
Willebrand factor positive cells being GFP-negative. See Figure 2 in the 
Original Publication III.  
Intra-laboratory pre-validated angiogenesis in vitro assay (IV) 
The objective of this part of the study was to intra-laboratory validate the 
optimized test method for testing the modulators of angiogenesis. The co-
culture assay published by Bishop et al. (1999) and Friis et al. (2003) was 
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further developed, optimized and finally validated in the laboratory in 
accordance with Organisation for Economic Co-operation and 
Development (OECD) guidelines (OECD, 2005), The European Agency for 
the Evaluation of the Medicinal products guideline CPMP/ICH/281/95 
(EMEA, 1996) and European Centre for the Validation of Alternative 
Methods (ECVAM) guidance documents (ECVAM, 2002).  
Method optimization 
In the method optimization phase, the most optimal culture conditions 
and detection limits for the assay were verified, and the optimal values and 
criteria for the validation of the assay were determined. The sensitivity of 
the method was evaluated in Linearity and Cell Batch Variation Test by 
studying linearity and the upper and lower limits of detection of HUVEC 
batches. The lowest combination of growth factors that induced tubule 
formation was a combination of 1 ng/ml VEGF and 0.1 ng/ml FGF-2. This 
was selected as the lower limit of detection of the assay. The growth factor 
cocktail that caused maximal tubule formation was a combination of 10 
ng/ml VEGF and 1 ng/ml FGF-2. This combination was upper limit of 
detection and the positive control of the assay. The tubule formation was 
dependent on the growth factor concentration, and with higher growth 
factor concentrations than positive control value, the response decreased.  
Validation acceptance criteria 
The prevalidation phase defines the robustness and intra-laboratory 
reproducibility of the method and how well it predicts the effects in vivo 
(Curren et al. 1995). In the intra-laboratory validation study, the total 
variation of the test method was tested by two different technicians and by 
two different result analysts in three separate tests (referred to as “days” in 
Table 5 in the Original Publication IV). This part was performed by 
studying the negative and positive control values, i.e. the predetermined 
lower and upper limits of the assay. Negative control was always zero (0). 
The CV% of positive control was found to be between 6.27-7.82%. The 
CV% between microscopic analysts was very low; CV% was 0.34% when 
the results of technician 1 were analyzed and 2.37%, when the results of 
technician 2 were analyzed. The total CV including the total error of the 
test method was CV= 1.39%. All the results were in the predetermined 
technical criteria set for positive control. However, the variation in the 
positive control, that was accepted in the technical criteria, resulted in 
significant overall person to person variation. The acceptance criteria and 
the results of the validation study are summarized in Table 5. in the 
Original Publication IV. 
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Reference chemical study 
A chemical study with the method was performed to test the performance 
and the reproducibility of the assay. Six reference chemicals, angiogenesis 
inhibitors, were tested in the assay by two different technicians. The 
validation criteria were used as acceptance criteria for the test.  All the 
potent inhibitory chemicals selected for the assay inhibited tubule 
formation, and the results between technicians were in good concordance 
(see Figure 4 in the original publication IV). The estimated values of 
concentrations causing mild, moderate or strong inhibition in this assay 
are summarized in Table IX. The validation of the in vitro test system 
includes the comparison of the efficacy of in vitro test with known in vivo 
effects. The results of the chemical test were compared with previous 
publications on different in vitro assays, animal tests and maximal plasma 
concentrations (Cmax) from clinical trials. The results were comparable to 
other in vitro methods, however, the validated method seemed to respond 
to inhibitors at lower concentrations whan previously used in vitro assays, 
especially when acetyl salicylic acid, levamisole and anti-VEGF were 
evaluated.  Compared to selected animal tests, the interpretation of the 
results was more difficult, but hardly any correlation was detected. Results 
from clinical trials were in good concordance with acetyl salicylic acid and 
erlotinib (moderate results in the assay were comparable to Cmax), in 
some extent with levamisole, 2-methoxyestradiol, thalidomide and anti-
VEGF (mild inhibition was comparable to Cmax). The validated in vitro 
assay seemed more sensitive as inhibitory action was present at lower 
concentrations, especially with anti-VEGF. 
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Discussion 
There is an urgent clinical need for adipose tissue substitute that would 
induce rapid vascularization and sustained formation of adipose tissue 
(Choi et al. 2010). Patients with soft tissue defects may have scars, defects 
and other abnormalities as well as impaired tissue function that affects the 
patients in their everyday life, as well as emotionally (Patrick 2001). 
Treating of the soft tissue defects and chronic wounds are a medical and 
economic challenge to health care (Ferreira et al. 2006; Levin and Condit 
1996). It has been estimated that approximately 5 million U.S. chronic 
wound patients generate annual over $20 billion costs for health care and 
the costs are growing 10% every year (Gordois et al. 2003). In Australia, 
wounds are estimated to cost $2.6 billion a year, and in Germany, the costs 
for care and treatment of pressure ulcers are between €1-2.3 million 
(Muller-Buhl et al. 2012). Moreover, according to American Society for 
Plastic Surgeons (ASPS) 13.8 million cosmetic plastic surgery procedures 
and 5.5 million reconstructive plastic surgery procedures were performed 
in the U.S. in 2011, with a total rise of 87% in cosmetic procedures during 
the last decade (ASPS, 2011). 
Adipose tissue engineering has traditionally focused on restoring the 
volume loss with not much emphasis on tissue function (Vermette et al. 
2007). Tissue engineered fat in vitro and in vivo has been studied 
tremendously during the last decade. However, there are still no 
universally accepted in vitro or in vivo models for neoadipogenesis (Bucky 
and Percec 2008). The main reason for the failure of all the current soft 
tissue applications is inadequate angiogenesis (Torio-Padron et al. 2007; 
Vermette et al. 2007).  Impaired angiogenesis leads to failure of healing of 
ulcers, wounds, and infarcted tissue (Cao 2010; Fan et al. 1995). The 
successful induction of vascularization is therefore a key factor in 
successful tissue engineering. Solely revascularization of ischemic tissues 
would benefit millions of people (Carmeliet and Jain 2011).  
Clinically relevant in vitro angiogenesis models are needed for tissue 
engineering applications, but also for investigation of the in vivo 
angiogenesis process (Lai et al. 2009; Ucuzian and Greisler 2007) e.g. for 
the treatment of cancer, macular degeneration or peripheral and coronary 
vascular diseases (Nillesen et al. 2007; Ucuzian and Greisler 2007). 
Understanding the role of angiogenesis in adipose tissue is of especial 
importance, as vasculature regulates both the adipose tissue mass 
development and adipose tissue reduction and obesity is a cause of a 
distruction in normal adipose tissue homeostasis (Rupnick et al. 2002). 
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Since no adequate application for soft tissue restoration nor optimal in 
vitro assays exist, the main aim of the current study was to study induction 
of angiogenesis and adipogenesis. In the first part of the study, a novel 
acellular angiogenic and adipogenic agent was produced and its effect was 
studied in vitro and in vivo. The angiogenesis induction for the tissue 
engineered constructs is a prerequisite and a solution is urgently needed. 
Moreover, the creation of reproducible and relevant in vitro angiogenesis 
assays aids in the angiogenesis research, but also in the development of 
implantable tissue engineered products. Therefore, the second part of the 
study focused on developing in vitro methods for angiogenesis induction. 
In the following chapters, the main findings will be discussed.  
The cytokine content of adipose tissue extract 
As adipose tissue is known to secrete numerous cytokines and to have a 
role as an active endocrine organ, the freshly isolated adipose tissue is 
suspected to be the most potential natural source of bioactive factors for 
inducing angiogenesis and adipogenesis (Nillesen et al. 2007; Saiki et al. 
2006). The growth factor and cytokine content of the adipose tissue extract 
revealed that ATE contains all the relevant angiogenesis stimulating (e.g. 
VEGF, IGF-I, bFGF, angiogenin, leptin, HGF, IL-6, IL-8) factors 
(Christiaens and Lijnen 2010; Ziche et al. 2004), main adipokines 
(adiponectin, leptin) and a wide variety of other regulators of angiogenesis 
and adipogenesis (e.g. Ang-2, TIMPs). The cytokine profile of adipose 
tissue extract largely corresponds to previous reports that have studied 
hASC cytokine release (Verseijden et al. 2009; Rehman et al. 2004; Kilroy et 
al. 2007; Traktuev et al. 2008; Rubina et al. 2009) or cytokine release from 
adipose tissue explants (Fain et al. 2004). In addition, IFN-ɇ, TNF-Ʉ, IL-8, 
bNGF, MCP-1, MCP-2 and leptin, known to be secreted by macrophages or 
mature adipocytes, were detected at high or moderate levels in the current 
study. In contrast to Fain et al. (2004) adipose tissue explant study, the 
cytokine levels of ATE were mainly increased during time, only two 
angiogenesis inducers, NAP-2 and angiogenin (Gao and Xu 2008), 
occasionally possibly seen to decrease. NAP-2 contributes to early 
inflammatory process (Petersen et al. 1994) and vascular regeneration after 
injury (Gleissner et al. 2008). Angiogenin is reported to be elevated in 
obesity (Silha et al. 2005). Nevertheless, although the overall number of 
cytokines was increased over time, only two factors, VEGF and IL-6, were 
significantly increased during incubation. Increase in VEGF and IL-6 
expression indicates possible induced angiogenic potential of the 24 hr 
extract. The 24 hr rise in VEGF may be due to increase in IL-6, which is 
known to enhance VEGF production in adipose tissue (Rega et al. 2007). 
Moreover, hypoxic conditions, which may have occured during ATE 
incubation, contribute to increase in VEGF production (Rehman et al. 
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2004). Roughly, overall, according to the main factors present in ATE, ATE 
is a proliferation inducing (bFGF, GRO), angiogenic (IL-6, VEGF-D, bFGF, 
leptin, angiogenin, angiopoietin-2, GRO, MIF, NAP-2) and adipogenic 
(leptin, bFGF, IGFBP-6, adiponectin) agent, that is also capable of 
activating further cytokine production in tissue (Fas/TNFRS6, IL-6, MIF). 
The clinical use of high concentrations of inductive growth factors can lead 
to unwanted side effects, such as abnormal vascular function or 
stimulation of tumor growth (Brey et al. 2005; Epstein et al. 2001) and has 
led to withdrawal of growth factor related drugs from the market. It is 
noteworthy, that also several endogenous angiogenesis/adipogenesis 
inhibitors were detected in ATE (such as TIMPs), which suggests that a 
correct interplay of factors in tissue remodeling can be achieved with ATE, 
suspectedly preventing any excess stimulatory effect and thus increasing 
the clinical safety of this material.  
It has become evident that obese individuals secrete more 
inflammatory cytokines than lean individuals (Fain et al. 2004) and that 
the excess cytokine production has inductive effects on adipose tissue 
accumulation. As adipose tissue samples are commonly obtained from 
plastic surgery resections or from liposuctions, it must be kept in mind 
that some of the patients may have increased BMI and therefore the 
extract cytokine profile might reflect the donor BMIs. Increase in IL-6, IL-
10, MIF, MIP-1Ʉ, TIMP-1, TIMP-2, TECK, ENA-78, PARC, VEGF-A, -C and –
D, Ang-2, HGF and angiogenin in obese individuals has been reported 
(Fain et al. 2004; Silha et al. 2005; Skopkova et al. 2007). Moreover, higher 
levels of adiponectin, leptin, HGF (Fain et al. 2004) and RANTES 
(Skopkova et al. 2007) have been reported in lean individuals. On the other 
hand, adiponectin, TNFɄ and IL-6 have also reported to remain stable 
between lean and obese states (Skopkova et al. 2007). In ATE, adiponectin, 
leptin, and RANTES were expressed at quite high levels. This, along with 
the possible decrease in NAP-2 and angiogenin, and low IL-6 and VEGF in 
the 1 hr time point, indicate that the cytokine content of ATE seem not to 
correlate to, or have a profile of obese adipose tissue or chronic 
inflammation. It is also noteworthy, that leptin and adiponectin, as 
circulating hormones, are mainly released by adipose tissue to the body 
(Fain et al. 2004). Therefore, they are secreted at considerably high levels 
from adipose tissue compared to most other factors. However, as there is 
increasing knowledge on the importance of appropriate combination of 
factors for inductive angiogenesis/adipogenesis, the paracrinically acting 
factors, although secreted at much lower levels than circulating hormones, 
are invaluable in contributing to the effects obtained with ATE. Therefore, 
the changes in the overall composition of ATE are assumably more 
important than the actual concentrations of factors.  
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Adipose tissue extract is an angiogenesis and 
adipogenesis inducing agent in vitro 
The ability of ATE to induce angiogenesis and adipogenesis were studied 
in respective in vitro assays. ATE was shown to induce accelerated and 
significantly higher triglyseride accumulation in hASC compared to 
commonly used standard adipogenic treatment (Gregoire 2001). The 
strongly adipogenic nature of ATE was also seen as increased expressions 
of ACBP, and especially, key inducer of adipogenesis, PPARɇ2, 
superseeding the standard IBMX induced adipogenic treatment both 
morphologically and genetically. The most striking finding is that contrary 
to a standard adipogenic treatment, a vast majority of the cells 
homogenously differentiated towards mature adipocytes even at low 
concentrations, and moreover, no contact inhibition for triglyseride 
accumulation was required. The strongly adipogenic nature of ATE in vitro 
is not surprising, and it directly reflects the source and cytokine profile of 
ATE. ATE is therefore useful for modeling natural adipogenesis in vitro.  
The ATE-induced endothelial cell tubule formation in vitro was 
morphologically similar to the VEGF and bFGF induction. Angiogenesis 
induction was achieved with moderate protein levels, and as this induction 
was time-dependent, it was, although also dose-dependent, still more 
composition-dependent. The possible candidates for the increased 
angiogenic capability of the later time point are VEGF and IL-6, the only 
two factors that were significantly increased during incubation. The 
angiogenic nature of ATE in in vitro angiogenesis assay is moderate. This 
seems  to  be  one  advantage  of  ATE.  No  excess  angiogenesis  was  seen  in 
vitro. 
Adipose tissue extract induces sustained soft tissue 
formation in vivo 
No adequate information on the long-term stability and inductibility of 
different adipose tissue engineering strategies exists. Previous studies show 
some adipose tissue formation but no vascularization (Hemmrich et al. 
2005; Tsuji et al. 2009), limited longevity of the adipose tissue or lack of 
information on long-lasting (over 3 month) effects (Borzacchiello et al. 
2007; Hemmrich et al. 2005; von Heimburg et al. 2003). The specific 
question in the current study was whether ATE could be inductive in soft 
tissue without cell incorporation and second, whether the effect could last 
in the implantation site after biomaterial degradation.  
The extensive capillary proliferation early after implantation was 
evident. The induction of vascularization in vivo during the first four weeks 
was well in line with the protein release rate of the implants detected in 
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our study in vitro. As with in vitro studies, the angiogenesis/adipogenesis 
effective concentrations of ATE were fairly low, suggesting that the orderly 
combination of factors is truly more important than high concentrations of 
factors. The concentrations of inductive factors should rather mimic 
naturally occurring concentrations.  
The histology of the newly formed adipose tissue resembled that of 
endogenous adipose tissue when observed at late time points. It is an 
important finding that ATE is able to induce efficient tissue restoration 
with normal vascular remodeling. No excess angiogenesis was seen in the 
formed fat pads in vivo. Nevertheless, the adipose tissue volume and tissue 
thickness were increased several folds in ATE-implants compared to 
control tissue and control implant, and the formed fat pads were seen to 
remain in tissue until the follow up time (9 months). The sustained effect 
in this extent, and for this period of time, has not been demonstrated 
previously by any of the applications, neither with hASC seeded scaffolds 
nor with acellular scaffolds.  
The timing of adipose tissue appearance in ATE-implants most likely 
reflects the release properties of the crosslinked hyaluronic acid used in 
the study. The inductive factors are first released by diffusion from the 
implant, and later simultaneously with the degradation of the material. 
The particular hyaluronic acid is clinically used soft tissue filler, designed 
to be a slowly-degrading material in tissue. The inductive effect could be 
possibly accelerated with a selection of a different type of biomaterial. 
Moreover, the concentration dependency of the extract shown in in vitro 
studies indicates that even higher inductive effect could be possibly 
reached with increased concentrations of inductive extract. It is also 
noteworthy, that tissue fillers like hyaluronic acid are known to contribute 
to angiogenesis and adipogenesis (Hanson et al. 2011; Hemmrich et al. 
2008; Ventura et al. 2007) in tissue. This  was  seen  in  this  study  with  the  
specific control tissue filler as an increase in the tissue thickness and 
adipogenesis compared to normal rodent tissue. The tissue increase in 
control tissue filler, was, however, often contributed by connective tissue 
formation induced by the control implant, not actual adipose tissue 
accumulation. 
Interestingly, it was recently reported that bone marrow mononuclear 
cells used in tissue engineered vascular grafts had disappeared from the 
grafts within a few days (Roh et al. 2010; Hibino et al. 2011). The newly 
formed vessels in tissue were then found to be solely derived from the 
host, and the cells in the graft actually just promoted the host tissue 
regeneration instead of themselves differentiating into the vessels (Hibino 
et al. 2011). A significant proportion of the beneficial effects of cell therapy 
have also previously reported to be from the angiogenic factors secreted by 
the cells (Rehman et al. 2004). These studies support our hypothesis and 
current results that efficient acellular inductive angiogenesis/adipogenesis 
is possible by using solely an appropriate combination of natural cytokines, 
eluting from the scaffold into tissue (Roh et al. 2010; Hibino et al. 2011).  
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Donor and species variability of adipose tissue extract 
The cytokine profiles of different ATE lots revealed slight variations 
between donors. There were also donor differences in adipogenesis 
induction. All ATE lots induced adipogenesis, nevertheless, some lots were 
slightly more potent than others. The observed differences between donors 
may reflect differences in the BMIs of the individuals, values which were 
not systematically followed during the study. The donor age seemed not to 
have effect on the adipogenic potential. The possible effect of gender could 
not be determined, as most of the donors were females. The lot differences 
of ATE were detected also in angiogenic potential, but angiogenesis 
induction was also composition (time-point) dependent. The found 
differences may also be due to the preparation process of ATE. The 
processing of very different sizes of tissue samples and changes in the 
extraction volumes contributed to the variation in protein and cytokine 
concentrations.  
ATE had also species variability in the protein concentration and in the 
in vivo effectivity. Human ATE induced more capillary formation in vivo 
than rat ATE in rat subcutaneous tissue. Higher protein concentration of 
human ATE compared to rat ATE may have had contribution to this. 
Nevertheless, as rat ATE was overall slightly more efficient in adipose 
tissue accumulation in rat tissue than human ATE, the results could also 
reflect the marked known differences between rodent and human adipose 
tissue in the expression, response and function of adipokines (Wang et al. 
2008). As human (xenogenic) factors seem to act differently in rat adipose 
tissue remodeling than rat (allogenic) factors, these possible species 
differences set challenges to the further in vivo studies with the extract.  
Adipose tissue extract, a novel acellular inductive 
agent, is potential for clinical use 
The adipose stem cell therapy is currently the most common soft tissue 
engineering strategy. Although promising results have been achieved with 
this therapy approach, it is time-consuming as cells need to be expanded in 
vitro. Moreover, in this approach, more than one operation is required, and 
only autologous therapy is possible. In the current study, we aimed at 
producing a cell-free, protein-rich extract with an easy and gentle 
extraction method. As this procedure does not require any special 
equipment or refined conditions, it could be carried out e.g. in operation 
room conditions during surgery. The protein and growth factor 
concentrations of several extracts from different extraction conditions 
were measured during this study.  The extraction times varied from 15 min 
to 48 hours, and several aliquots were also collected from single sample.  
Two different incubation conditions were also tested (room temperature 
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or  5%  CO2 buffered 37°C cell incubator. In all of the conditions, protein 
and growth factor concentrations were similar. Even when short time 
points were used, efficient protein production was achieved. Interestingly, 
in a clinical point of view, the sample taking, extraction and applying the 
extract into patient wound or defect would be possible during single 
surgery from one small tissue sample. This could reduce markedly costs 
and support patient comfort and recovery.  
Chronic wounds are an enormous current medical challenge. It has 
been reported, that the costs of chronic leg ulcer treatment could be 
reduced by a careful selection of the dressing product (Muller-Buhl et al. 
2012).  In  addition,  in  studies  in  Sweden  and  UK,  the  frequency  and  
duration of dressing changes was shown to have substantial effect on the 
treatment costs (Ragnarson Tennvall and Hjelmgren 2005). ATE could be 
potentially used to induce also chronic wound healing. The use of ATE, if 
successful, would progress healing, or, importantly, reduce the frequency 
of needed dressing changes. This could markedly reduce the cost of 
chronic wounds.   
During in vivo studies, no adverse reactions or fibrous capsule 
formation occurred. The evaluation of inflammatory effects in tissue 
revealed that ATE-implants did not show increase in irritating effects over 
the control implant. However, mild inflammatory cell inftilration was seen 
shortly after implantation. Macrophage infiltration is known to be a key 
inducer of adipose tissue remodeling (Rhodes 2007; Saillan-Barreau et al. 
2003; Sun et al. 2011). Moreover, macrophages are known to promote 
angiogenesis (Ye and Gimble 2011) and to be necessary for neoformation of 
vessels in host tissue (Hibino et al. 2011). A mild inflammatory response, 
also seen in the current study, is therefore known to be beneficial and 
according to Breuer (2011), actually essential for the tissue regeneration. 
Moreover, there was no difference in the immunological reactions between 
allogenic (rat ATE in rat) and xenogenic (human ATE in rat) implants. A 
key feature of a soft tissue substitute, good biocompatibility (Choi et al. 
2010) was therefore achieved with the ATE-HA implant; thus, ATE can be 
considered to be biocompatible and safe and has potential to be used 
clinically.  
However, there are current reports on the negative side-effects of the 
clinical use of inductive growth factors. Possible side-effects of angiogenic 
growth factor therapy can be hemangioma, hypertrophic scar or 
glomeruloid body formation, and systemic effects tumor formation, 
retinopathy or arthritis (Beer et al. 1998; Dor et al. 2003; Markkanen et al. 
2005; McHoney 2010). A warning example is Regranex (becaplermin), a 
recombinant PDGF-B protein product approved for clinical use for the 
treatment of chronic wounds.  Regranex gel contains 100 µg of protein per 
1g of gel, and is commonly administered daily. In long term safety studies 
this product users have been reported to have increased cancer risk. (EMA, 
2010) Moreover, individuals treated with recombinant human therapeutic 
proteins have been reported to develop autoantibodies against cytokines 
and growth factors such as to interferons, interleukins, GM-CSF and TNF 
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(Arend et al. 1991; Meager et al. 2010). However, the biological significance 
of these auto-antibodies is unclear as they may be associated with 
pathological conditions, but they are also suggested just to be part of 
normal mechanism preventing growth factor overstimulation (Sauerborn 
et al. 2011; van der Meide and Schellekens 1997). Due to the reported side-
effects, the use of high concentrations of inductive growth factors should 
be avoided (Brey et al. 2005; Epstein et al. 2001). Although these safety 
precautions may not be underestimated, ATE is suspected to be safer than 
currently used growth factor therapies. As ATE has the natural 
combination of a variety of factors, the overall doses of adipogenic and 
angiogenic factors are markedly reduced from single growth factor 
therapies. Compared to e.g. Regranex, the concentrations of growth factors 
are 100 to 1000 times lower, and when combined to a biomaterial, the 
concentration and activity of the extract can be controlled. Moreover, in 
animal tests, only one fairly low dose was found to be inductive, so the 
administration schedule would be most likely less frequent than with 
current methods. Finally, ATE is not a recombinant protein product, but it 
is completely natural, and the first clinical studies would be performed 
with autologous extract.  
Development of human in vitro vascular analogues 
From July 11, 2013 onwards, the European Union directive prohibits the 
performance of animal testing in the European Union for cosmetic 
products or ingredients of cosmetic products (EC 2009). As the currently 
used (angiogenesis) in vitro methods have wide variability and they often 
lack in vivo relevance (Auerbach et al. 2003), there is an urgent need for 
appropriately validated in vitro assays that would provide relevant results 
of the effects of drugs and chemicals in human. Human cell and tissue 
models represent a more reliable way of predicting the effectiveness of 
drugs in humans, and moreover, adequate in vitro assays would reduce the 
use of animal tests in preclinical screening studies.  
hASC contribute to angiogenesis and have multipotentiality in 
hASC angiogenesis in vitro assays 
The recruitment of pericytes along vascular tubules is an essential step in 
vessel maturation, needed to induce basement membrane formation and 
to prevent vessel regression (Gerhardt and Betsholtz 2003). The failure of 
endothelial cells to establish mature structures in vitro is  often  due  to  
absence of stabilizing mural cells (Merfeld-Clauss et al. 2010). Moreover, 
the  creation  of  3D  tissue  models  and  di-  or  tri-culture  of  cells  may  be  
challenging. Several different solutions e.g. fibroblast feeder layers, coating 
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of wells or 3D matrices with natural ECM components, as well as inductive 
growth factors have been tested while trying to improve the survival and 
induction of the cells. However, scaffolds, often used to create 
multilayered tissue constructs, may also interfere with the cell-to-cell 
interactions and the cell assembly (Norotte et al. 2009). 
In the current study, our specific effort was to develop an inductive 
prevascular-like network with properties of mature vessels that could be 
used for studying angiogenesis in vitro, and especially, that would aid in 
the development of tissue models by acting as a natural scaffold and 
supporting target cell differentiation. The specific emphasis was on use of 
unsorted ASC. As ASC have strong plasticity, high proliferation and 
differentiation capacity and they provide angiogenic environment by 
secreting inductive factors, they are an ideal component for in vitro 
angiogenesis modeling. Unsorted stromal cells have been previously 
shown to promote angiogenesis and myogenesis in vivo (Iwashima et al. 
2009; Kang et al. 2010). Moreover, co-culture of endothelial cells and 
mesenchymal cells has been previously shown to promote formation of 
capillary network in vitro and in vivo (Koike et al. 2004; Merfeld-Clauss et 
al. 2010; Kang et al. 2009). However, only few studies have previously 
characterized human hASC and HUVEC scaffold-free co-cultures and their 
angiogenic properties (Merfeld-Clauss et al. 2010; Traktuev et al. 2008) or 
hASC monoculture angiogenic properties (Miranville et al. 2004). 
hASC and HUVEC angiogenesis assay had excellent reproducility and 
minimal limitations in technical performance. Although the proliferative 
and differentiation capacity of adult stem cells is known to decrease after 
serial passaging (Hass et al. 2011; Lindroos et al. 2009), hASC and HUVEC 
co-culture was passage independent. The growth factor induction and co-
culture induced high proliferation of both cell types in hASC+HUVEC co-
culture, which may explain the passage independency. hASC did not only 
stimulate the tubule formation and maturation, but were also seen to 
differentiate into endothelial-like cells in this system.  This was seen as a 
mosaic of GFP-infected HUVEC and hASC in angiogenesis assay. 
Moreover, in hASC monoculture, PECAM-1 gene expression was increased 
indicating endothelial differentiation, which was also seen as vWf-positive 
tubules in hASC monoculture. Although freshly isolated hASC, or more 
precisely, stromal-vascular fraction cells, may contain microvascular 
endothelial cells (Rehman et al. 2004; Wosnitza et al. 2007), hASC 
identical to this study have been shown to lack the expression of 
hematopoietic and angiogenic markers e.g. CD31, CD106 and CD146 
(surface marker expression 0.6± 0.7, 0.7± 0.7 and 0.4± 0.2, respectively 
(Lindroos et al. 2009; Lindroos et al., 2010). This study therefore supports 
the earlier studies (Planat-Benard et al. 2004; Rubina et al. 2009; Traktuev 
et al. 2008) and demonstrates that hASC are able to contribute to vessel 
formation maturation in vitro by stimulating endothelial cell proliferation 
and also by differentiating into mature vascular structures with 
endothelial, pericytic and smooth muscle cell properties. Moreover, the 
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basement membrane formation in this extent has not been shown in any of 
the previous in vitro studies. Most of the current angiogenesis assays do 
not express basement membrane markers and therefore can be suspected 
to consist of immature tubules with no essential elements of mature 
tubules.  
The tissue engineered grafts are limited in size due to a lack of proper 
induction of vascularization (Jain et al. 2005; Norotte et al. 2009). hASC 
and HUVEC angiogenesis tubule network assay could be particularly 
suitable for engineering different tissue models. The hASC and HUVEC 
angiogenesis assay presents an advanced feature, a three-dimensional 
multilayered tubule network, with thickness of around 200 µm. This 
tubule network could allow the creation of multilayered, yet, scaffold-free, 
tissue constructs, especially for soft tissue applications. This dynamic 
structure might provide the missing inductive platform for 3D tissue 
models, the major issue that has not yet been resolved for in vitro tissue 
models or implantable constructs. 
To accelerate the use of this angiogenesis assay in tissue engineered 
constructs, we developed a xeno-free modification for the assay. From a 
clinical point of view, to use this tubule network in implantable constructs, 
animal derived components such as fetal serum should essentially be 
removed. Moreover, the cells used in the constructs must be tissue- and 
donor-specific. Currently, HUVEC are used as endothelial cells in the 
assay, as they are a widely used cell source, easy to obtain, carefully 
characterized in our laboratory and have excellent proliferation capacity in 
vitro. However, as endothelial cells are known have specialized phenotypes 
depending on the tissue (Jain 2005), tissue –specific endothelial cells are 
most likely required for tissue grafts. However, endothelial cells are also 
known for their high plasticity and the ability to respond to their 
microenvironment (Garcia-Cardena et al. 2001). According to the study by 
Merfeld-Clauss et al. (Merfeld-Clauss et al. 2010), the endothelial cells 
could be possibly replaced with any tissue specific endothelial cells (e.g. 
microvascular endothelial cells in adipose tissue) with no effect on tubule 
formation capability in this type of in vitro assay. Therefore, we can suspect 
that this developed tubular network platform is easily modified to be 
suitable in several different in vitro tissue model applications where dense 
tubular network is needed. However, for implantable constructs, the 
comparison of different endothelial cell sources must be performed. 
Adipose stromal cells, on their behalf, have less immunogenicity and 
their potential to be used for allogenous therapy is currently under 
prominent research. For this reason, the hASC monoculture assay here 
studied would be especially fascinating for tissue engineering. The 
angiogenic differentiation potential of hASC monoculture was presented in 
this study. In addition to the current study, the tubule formation in plain 
hASC scaffold-free monoculture has been shown previously only by 
Miranville et al. (Miranville et al. 2004) and Heydarkhan-Hagvall et al. 
(Heydarkhan-Hagvall et al. 2008). Nevertheless, the hASC monoculture 
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angiogenesis assay requires further optimization of the hASC culture 
conditions, such as cell number, the compositition of inductive factors and 
cell passage, as the hASC monoculture angiogenesis assay did not show 
adequate repeatability to differentiate towards capillaries. There were 
outstanding differences between donors, which is largely due to the 
heterogenous nature of SVF cells.  
Intra-laboratory validated in vitro angiogenesis assay is a relevant 
bioassay in predicting effects of chemicals in humans 
In intra-laboratory validation, we standardized an angiogenesis in vitro 
assay under GLP quality system, and studied how well the assay reflects 
the current in vivo results.  
Optimization of the critical steps and factors in this assay, especially 
HUVEC isolation, passage and master bank were crucial for the outcome 
and the adequate performance of the assay. Due to the biological nature of 
the test, slight variation in positive control value was observed, and 
therefore we were obliged to allow a range of values (with minimal average 
score of 5.75 in the analysis scale) for positive control in the technical 
quality control criteria. This pre-set acceptance criteria resulted in 
significant person to person variation between technicians in positive 
control value during validation. Although a routine method, this assay is a 
biological system that is very sensitive to even minimal changes in the 
technical procedure. The variation between technicians did not have affect 
on the overall outcome of the performance of the assay, as the results were 
compared to internal positive and negative controls in each testing time in 
the assay. Interestingly, the inhibitory concentrations from our study were 
in good concordance with the therapeutic plasma concentrations from 
clinical studies (maximal concentration in plasma, Cmax), however, they did 
not reflect the results of currently used animal tests.  
Currently, the applicability domain of this intra-laboratory validated 
angiogenesis assay contains pharmaceuticals and conditioned media of 
cells. However, for optimal biological performance, the variable test items 
may require adjustments in the setup of this assay, like adjustment of test 
media. The only restrictions of the assay are the solubility and solvent of 
the test chemicals, as the commonly used solvents (DMSO, ethanol and 
methanol) have accepted limits in cell culture (approximately maximal 
0.5% of the cell culture medium). This may in some cases reduce the 
concentrations of chemicals that can be tested in the assay. 
It is also noteworthy, that in validation, the reproducibility and 
applicability of the assay is tested and GLP assures the adequate quality of 
the studies, but neither of these guarantees the biological relevance of the 
assay. This needs to be studied in optimization phase prior to validation 
phase. Therefore, in addition to the reference chemicals, the functionality 
of the assay was earlier tested in the optimization phase with the following 
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chemicals; endostatin, interleukin-1 soluble receptor 1 (IL-1 SR1), suramin, 
mevinolin, paclitaxel, fumagillin, anti-EGFR, cyclo-oxygenase-2-specific 
inhibitor NS-398, indomethacin, VEGF, bFGF, anti-bFGF and PDGF-B.  
The overall variation in controls, and variation between different test 
times was very low (CV%=1.39% and CV=0.34-2.37%, respectively). This 
angiogenesis assay can be therefore concluded to be successfully intra-
laboratory validated and can now be used for drug screening in the 
preclinical phase of drug discovery. Moreover, as most of the validated in 
vitro assays are used for safety studies, this currently validated in vitro 
angiogenesis assay is one of the few validated routine assays that are used 
for efficacy studies in addition of being applicable also for testing of 
angiotoxicity of chemicals.  
Future perspectives  
The demand for the engineered soft tissue is increasingly growing. 
Effective cell free constructs would be potent for allogenous use and allow 
the development of commercially available”off-the-shelf” products. As ATE 
was found to be biocompatible, it has potential to become this type of 
tissue product. However, the results of small animal studies need further 
verifications until applied to clinical therapy, and therefore large animal 
studies need to be performed. In addition, the first clinical studies will be 
performed with autologous material.  
In the current in vivo study, the administration of the injectable 
implant was performed only once, at the onset of the study, with fairly low 
concentrations of ATE, but with effective results. Therefore, the inductive 
effect of ATE could potentially be even improved with repeated 
administration or increased dose of ATE. However, the optimal dose and 
efficacy, and administration schedule, i.e. the therapeutic window for ATE 
requires further investigation. Moreover, the systemic toxicity and the 
safety assessment (non-tumorigenicity) of ATE, especially in high 
concentrations, as well as the effects of simple ATE substance need to be 
evaluated. The current research for ATE therefore concentrates on 
improvement of safety of the product as well as on the development of 
allogenous product and studying the optimal dosage of ATE.  
The possibility to modify the cytokine content of ATE is also a tempting 
thought. As the angiogenic and adipogenic factors are known to act in a 
cascade in different phases of the refined process of adipose tissue 
formation  as  reviewed  e.g.  by  Papetti  and  Herman  (2002),  there  is  a  
possibility to stimulate different phases of angiogenesis /adipogenesis by a 
simple adjustment of the extraction time of ATE, or further tailoring ATE 
by precipitating single or a few cytokines from the extract with presently 
available methods. For instance, as IL-6 is known to e.g. impair blood-
brain-barrier function by increasing the permeability of endothelium 
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(Abbott et al. 2006), the presence of high IL-6 in ATE, in certain cases, 
might not be preferable. This could be avoided by simply using the 1hr 
time point extract, or by precipitating IL-6 from the 24 h extract. However, 
the optimal composition of ATE for different applications needs further 
studies. It also remains to be resolved whether the range of indications of 
ATE could be broadened i.e. whether the inductive effect of ATE applies to 
other tissues than soft tissue. 
Interestingly, proresolving lipid mediators, resolvins, synthesized from 
omega-3 fatty acids, are known to suppress inflammation, and deficiency 
of these mediators leads to delayed wound healing and inflammation in 
diabetes (Hellmann et al. 2012).  As an adipose tissue product, ATE also 
contains lipids and could therefore well be a source of these wound healing 
inducers. This would be an additional advantage of ATE. However, prior to 
further conclusions in this task, the precise triglyceride concent of ATE 
needs to be further characterized.  
No in vitro assay of natural adipogenesis yet exists (Bucky and Percec 
2008; De Gemmis et al. 2006). However, it is important to obtain 
information on expression and functional role of pro-and anti-angiogenic 
components as well as adipogenic agents in in vitro models of adipogenesis 
(Christiaens  and  Lijnen  2010).  As  ATE  was  found  to  be  efficient  for  
modeling natural adipogenesis in vitro, ATE has potential to be used in the 
development of a standardized adipogenesis cell assay for preclinical drug 
and chemical screening. For in vitro use, the donor-dependent variation 
seen in our study, is possible to overcome by using a pool of extracts from 
several donors. ATE may also be used as a specific cell culture supplement 
in different in vitro studies. 
The applicability domain of the intra-laboratory validated angiogenesis 
assay will be possibly further expanded in future studies by testing the 
assay with different chemicals. Moreover, the possibility of the use of hASC 
and HUVEC angiogenesis assay in drug and chemical screening will be 
explored. 
An intriguing application for future studies of tissue engineering and 
3D in vitro tissue models would be the combination of ATE and hASC 
tubule network structure. It has been reported that immature vessels are 
mostly regressed in vivo and are not integrated into host tissue after 
implantation (Rouwkema et al. 2006). However, if we combined ATE with 
the tubules, we could possibly enhance the blood vessel maturation and 
integration into host tissue and even further, create a unique 3D soft tissue 
model. 
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Summary and conclusions 
In this study, a novel cell-free angiogenesis and adipogenesis inducing 
agent, adipose tissue extract (ATE) was produced from mature human 
adipose tissue. ATE contains a wide variety of promotors of angiogenesis 
and adipogenesis and induces angiogenesis and adipogenesis in vitro and 
in vivo. The second part of the study focused on developing in vitro 
methods for angiogenesis induction. hASC angiogenesis assays were 
developed and fibroblast and HUVEC angiogenesis co-culture assay was 
validated. 
 
Based on the studies performed, the main findings and conclusions are: 
 
x ATE contains all the most important angiogenic and adipogenic 
factors of mature adipose tissue. 
x ATE induces adipogenesis and angiogenesis in vitro in respective 
cell culture assays. 
x ATE is able to induce efficient soft tissue restoration with 
normal vascular remodeling. The effect is sustained, and 
remains after scaffold degradation. 
x ATE-implants do not show increase in irritating effects over the 
control implant. No adverse reactions or fibrous capsule 
formation occur, and therefore ATE can be considered to be 
biocompatible and safe and applicable for clinical use.  
x The current study supports the previous results that the tissue 
engineering grafts need not to contain cells.  The natural 
inductive cytokines, in an appropriate combination, eluting 
from the scaffold into tissue, can be sufficient for the stimulating 
angiogenic/adipogenic effect. 
x ATE was found to be efficient for modeling natural adipogenesis 
in vitro, and therefore ATE has potential to be used in the 
development of a standardized adipogenesis routine cell assay to 
be used in preclinical phase of drug discovery for efficacy testing 
of novel drugs for e.g. obesity and diabetes. 
x Through optimization and intra-laboratory validation, we 
obtained a routine angiogenesis assay with minimal variation 
(overall CV=1.39%). This human cell in vitro angiogenesis assay 
mimics the in vivo effects, and thus it can be used to supplement 
animal tests in efficacy and angiotoxicity testing of 
pharmaceuticals and chemicals.  
     109 
 
 
x The adipose stromal cell 3D multilayered mature tubule network 
is an excellent tool for studying cell interactions during vascular 
development, and moreover, is useful for designing 
multilayered, scaffold-free, in vitro tissue models or implantable 
constructs.  
   
It can be concluded that ATE is an angiogenic and adipogenic substance 
that is also capable of inducing cell proliferation and activating further 
cytokine production in tissue. ATE has potential to be used to induce 
revascularization of ischemic tissues and to be used in tissue products that 
fail due to inadequate vasculature in soft tissue engineering. The 
developed in vitro angiogenesis assays are valuable tools for basic research 
and preclinical drug screening studies as well as for tissue engineering 
applications.  
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Human Adipose Tissue Extract Induces Angiogenesis
and Adipogenesis In Vitro
Jertta-Riina Sarkanen, M.Sc.,1–3 Ville Kaila, B.Med.,1 Bettina Mannerstro¨m, Ph.D.,3–5 Sari Ra¨ty, M.D., Ph.D.,6
Hannu Kuokkanen, M.D., Ph.D.,7 Susanna Miettinen, Ph.D.,3–5 and Timo Ylikomi, M.D., Ph.D.1,2,8
The induction of adequate vascularization, a major challenge in tissue engineering, has been tried with nu-
merous methods but with unsatisfactory results. Adipose tissue, an active endocrine organ with dense vascu-
lature, secretes a wide number of angiogenic and adipogenic factors and seems an attractive source for these
bioactive factors. We produced a novel cell-free extract from mature human adipose tissue (adipose tissue extract
[ATE]) and analyzed the ability of this extract to induce angiogenesis and adipogenesis in vitro and studied the
cytokine and growth factor composition of ATE with ELISA and cytokine array. We demonstrate that ATE,
when added as cell culture supplement, effectively induced triglyceride accumulation in human adipose stem
cells at concentrations from 200 mg/mL upward in less than a week and caused elevated levels of adipocyte
differentiation markers (proliferator-activated receptor gamma and acyl-CoA-binding protein) when treated
with at least 350 mg/mL of ATE. ATE induced angiogenesis from 450 mg/mL upward after a week in vitro. ATE
contained numerous angiogenic and adipogenic factors, for example, vascular endothelial growth factor, basic
fibroblast growth factor, interleukin-6, adiponectin, angiogenin, leptin, and insulin-like growth factor-I, as well
as lower levels of a wide variety of other cytokines. We here present a novel cell-free angiogenesis- and
adipogenesis-inducing agent that is cell-free and easy to produce, and its effect is dose dependent and its
composition can be easily modified. Therefore, ATE is a promising novel agent to be used for angiogenesis
induction to overcome the challenge of vascularization and for adipogenesis induction in a wide variety of tissue
engineering applications in vitro and in vivo. ATE is also efficient for reproduction and modeling of natural
adipogenesis in vitro for, for example, obesity and diabetes studies.
Introduction
Nutrient shortage due to inadequate vascularizationlimits the size of tissue-engineered implants1–4 and
prevents their successful use in tissue engineering.3–5 Gly-
cosaminoglycans, single synthetic growth factors (e.g., vas-
cular endothelial growth factor [VEGF] or basic fibroblast
growth factor [bFGF]), or in vitro differentiated cells have
been used for angiogenesis induction,1,6–8 but the results
have been only modest and the obtained effect transient.9 To
gain sustained and significant induction of angiogenesis, si-
multaneous effect of multiple growth factors is needed.1,10,11
However, the use of synthetic growth factors is expensive,
and moreover, tailoring the optimal combination of growth
factors has proven to be extremely difficult.12
Adipose tissue is an active endocrine organ consisting of
mature adipocytes, adipose stem cells, macrophages, endo-
thelial cells, and extracellular matrix components.13,14 Adi-
pose tissue is rich in blood vessels and a major source of
growth and differentiation promoting factors (cytokines and
adipokines)10,15–20 known to release bioactive levels of, for
example, leptin, adiponectin (Acrp30), angiotensin II, acyla-
tion-stimulating protein, adipsin, resistin, prostaglandins,
glucocorticoids, cytokines (for example, tumor necrosis fac-
tor-a [TNF-a], interleukins [IL] 1b, 6, 8, and 10), chemokines
(for example, CC-chemokine ligand 5 [CCL5] and monocyte
chemoattractant protein [MCP-1]), growth factors (for ex-
ample, hepatocyte growth factor [HGF], VEGF, bFGF, insu-
lin-like growth factor [IGF], and transforming growth factor
b [TGF-b]), angiopoietins 1 and 2 (Ang-1 and Ang-2, re-
spectively), and plasminogen activator inhibitor 1.2,10,20–26
Several adipose tissue-derived growth factors and cytokines
stimulate angiogenesis and the formation of an extensive
capillary network required for the expansion and optimal
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function of the adipose tissue.25,27–29 The endocrine functions
and secreted factors as well as angiogenesis of adipose tissue
are reviewed in detail by Galic et al.,30 Poulos et al.,13 Kar-
astergiou and Mohamed-Ali,14 Kershaw and Flier,17 and
Christiaens and Lijnen.31 The advance of the use of adipose
tissue is that it is abundant and easy to obtain with minimal
invasive methods.20,32 Further, the methods for adipose stem
cell isolation and differentiation are well described in litera-
ture.33–35
In the light of the present knowledge of adipose tissue
function, we explored a new way of producing growth- and
differentiation-promoting factors of human origin. We ex-
tracted the factors from mature adipose tissue without af-
fecting the cell viability and studied the composition and
angiogenic and adipogenic potential of this adipose tissue-
derived cell-free extract (adipose tissue extract [ATE]). We
characterized ATE protein and cytokine content and studied
the effect of ATE on angiogenesis and adipogenesis at dif-
ferent concentrations in vitro. Three important factors were
characterized quantitatively with ELISA and a large variety
of factors qualitatively and semiquantitatively with cytokine
array. We here describe a novel method for producing
growth- and differentiation-promoting factors from human
adipose tissue and the detailed composition of the extract as
well as the ability of the extract to induce angiogenesis and
adipogenesis. We demonstrate that this protein-rich extract
has strong angiogenic and adipogenic potential and could be
used in angiogenesis or adipogenesis induction in a wide
variety of tissue engineering applications in vitro and in vivo
to overcome the major challenge of induction of vasculari-
zation.
Materials and Methods
The study was conducted in accordance with the Ethics
Committee of the Pirkanmaa Hospital District, Tampere,
Finland (R03058, R08028). The adipose tissue samples were
obtained from surgical operations and the human umbilical
cords from scheduled caesarean sections with informed
consents at the Tampere University Hospital, Tampere, Fin-
land.
ATE preparation
Adipose tissue specimens were cut into small pieces and
transferred into 50mL tubes (Sarstedt). Equal volume of
phosphate-buffered saline (PBS) or, for cell culture studies,
Dulbecco’s modified Eagle’s medium Nutrient Mixture F-12
(DMEM/F12; Gibco, Invitrogen) without supplements were
added into the tube and left for a minimum of 15min for
growth factor secretion at room temperature or at 37C in a
CO2 incubator. The tube was gently shaken during incuba-
tion. The extracts were collected at predetermined time
points (15min, 30min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, or 24 h),
centrifuged at 12,000 rpm for 5min, and sterile-filtered
through 0.2 mm filter (Sarstedt). The aliquots were stored at
- 20C until use.
Protein and growth factor expression of ATE
ATE samples derived from different patients and/or col-
lected at several different time points (described earlier) were
analyzed for the total protein concentration with BCA pro-
tein Assay Kit (Pierce Biotechnology) at different aliquots.
The total protein concentration was measured from all of the
tested time points (15min, 30min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, or
24 h). The concentrations of VEGF, bFGF, and IGF-I were
measured from a large number of human ATE samples from
two different time points (1 and 24 h) by enzyme-linked
immunosorbent assay (ELISA; Quantikine Human VEGF
Immunoassay, Quantikine Human FGF basic Immunoassay,
or Quantikine Human IGF-I Immunoassay, respectively;
R&D Systems) according to the manufacturer’s instructions.
All standards and samples were measured as duplicates.
Cytokine array analysis
Altogether, 120 growth factors and cytokines were tested
from six different extract samples at two different time points
(1 and 24 h) with RayBio Human Cytokine Antibody Array
C Series 1000 (RayBioTech, Inc.). The array was performed
according to the manufacturer’s instructions. The chemilu-
minescence was detected with FluorChem 8800 imaging
system (Alpha Innotech). The chemiluminescent signals were
measured with FluorChem software v. 3.1. and analyzed
qualitatively and semiquantitatively.
Isolation and culture of human adipose stem cells
Stem cell isolation procedure was performed as previously
described.33,35,36 Briefly, human adipose tissue specimens
were cut into small pieces and enzymatically digested with
0.05% collagenase I (Invitrogen) in DMEM/F12 for 60min at
37C in a gyratory water bath. The digested tissue was
centrifuged at 600 g for 10min at room temperature. The
digested tissue was filtered through a 100mm filter (Sarstedt),
centrifuged, and filtered through a 40mm filter (Sarstedt).
Human adipose stem cells (hASCs) were seeded in DMEM/
F12 supplemented with 1% l-glutamine (l-glut; Gibco), 1%
antibiotic–antimycotic mixture (AB/AM; Gibco), and 15%
human serum (HS; Cambrex) into 75 cm2 cell culture flasks
((Nunc EasyFlask; Nunc) and allowed to attach overnight.
The next day, the cells were washed several times with PBS,
and the medium was changed to remove the debris. The
hASCs were maintained at 37C under a 5% CO2 air atmo-
sphere at a constant humidity. When to the cells reached 70%
confluence, they were divided at a ratio of 1:2–1:3 or further
used for adipogenesis studies.
Adipogenesis induction
To initiate adipogenic differentiation, hASCs were plated
at early passages (p1–p5) at a density of 10,000 cells/cm2.
The next day, six different culture conditions were applied to
hASCs. Cells were cultured in (1) the hASC culture medium:
DMEM/F12, 1mM l-glut, 1% AB/AM, and 15% HS; in (2)
the adipogenic control medium: DMEM/F12, 10% fetal bo-
vine serum (FBS), 1% AB/AM, 1% l-glut, 33mM biotin
(Sigma Aldrich), 17mM pantothenate (Sigma), 100 nM insulin
(Sigma), 1 mM dexamethasone (Sigma), and 0.25mM iso-
butyl-methylxanthine (IBMX; Sigma; IBMX was left in the
adipogenic culture medium for the first 24 h only); in (3)
DMEM/F12, supplemented with 15% HS, 1% penicillin/
streptomycin (Gibco), 1mM l-glut, and 350 mg/mL of ATE;
in (4) DMEM/F12, supplemented with 15% HS, 1% penicil-
lin/streptomycin, 1mM l-glut, and 700 mg/mL of ATE; in (5)
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DMEM/F12, supplemented with 15% HS, 1% penicillin/
streptomycin, 1mM l-glut, and 950 mg/mL of ATE; and in
(6) DMEM/F12, supplemented with 15% HS, 1% penicillin/
streptomycin, 1mM l-glut, and 1200 mg/mL of ATE. The
medium was changed every 3 days. Cells were cultured for
1 week, 2 weeks, or 4 weeks and examined for lipid accu-
mulation by Oil-Red-O (ORO; Sigma) staining or further
used for quantitative reverse transcriptase-polymerase chain
reaction (RT-PCR).
ORO staining
Lipid accumulation was assessed at 1 and 4 weeks after the
onset of the differentiation experiment by using ORO staining.
hASCs were fixed with 4% paraformaldehyde (Sigma) for
20min and rinsed several times with PBS. ORO stock (0.5%)
solution was prepared in 100% isopropanol (Merck & Co.,
Inc.), and for staining, it was diluted 3:2 in distilled water, left
at room temperature for 10min, and filtered through standard
filter paper. hASCs were incubated with 60% isopropanol for
2–5min, incubated with the ORO staining solution for 5min,
and rinsed several times with PBS. Phase-contrast micro-
graphs of the stained cells were taken with Nikon Eclipse TS-
100 microscope (Nikon) equipped with Nikon DS Camera
Control Unit DS L-1 (Nikon). The images were processed with
Adobe Photoshop software 7.0 (Adobe Systems) and Corel
Draw software 10.0 (Corel Corporation). The extent of ATE-
induced triglyceride accumulation was evaluated with ORO
extraction at 1 week from hASCs cultured with 1mg/mL of
ATE. The PBS was removed from wells and the wells were
allowed to dry. ORO was extracted from the cells by 10min
incubation with 100% isopropanol. The absorbance of the
extracted ORO from hASCs was measured at 510nm with
Victor3 1420 Multilabel Counter (Perkin Elmer).
Quantitative RT-PCR
Primers used for adipogenesis-specific genes were acyl-
CoA-binding protein (ACBP), a protein increased in cells
with high turnover of fatty acids,37 peroxisome proliferator-
activated receptor gamma (PPARc), a key inducer of adipo-
genesis and in part responsible for the induction of ACBP
during adipocyte differentiation,37 and a reference house
keeping gene ribosomal protein large P0 (RPLP0). All oli-
gonucleotides were from Oligomer Oy and are shown in
Table 1. The total RNA was extracted from 7 or 28 days
cultured hASC using TRIzol (Invitrogen) following the
manufacturer’s protocol. cDNA was synthesized using High-
Capacity cDNA Reverse Transcriptase Kit (Applied Biosys-
tems) according to manufacturer’s instructions. Quantitative
RT-PCR analysis was performed in a 96-well optical reaction
plate with an ABI Prism 7000 sequence detector (Applied
Biosystems Inc). Reactions were performed using SYBR
Green PCR Master Mix kit (Applied Biosystems), 50 ng
cDNA sample, and 10mM primers using conditions of 10min
at 95C, followed by 45 cycles of 15 s at 95C and 60 s at 60C.
All reactions were performed in duplicates. The results were
processed with ABI Prism 7000 PCR Quantification Software
(Applied Biosystems). Relative RNA expression was calcu-
lated in comparison to RPLP0 RNA expression using the
method by Pfaffl38:
Ratio of relative expression= (Etarget)DCP target (control sample)/
(Eref)
DCP ref. (control sample)
Coculture of human umbilical vein endothelial cells
and fibroblasts
The human umbilical vein endothelial cells (HUVECs)
were isolated from human umbilical cord veins as described
by Jaffe et al.39 Briefly, the cord was separated from the
placenta, the umbilical vein was cannulated with a 20G
needle, and the needle was secured by clamping the cord
over the needle with a surgical clamp. The vein was perfused
with PBS to wash out blood and then the opposing end of the
umbilical vein was clamped with a surgical clamp. Subse-
quently, the vein was infused with 0.05% collagenase I. The
umbilical cord was incubated in a cell incubator at 37C for
15min. After incubation, the collagenase I solution contain-
ing HUVECs was flushed from the cord by perfusion with
PBS into a 50mL polypropylene tube (Sarstedt). The cells
were centrifuged at 200 g for 10min, washed once with
medium, centrifuged again, resuspended in EGM-2 BulletKit
medium (Lonza), and seeded into 75 cm2 flasks. Medium
was changed every 3 days.
Human foreskin fibroblasts, BJ cell line, were purchased
from American Type Culture Collection (CRL-2522; ATCC)
and cultured in minimal essential medium (Gibco) supple-
mented with 10% FBS, 1% l-glut, 1% nonessential amino
acids (Gibco), and 1% AB/AM. To study the angiogenic
potential of the ATE, an angiogenesis coculture assay was
established as previously described by Friis et al.40 and Sar-
kanen et al.41 Briefly, fibroblasts were seeded at a density of
20,000 cells/cm2 into 48-well plate and were grown to con-
fluence (3 days). Next, the HUVECs were seeded on top of
confluent fibroblast cultures at a density of 4000 cells/cm2 in
EGM-2 BulletKit medium and were allowed to attach over-
night before angiogenesis induction.
Angiogenesis induction
Five different treatments were applied to cells the day
after plating HUVECs on top of the BJ fibroblasts (described
earlier). Treatments were (all in duplicates) (1) negative
control: the endothelial cell basal medium (EBM-2; Lonza)
supplemented with 0.1% gentamicin (GA-1000 from EGM-2
BulletKit), 2% FBS, and 1% l-glut; (2) positive control: EBM-2
supplemented with 2% FBS, 0.1% GA-1000, and 1% l-glut, as
well as 10 ng/mL VEGF (R&D Systems) and 1 ng/mL bFGF
(Sigma); (3) EBM-2 supplemented with 2% FBS, 1% l-glut,
0.1% GA-1000, and 450 mg/mL of ATE; (4) EBM-2 supple-
mented with 2% FBS, 1% l-glut, 0.1% GA-1000, and 900mg/
mL of ATE; (5) EBM-2 supplemented with 2% FBS, 1%
L-glut, 0.1% GA-1000, and 1300 mg/mL of ATE. The media
Table 1. Oligonucleotide Primers Used
for Quantitative Reverse Transcriptase-Polymerase
Chain Reaction Experiments
Antigen Sequence (5¢–3¢)
RPLP0 F-AATCTCCAGGGGCACCATT
R-CGCTGGCTCCCACTTTGT
ACBP F-GCAACTGTGGGCGACATAAA
R-GGCCTTGCCCGTGAAGT
PPARc2 F-CAGTGTGAATTACAGCAAACC
R-ACAGTGTATCAGTGAAGGAAT
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were changed once during the culture. The cells were cul-
tured for 7 days before the immunocytochemical staining
with an endothelial cell-specific antibody.
Immunocytochemistry
The endothelial tubules in angiogenesis coculture assay
were visualized with von Willebrand factor antibody
(monoclonal anti-vWF produced in rabbit; Sigma) immuno-
fluorescence staining. Cells were washed three times with
PBS, fixedwith ice-cold 70% ethanol for 20min, permeabilized
with 0.5% Triton X-100 ( JT Baker) for 15min, and blocked for
unspecific staining with 10% bovine serum albumin (Sigma)
for 30min. After blocking, cells were incubated with primary
antibody (anti-vWF, 1:500) at 4C overnight. The following
day, cellswerewashed three timeswith PBS, incubated 30min
with secondary antibody (polyclonal Antibody to Rabbit IgG
FITC; Acris Antibodies GmbH; 1:500), and washed again
three times with PBS. After staining, 500 mL of PBS was left in
the cell culture wells, and plates were stored at 4C. Fluores-
cence was visualized with Nikon Eclipse TS100 microscope
equipped with Nikon DS Camera Control Unit DS L-1, and
images were processed with Adobe Photoshop software and
Corel Draw software 10.0.
Statistical analyses
All statistical analyses were performed and graphs were
processed with GraphPadPrism 5.0 (GraphPad Software,
Inc.). Protein concentrations from different ATE aliquots
were subjected to one-way analysis of variance (ANOVA)
followed by Tukey’s multiple comparison test and growth
factor concentration measurements to nonparametric Mann–
Whitney test. RT-PCR results were subjected to one-way
ANOVA with Tukey’s multiple comparisons test. The vari-
ation in ATE-induced adipogenesis was analyzed with un-
paired t-test. Differences were considered significant when
*p< 0.05, **p< 0.01, and ***p< 0.001.
Results
Protein and growth factor expression of ATE
The total protein concentration was measured with BCA
Protein Assay Kit (Fig. 1A). The protein concentration was
generally highest at 1 and 2h, after which the protein con-
centration decreased with time. From the tested time points,
three time points were chosen for future use. The selected
total protein concentrations (determined with calculated
mean) were 2.017mg/mL (standard deviation [SD]= 0.5222)
at 1 h, 1.783mg/mL (SD= 0.1516) at 2 h, and 1.120mg/mL
(SD = 0.1917) at 24 h. Extracts that were incubated in PBS or
in cell culture medium (DMEM/F12) or incubated at room
temperature or at 37C in a cell culture incubator had similar
protein concentrations.
The concentrations of IGF-I (Fig. 1B), bFGF (Fig. 1C), or
VEGF (Fig. 1D) were measured with ELISA. The IGF-I con-
centration was significantly higher at 1 h than at 24 h (1 h
median = 709.6; 24 h median = 126.2; p< 0.0148). The bFGF
concentrations did not significantly differ from each other
between time points (1 h median = 217.0; 24 h median= 522.2;
p < 0.1031). In contrast to other growth factor results, the
VEGF concentrations were significantly higher at 24 h than at
1 h (1 h median= 6.020, 24 h median= 72.36, p< 0.0001).
Adipogenic potential of ATE
The adipogenic potential of ATE was tested by culturing
hASCs up to 4 weeks with ATE (Fig. 2A). As a negative
control, hASC culture medium (cultured for 14 days) and, as
a positive control, adipogenic induction medium (cultured
for 28 days) were used. hASCs were cultured in the presence
of 350, 500, 700, or 1200mg/mL of ATE in 15% HS supple-
mented medium for 14 days. ATE was shown to induce a
homogeneous, dose-dependent, adipogenic conversion to a
majority of cells in the culture from early days (3) onward
in vitro. Mild adipogenic effect was seen when at least
FIG. 1. Total protein concen-
tration and selected growth
factor concentrations of ATE.
Total protein concentrations (A)
were measured with BCA pro-
tein assay fromATE samples at
1, 2, and 24h and IGF-I (B),
bFGF (C), and VEGF (D) con-
centrations with ELISA from
ATE samples at 1 and 24h. The
median is shown in each graph
as a horizontal line. The signif-
icance was tested for total pro-
tein concentrations with
nonparametric Kruskal–Wallis
test followed by Dunn’s multi-
ple comparison post-test and
for single growth factors with
Mann–Whitney test (*p<0.05,
**p<0.01, and ***p<0.001).
ATE, adipose tissue extract;
VEGF, vascular endothelial
growth factor; bFGF, basic
fibroblast growth factor; IGF,
insulin-like growth factor.
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200 mg/mL of ATE was used (data not shown), the effect
being more extensive when longer culture times or higher
concentrations of ATE (up to 2000 mg/mL tested; data not
shown) were used. The results represent average of at least
10 separate experiments, each performed as duplicates. The
results in Figure 2 are from 1h extracted ATE containing
1.4mg/mL protein. The variation in ATE-induced triglycer-
ide accumulation between different adipose tissue samples
was quantified with ORO extraction. ATE samples containing
1mg/mL of ATE (n = 32) induced 1.5- to 4.1-fold (median
2.28, SD = 0.57, CV = 24.7%) triglyceride accumulation com-
pared with adipogenic control treatment. No significant dif-
ference in adipogenesis induction (calculated from the same
samples) was found between 1 h (n= 17) and 24 h (n= 15) ATE
samples ( p= 0.878, SD = 0.3507, and CV = 9.84%).
The results of the relative mRNA expression levels are
shown in Figure 2B. The expression of adipogenic markers
was dependent on time and dose. One week after the onset
of differentiation treatments, only ACBP expression showed
mild 1.7-fold induction, when compared with negative con-
trol (hASC culture medium). However, at 4 weeks, ACBP
expression was increased threefold with high concentrations
of ATE (1200–1500 mg/mL). Similarly, PPARg expression
was induced almost sevenfold with 1200–1500 mg/mL of
ATE, when compared with controls, and was significantly
higher at 4 weeks than at 1 week ( p < 0.0001). The adipogenic
control medium did not cause elevated expression levels of
adipogenesis-related genes in either of the time points.
Angiogenic potential of ATE
The angiogenic potential of ATE was tested by culturing
fibroblasts and HUVECs in angiogenesis coculture assay for
7 days with ATE. As a negative control, the HUVECs were
grown in normal endothelial cell growth medium. As a
positive control (Fig. 3), the HUVECs were treated with
angiogenic growth factors, 10 ng/mL of VEGF, and 1ng/mL
of bFGF. In the presence of ATE, tubule-like structures were
developed in the angiogenesis assay from day 4 onward
(data not shown). Treatment with ATE stimulated time- and
dose-dependent induction of tubule formation in the assay
and production of typical long, thin, branched capillary-like
structures that were very similar to the angiogenesis positive
control, VEGF/bFGF treatment. At day 7, tubule formation
was observed in angiogenesis coculture assay treated with
450, 900, or 1300 mg/mL of ATE. The results represent av-
erage of at least 10 separate experiments, each performed as
duplicates. The results in Figure 3 are from 1h extracted ATE
containing 1.8mg/mL protein, 120 pg/mL bFGF, 140 pg/mL
IGF-I, and 3.6 pg/mL VEGF.
Cytokine expression pattern of ATE
Altogether, 120 growth factors and cytokines were tested
from six different extract samples at two different time points
(1 and 24 h). The results of the array are shown in Supple-
mentary Figure S1; Supplementary Data are available online
at www.liebertonline.com/tea. Generally, at 24 h, more cy-
tokines were released than at 1 h. All of the highly expressed
cytokines at 1 h, angiogenin, adipocyte complement-related
protein 30 (Arcp30, adiponectin), IGF-binding protein 3
(IGFBP-3), tissue inhibitor of matrix metalloprotease 2 (TIMP-
2), and fibroblast-associated/tumor necrosis factor receptor
superfamily member 6, were stably released and were also
high at 24 h. However, IL-6, leptin, neutrophil-activating
protein 2, CCL5 (e.g., RANTES), Ang-2, bFGF, FGF-9, growth-
regulated oncogene (GRO), IGF-binding protein 6 (IGFBP-6),
macrophage migration inhibitory factor, TIMP-2, VEGF-D,
macrophage inflammatory protein 1a, IL-8, tumor necrosis
factor-related apoptosis-inducing ligand receptor 4, IL-12 p40,
and macrophage-stimulating protein expressions were in-
creased over time and were very high or high at 24 h, but not
FIG. 2. Adipogenic differentiation of hASCs in the presence of different concentrations of ATE. (A) The hASCs were
cultured for 14 days, except adipogenic control, which was cultured for 28 days. As a negative control, hASC culture medium
was used. Different concentrations of ATE were applied as cell culture supplement causing dose-dependent adipogenic
differentiation of hASCs. The cells were stained with Oil-Red-O. Scale bar: 100 mM in each image. (B) The relative mRNA
expression levels of PPARg and ACBP after 1 or 4 weeks of differentiation. Data are presented as mean– standard deviation.
The significance was tested with one-way analysis of variance followed by Tukey’s multiple comparison test (*p< 0.05,
**p < 0.01, and ***p < 0.001). hASC, human adipose stem cell; PPARg, proliferator-activated receptor gamma; ACBP, acyl-CoA-
binding protein. Color images available online at www.liebertonline.com/tea
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at 1 h. IL-6 had a significant increase ( p< 0.001) as tested with
one-way ANOVA after semiquantitative analysis of chemi-
luminesence signals with FluorChem software v. 3.1. Mod-
erate or low levels of numerous other cytokines, especially at
24 h, were released, as seen in Supplementary Figure S1.
Discussion
An effective method for angiogenesis induction is urgently
needed in the tissue-engineered constructs. Adipose tissue
will not develop unless there is adequate blood vessel for-
mation in the developing tissue, and moreover, to function
efficiently as an endocrine organ, an extensive vasculariza-
tion in adipose tissue is needed.42 Adipose tissue itself se-
cretes considerable amounts of multiple angiogenic and
adipogenic factors in appropriate combination to the new
adipose tissue to develop. Therefore, the freshly isolated
adipose tissue can be suspected to be the most potential
natural source of bioactive factors for inducing angiogenesis
and adipogenesis.1,25 In fact, adipose stem cell-conditioned
medium, widely studied previously,2,10,19,20,22,25,43,44 has
shown to promote endothelial cell survival and tubule for-
mation as well as to stimulate wound healing. In this study,
our aim was to find out whether extracted components from
mature adipose tissue are effective and useful in inducing
especially angiogenesis to overcome the challenge of vascu-
larization and further adipogenesis in soft tissue engineering.
In contrast to previous studies, we specifically aimed at
producing a cell-free, protein-rich extract from viable human
adipose tissue cells with an easy extraction method. This
procedure could be carried out, for example, in operation
room conditions during surgery for autologic transfer of
these factors. The viability of those hASCs that were first
used for ATE extraction was further tested in our study by
isolating the cells from these adipose tissue specimens and
culturing them for several passages. The hASCs had normal
morphology and proliferation capacity (data not shown).
ATE was shown to contribute to adipogenesis when at
least 200mg/mL of ATE was used in cell culture. The adi-
pogenic differentiation of hASCs was seen less than after 1
week in vitro with ATE, and a vast majority, if not all, of the
cells were homogenously differentiating toward mature ad-
ipocytes, already with fairly low concentrations of ATE. ATE
was shown to induce accelerated and even fourfold higher
triglyceride accumulation compared with previously used
adipogenic control treatment.2,45 Donor-dependent adipo-
genic ability was seen to some extent, but not the time-
dependent ability. Important adipogenic genes, ACBP, as
well as PPARc, suppression of which has been previously
shown to impair angiogenesis,46 were significantly increased
(approximately three or sixfold, respectively) with ATE-dif-
ferentiated cells compared with control. ATE is therefore
efficient for reproduction and modeling of natural adipo-
genesis in vitro. This type of appropriate and reproducible
in vitro model for adipogenesis does not yet exist.47
Angiogenesis induction, on its behalf, required often
higher concentrations of ATE, at least 450mg/mL, than adi-
pogenesis induction. However, ATE-induced angiogenesis
was dependent on donor and time, 24 h being occasionally
more favorable to angiogenesis than 1 h. All the different
batches of ATE were able to induce adipogenesis, but not
necessarily angiogenesis, especially at lower concentrations.
On the other hand, in some cases at 24 h time point, angio-
genesis was effectively induced at 450 mg/mL, but the
FIG. 3. Tubule formation of HUVECs in the presence of ATE in angiogenesis coculture assay. Different concentrations of
ATE were applied as cell culture supplement for dose-dependent induction in tubule formation of HUVECs. Cells were
cultured for 7 days and immunostained with von Willebrand factor primary antibody (1:500; Sigma) and secondary antibody
(polyclonal antibody to rabbit IgG FITC; Acris Antibodies). As a negative control, HUVEC culture medium was used.
Positive control was treated with 10 ng/mL of VEGF and 1ng/mL of bFGF. Scale bar: 500 mM in each image. HUVEC, human
umbilical vein endothelial cell. Color images available online at www.liebertonline.com/tea
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angiogenic effect did not increase with higher concentrations
of ATE. This effect was also seen in our previous angiogen-
esis study with VEGF and bFGF,41 when increase in the
growth factor concentration increased the tubule formation
only until certain threshold. Therefore, the lower and upper
limits of angiogenic potential of ATE need to be further
carefully studied. Overall, ATE induced morphologically
similar tubule formation as well-known inducers of angio-
genesis, VEGF, and bFGF. The present study therefore con-
firms the previous results that combination of several
inductive factors, and in appropriate combination, is bene-
ficial for inducing angiogenesis.1,10,11 To further evaluate the
responsible factors for the angiogenic and adipogenic effect
in ATE, we analyzed a number of growth factors and cyto-
kines involved in tubule formation, in stabilization of blood
vessels, as well as in triglyceride accumulation, as reviewed,
for example, by Semenza,11 Ziche et al.,48 and Papetti and
Herman.49 We found that ATE contains a wide variety of
these crucial factors at levels that have also previously shown
to be bioactive.10,20 The analyses revealed that ATE contains
high levels of angiogenesis-stimulating (e.g., VEGF, IGF-I,
bFGF, angiogenin, leptin, HGF, IL-6, IL-8) and -inhibiting
factors (e.g., TIMP-2, Ang-2, adiponectin, also known as
Acrp30),31,48 the most abundant being VEGF, IL-6, angio-
genin, and adiponectin, of which VEGF and IL-6 expression
was significantly increased over time, indicating the induced
angiogenic potential of 24 h extract. The 24 h rise in VEGF
concentration may be due to increased expression of IL-6
shown to upregulate VEGF production in adipose tissue,42
but also possibly due to partial hypoxia during incubation,
known to induce VEGF production.10 ATE also contains a
wide number of other cytokines affecting angiogenesis and/
or adipogenesis, of which many (e.g., macrophage colony-
stimulating factor, GRO, intercellular adhesion molecule 1,
FGF-9, and IGFBP - 3 and - 6) were increased over time.
The previous studies on adipose stem cell cytokine con-
tent2,10,19,20,22,25,44,50 show a corresponding yet slightly dif-
ferent cytokine profile. Similar patterns of highly expressed
factors in hASCs to our study were reported by Verseijden
et al.,2 Rehman et al.,10 Kilroy et al.,19 Traktuev et al.,20 and
Rubina et al.22 In contrast to Traktuev et al.,20 IFN-g, TNF-a,
IL-8, bNGF, MCP-1, MCP-2, and leptin were detected in our
study. In contrast to Rehman et al.,10 we hardly detected any
TGF-b or granylocyte macrophage-stem cell factor in ATE.
The differences compared with previous stem cell studies
can be largely explained by the source of ATE, which, on the
contrary to previous studies, contains several different cells
of adipose tissue. This finding is supported by the previous
literature data, according to which several ILs and TNF-a,
the pro-inflammatory cytokines contributing to angiogene-
sis, are mainly secreted by inflammatory cells, especially
macrophages.30,51 Adiponectin, a major adipogenic hormone
reported to have a dual role as an inhibitor52 and stimula-
tor53,54 of angiogenesis, as well as leptin, one of the major
adipogenic and angiogenic hormone, is secreted by mature
adipocytes.14,30,31,42 TIMPs, the inhibitors of angiogenesis
and contributors to adipogenesis, are released from connec-
tive tissue cells and macrophages.51 In a previous study by
Uriel et al.,55 a rodent homogenized ATE was found to con-
tain several basement membrane components; nidogen, col-
lagen type IV, fibronectin and laminina4. This allows us to
suspect that human ATE also contains several of these
basement membrane components, although this needs to be
further studied.
The angiogenic and adipogenic factors are known to act in
a cascade in different phases of the refined process of adipose
tissue formation as reviewed, for example, by Papetti and
Herman.49 The possibility of modification of factor content is
an interesting advantage of ATE. With ATE we possibly
could stimulate different phases of angiogenesis and adipo-
genesis by a simple adjustment of the extraction time of ATE
to be favorable to the release of certain factors. Moreover,
ATE could also possibly be further tailored by precipitating
single or few growth factors from the extract with presently
available methods for further use.
The results suggest that ATE is more effective for both
angiogenesis and adipogenesis induction than the presently
available and previously tested methods. ATE contains all
the most important angiogenic and adipogenic factors of
mature adipose tissue. ATE is completely cell-free and
therefore suspected to be nonimmunogenic, which could also
allow allogeneic use of ATE. ATE has potential to be used to
induce revascularization of ischemic tissues and to be used in
tissue products that fail because of inadequate vasculature
in, for example, soft tissue engineering for replacement of
adipose tissue transplants, which do not function properly.56
Moreover, ATE is efficient for modeling natural adipogenesis
in vitro to be used in preclinical phase of drug discovery for
efficacy testing of novel drugs for, for example, obesity and
diabetes.
Conclusions
We here presented a novel cell-free angiogenesis- and
adipogenesis-inducing agent, ATE, produced from mature
human adipose tissue. ATE contains a wide variety of pro-
moters of angiogenesis and adipogenesis and efficiently in-
duces angiogenesis and adipogenesis in vitro. ATE has strong
potential to be used for angiogenesis or adipogenesis in-
duction in numerous tissue engineering applications in vitro
and in vivo.
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Original Article
Bioactive Acellular Implant Induces Angiogenesis
and Adipogenesis and Sustained Soft
Tissue Restoration In Vivo
Jertta-Riina Sarkanen, M.Sc.,1–3 Pekka Ruusuvuori, Ph.D. (tech),4 Hannu Kuokkanen, M.D., Ph.D.,5
Timo Paavonen, M.D., Ph.D.,6 and Timo Ylikomi, M.D., Ph.D.1,2,7
Soft tissue defects resulting from trauma, tumor resection, or congenital causes provide a challenging problem to
reconstructive surgery and tissue engineering. Current therapeutic procedures lack the ability to induce rapid
formation of neovascularization. Therefore, to date, no adequate application for the reconstruction of soft tissue
defects is available. We have previously shown that bioactive factors extracted from adipose tissue (adipose
tissue extract [ATE]) induce both adipogenesis and angiogenesis in vitro. These bioactive factors were incor-
porated into hyaluronan (HA) hydrogel, and the ATE-HA implant-induced angiogenesis and adipogenesis were
studied. The developed implant was shown to gradually release the bioactive factors, and the presence of
the implant in human adipose stem cell culture was able to induce adipogenic differentiation as evaluated by
Oil-red-O staining. In animal experiments, the implants were placed under dorsal subcutis of rodents. Either rat-
(rATE, allograft) or human- (hATE, xenograft) derived ATE was incorporated into implants. Local inflammation
reactions, angiogenesis, and adipogenesis were followed from 1 week to 40 weeks. Angiogenesis was assessed
by microvessel density analysis; adipogenesis was assessed by automated image analysis, and immunological
effects by immunostaining and counting inflammatory cells. The key requirements for soft tissue replacement—
host compatibility, bioactivity, and sustainability—were all achieved with the novel ATE-HA implant. This
acellular implant induced microvessel induction early after implantation and adipose tissue deposition from 12
weeks onward as well as subcutaneous tissue volume increase. The ATE-HA implant was replaced by mature
adipose tissue with capillaries, nerve bundles, and healthy connective tissue without local inflammation or
capsule formation. The large fat pads remained in tissue until the end of the follow-up time, for 9 months. No
adverse effects were detected at the site of implantation, and according to irritating ranking, the ATE-implant
was considered to have excellent biocompatibility. The results demonstrate that an acellular HA hydrogel
implant induces significant increase in adipogenesis and angiogenesis in vivo compared to the plain HA implant,
and ATE has excellent potential for use in tissue engineering for sustained reconstruction of soft tissue defects.
Introduction
Soft tissue engineering seeks to fabricate replacementparts for trauma- or disease-related soft tissue defects
(burns, scars, and chronic wounds), for surgical resections,
and for congenital malformations.1–3 In addition, cosmetic
use, such as filling of facial wrinkles, is an important appli-
cation of reconstituted soft tissue.1–3 Soft tissue defects and
chronic wounds are a medical and economic challenge to the
healthcare system,4,5 and there is an urgent clinical need for
an adipose tissue substitute that would induce rapid vascu-
larization and sustained formation of adipose tissue.2
Despite the progress in soft tissue engineering over the last
years, tissue-engineered adipose tissue is still a great chal-
lenge, and adequate application for the reconstruction of soft
tissue does not exist.6,7
Current therapeutic procedures for soft tissue replacement
include filling the defects with synthetic or natural bioma-
terials, using autologous fat grafts or stem cell therapy.2,8–10
Synthetic materials induce unwanted allergic reactions, and
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fat grafts have drawbacks such as resorption of transplants.10
Stem cell therapy is promising, although time consuming,
and only autologic transfer of cells is possible.9,10 The ade-
quate induction of angiogenesis is a prerequisite for suc-
cessful adipose tissue reconstruction.11–13 It was recently
reported that in tissue-engineered vascular grafts, the neo-
vasculature was solely derived from the host cells via vas-
cular remodeling, not from implanted cells.14,15 The cells of
the tissue-engineered vascular graft actually promoted the
host tissue regeneration instead of themselves differentiating
into the vessels.16 The key inductive molecules would
therefore be sufficient for adequate induction of vascular
development.15 In fact, an acellular soft tissue substitute that
would induce its own replacement would be advantageous
to soft tissue engineering.14,17,18 Inductive adipogenesis
would not require stem cell harvest from the patient, and an
acellular alternative would prevent severe immune re-
sponses and could allow the alloplastic use of the im-
plant.1,17,19–24 Several studies have already been performed
to provide a suitable microenvironment for the formation of
blood vessels and adipose tissue without the need to trans-
plant cells. This has been tried by incorporating growth
factors or extracellular matrix proteins into biomateri-
als.14,17,20,25–28 The controlled release of multiple angiogenic
factors has shown to promote tissue regeneration at the site
of the implantation.14,29,30 However, the creation of the op-
timal environment for inductive adipogenesis has been dif-
ficult, especially in long-term.8 Overall, all current therapy
approaches for soft tissue induction, mostly due to inade-
quate vascularization,13,28,31 fail to produce long-term satis-
factory and repeatable results,8 and therefore the sizes of the
tissue-engineered implants are limited.31–33
Adipose tissue is known to be a very active endocrine
organ and an excellent source of growth factors and cyto-
kines,30,34,35 and it can be thought to bear excellent potential
for adipose tissue induction.34 We have recently character-
ized and developed the process to extract growth factors and
cytokines from adipose tissue (the adipose tissue extract
[ATE]), and have shown that ATE is capable of inducing
effectively both angiogenesis and adipogenesis in vitro, and
has therefore potential to be used in soft tissue engineering.34
The main objective of the current study was to create an
acellular implant by incorporating ATE into a biodegradable
biomaterial that would release these angiogenic and adipo-
genic substances locally in tissue. The ATE was combined
with hyaluronan (HA) hydrogel and implanted subcutane-
ously in rodents. HA is a glycosaminoglycan and a natural
component of the extracellular matrix that takes part in
binding growth factors and cytokines,9 is known to modu-
late inflammation and tissue reparation36 and to promote
angiogenesis,37,38 and is therefore considered a very potential
material for soft tissue engineering.36 HA has been previ-
ously used, for example, for inducing formation of bone
and cartilage26 and soft tissue.8,31 Several FDA-approved
injectable HA hydrogel materials are already in clinical use,
and the adverse reactions of HA derivatives have been
minimal.39,40
In the current study, the local effects after implantation of
the grafts, inflammation reactions and induction of adipo-
genesis and angiogenesis, were followed. The efficacy and
immunological effects were evaluated both short term and
long term (from 1 to 40 weeks) in vivo, and both from allo-
graft (rat ATE-HA implant in rat) and xenograft (human
ATE-HA implant in rat). The present study shows that
acellular HA implant with ATE induces significantly more
angiogenesis and adipose tissue formation in tissue than the
control HA implant. The ATE implants are regarded as
nonirritant, and the effects of implantation are sustained, at
least for 9 months.
Materials and Methods
The adipose tissue samples were obtained from surgical
operations with informed consents at the Tampere Uni-
versity Hospital, Tampere, Finland, in accordance with the
Ethics Committee of the Pirkanmaa Hospital District, Tam-
pere, Finland (R03058). All animal experiments were per-
formed according to the Finnish animal protection laws and
approved by the Department for Social Welfare and Health
Services of the State Provincial Office of Western Finland.
ATE preparation
Human adipose tissue specimens were obtained as sub-
cutaneous tissue samples from surgical operations, and rat as
subcutaneous fat adipose tissue specimens were obtained
from sacrificed rats. Adipose tissue was cut into small pieces
and transferred into 50-mL tubes (Sarstedt). Equal volume
of the Dulbecco’s Modified Eagle’s Medium Nutrient Mix-
ture F-12 (DMEM/F12; Gibco, Invitrogen), without supple-
ments was added into the tube and left for 24 h for growth
factor secretion at 37C in a CO2 incubator. The tube was
gently shaken during incubation. The extracts were collected,
centrifuged at 12,000 rpm for 5min, and sterile-filtered
through a 0.22-mm filter (Sarstedt). The aliquots were stored
at - 20C before use.
Measurement of protein concentration
ATE samples, collected at 24 h, and phosphate-buffered
saline (PBS) samples, from the protein release study, col-
lected at several time points were analyzed for the total
protein concentration with the BCA protein Assay Kit (Pierce
Biotechnology).
Preparation of implants
The resulting sterile ATE, either from (1) human, hATE, or
from (2) rat, rATE, was mixed with HA (nonanimal-derived
partially cross-linked hyaluronic acid Restylane; Q-Med) in
such a ratio that the implant contained 57% ATE and 43%
HA hydrogel. As a control implant, HA with incorporated
PBS was used, with corresponding volumes of HA (43%) and
PBS (57%). The final human ATE concentration in the im-
plant was 1.48mg/mL of hydrogel (148mg in each implant),
and the final rat ATE concentration in the implant was
0.75mg/mL of hydrogel (75 mg in each implant).
Isolation and culture of human adipose stem cells
Stem cells were isolated as described previously.34,41–43
Briefly, human adipose tissue specimens were cut into pieces
and enzymatically digested with 0.05% collagenase I (In-
vitrogen). The digested tissue was centrifuged at 600 g for
10min and filtered through 100- and 40-mm filters (Sarstedt).
Human adipose stem cells (hASCs) were seeded and cultured
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in DMEM/F12 supplemented with 1% l-glutamine (l-glut;
Gibco), 1% antibiotic–antimycotic mixture (AB/AM; Gibco),
and 15% human serum (Lonza).
Protein release studies
The protein release from the implants was tested by
incubating the implants in PBS at 37C up to 3 weeks. The
48-well plate inserts (Scaffdex Oy) were filled with HA-ATE
hydrogels, prepared as described above, and put on the top
of PBS-filled 48-well plate wells (Nunc). Aliquots of PBS
were collected at predetermined time points and analyzed
for total protein concentration with BCA protein Assay
(Pierce Biotechnology).
Adipose stem cell differentiation with bioactive
HA implant
To study the adipogenic effect of bioactive implants in cell
culture, hASCs were plated in 48-well plates at early pas-
sages (p1–p3) at a density of 10,000 cells/cm2. Cells were
seeded and cultured in the hASC culture medium as de-
scribed above. The next day, the hATE implants were created
as described above. The 48-well inserts (Scaffdex) were filled
with hATE-HA hydrogel and placed into cell culture wells.
The medium was changed twice during the study. Cells were
cultured for 6 days and examined for lipid accumulation
with Oil-red-O (ORO; Sigma) staining.
ORO staining
Lipid accumulation was assessed at 6 days after the onset
of the differentiation experiment by using ORO staining.
ORO staining was performed as described previously.34
Briefly, hASCs were fixed with 4% paraformaldehyde
(Sigma) for 20min, incubated with 60% isopropanol for 2
to 5min, and stained with 3:2 diluted and filtered 0.5%
ORO stock solution (Merck & Co., Inc.; prepared in 100%
isopropanol) for 5min. Images were taken with the Nikon
Eclipse TS-100 microscope (Nikon) equipped with the Ni-
kon DS Camera Control Unit DS L-1 (Nikon). The images
were processed with Adobe Photoshop CS3 software
(Adobe Systems) and Corel Draw software 10.0 (Corel
Corporation).
Animal model of acellular soft tissue induction
Twenty-six male Sprague-Dawley rats (weight 325 – 75 g,
average age of 8 weeks) were housed per 2, with 12 h light
and 12 h darkness, and fed pelleted diet and water ad libitum.
Rats were anesthetized with a mixture of Domitor (mede-
tomidin hydrochloride; Orion Pharma) 1mg/mL (0.5mg/
kg) and Ketalar (ketamin hydrochloride; Pfizer) 10mg/mL
(75mg/kg). Three different types of hyaluronic acid im-
plants, each incorporated with different substances, were
created as described above. About 100 mL of the resulting gel
mixture was immediately injected with a 1-mL syringe and a
27-gauge needle (Terumo Europe) into dorsal subcutis of rat.
Implants were carefully injected in between the upper sub-
cutis and the muscle layer into rat dorsal subcutis. Three
animals in each time point were used (n = 3); three constructs
per rat were implanted, and the places of implants were
varied in different time points. The injected implant was
*8mm in diameter. Implants were left under subcutis for 1,
4, 12, 20, or 40 weeks, after which animals were sacrificed.
The remaining implant and its surrounding tissue were
carefully cut from the implant site in the dorsal subcutis and
further processed for histological analysis.
Hematoxylin and eosin staining
The histological specimens were cut into 1-mm2 pieces
and fixed in 4% paraformaldehyde overnight, dehydrated
with a graded ethanol series, and embedded in paraffin.
Specimens were cut into 5-mm-thick slices with a microtome
(Microm HM 430, Microm GmbH) and stained with hema-
toxylin and eosin (H&E) for histology. Briefly, samples were
deparaffinized by treating them three times for 5min each
with xylene (VWR International, LLC) and after that with
graded laskeva ethanol series. The samples were stained for
10min with Mayer Hematoxylin or Papanicolauslo¨sung 1a
Harris’ Ha¨matoxylinlo¨sung (Merck KGaA), rinsed with tap
water 10min and with distilled water 2min, then stained with
1% eosin for 15 s, and rinsed with tap water and further
with distilled water. The samples were then dehydrated
with 94% and 100% ethanol, treated 3· 5min with xylene,
and mounted with Entellan (Merck KGaA) for storage.
Images were taken with a Nikon Microphot FXA microscope
(Nikon) connected to a Sony DXC-S500 camera control unit
and Sony Twain Driver Software 1.0 (Sony Europe Limited)
and further processed with Adobe Photoshop CS 3 software
(Adobe Systems) and Corel Draw software 10.0. (Corel
Corporation). The microscopic images from H&E-stained
subcutaneous tissue slices were merged with Canon Photo
Stitch 3.1 (Canon).
Immunohistochemistry
The histological specimens were cut into 1-mm2 pieces
and fixed in 4% paraformaldehyde overnight, dehydrated
with a graded ethanol series, and embedded in paraffin.
Specimens were cut into 3- or 5-mm-thick slices with a
microtome (Leica DM2000; Leica Instruments GmbH or
Microm HM 430; Microm GmbH, respectively). Samples
were deparaffinized with xylene (VWR International, LLC)
3· 5min each, rehydrated with graded ethanol series, and
washed with distilled water.
For anti-von Willebrand Factor and for anti-Neurofila-
ment-68 staining (anti–vWF produced in rabbit; Sigma;
1:5000 and anti-NF-68 produced in mouse; Sigma; 1:500,
respectively, both 4C overnight), tissue samples were trea-
ted 15min with 0.5% hydrogen peroxide (Mallinckrodt
Baker, Inc.) in methanol (Mallinckrodt Baker, Inc.), micro-
wave oven-treated 10min in a preboiled 0.01M sodium
citrate buffer, pH 6.0, cooled 20min in a sodium citrate
buffer, and treated with the Histostain Plus Broad Spectrum
Detection Kit (Zymed Laboratories, Inc., Invitrogen). The
color was developed with a DAB Substrate kit (Zymed
Laboratories) for 5min. The samples were counterstained for
5 s with Mayer Hematoxylin and mounted with Entellan
(Merck KGaA).
For anti-CD3 staining (CD3 [Clone SP7] rabbit monoclonal
antibody; Thermo Fisher Scientific; 1:100, 90min at room
temperature), the samples were microwave oven-treated
2· 7min in 10mM Tris–HCl, 1mM EDTA, pH 9.0., cooled
for 20min in Tris–EDTA buffer, and then treated with the
DAKO EnVision + System, HRP kit (DakoCytomation).
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For anti-CD79a staining (mouse anti-human Cd79a; AbD
Serotec, MorphoSys AG; 1:500, 4) and for anti-CD68 staining
(monoclonal mouse anti-rat CD68; AbD Serotec, MorphoSys
AG; 1:100, in 0.1% BSA in TBS, 4C overnight), samples were
treated with the Mouse on Rat HRP Polymer Kit (Biocare
Medical). The color was developed with the DAKO Cyto-
mation Liquid DAB Substrate Chromogen System (Dako),
and samples were counterstained with Papanicolauslo¨sung
1a Harris’ Ha¨matoxylinlo¨sung (Merck) and mounted with
Pertex (HistoLab Products Ab).
The results were analyzed with a Leica DM 2000 micro-
scope (Leica) from five different fields from three animals per
each time point. Images were taken with a Nikon Microphot
FXA microscope (Nikon) connected to a Sony DXC-S500
camera control unit and Sony Twain Driver Software 1.0
(Sony Europe Limited) and processed for publication with
Adobe Photoshop software CS3 (Adobe Systems), Corel
Draw software 10.0 (Corel Corporation), and Canon Photo
Stitch 2.0. (Canon).
Determining the capillary density
The number of formed capillaries was calculated micro-
scopically from three animals per time point (each containing
three different types of implants), and from five different
random high-power fields (hpf, 400 · ) in each implant at the
implant–tissue interface with a Leica DM 2000 microscope
(Leica Microsystems GmbH). The capillaries were confirmed
to be stained positive for vWf, and the capillaries needed to
have lumen that was visible in hpf (400 · magnification).
Both capillary proliferation and larger arteriole-like and
venule-like vessels were counted.
Automated quantitative analysis of the adipose
tissue formation
To quantitate the adipose tissue formation in rat subcutis,
an automated computer-assisted analysis tool was earlier
developed for fat deposit detection. The applicability of the
analysis tool for quantification of fat and for evaluating
the differences in the fat accumulation between time has
been previously described.44 Briefly, before analysis, the
samples were stained as described above in H&E staining.
H&E-stained slides were photographed with a Nikon
Microphot FXA microscope (Nikon) connected to a Sony
DXC-S500 camera control unit and Sony Twain Driver
Software 1.0 (Sony Europe Limited) and analyzed with the
analysis tool without any preprocessing to the images. The
analysis tool estimates the area of fat coverage by segment-
ing the hue component of the image with dual thresholding.
Size constraints were applied to remove small, fractioned
areas and excessively large areas, which typically belong
to background. Finally, the user was allowed to modify
the segmentation result by removing any possible false de-
tection and by adding missing areas. Adding of new areas
was implemented using the seeded region growing where
the user gives the seed point and the area grows around
this point.44
Measurement of the tissue expansion
The H&E-stained histological specimens were measured
with a Nikon TS-100 microscope using Nikon TS Elements
software. The total vertical height of the rat dorsal subcutis
sample (from the muscle layer to the epithelial layer) was
measured from each implant from two different sites at a
40-week time point.
Evaluation of the local immunological effects
of implantation
The local biological effects were quantitatively scored after
immunohistochemical staining as described previously45,46
and according to the International Organization of Standar-
dization (ISO) Standard ISO-10993:6–2007 ‘‘Tests for local
effects of implantation,’’ when applicable. The response was
evaluated per hpf (400 · ) from five different fields and from
three different animals per time point. The inflammation
score criteria were (as modified from ISO 10993-6:2007) as
follows: 0=no cell type detected; 1= rare; 1–5/hpf (except
for giant cells, 1–2/hpf); 2= 5–10/hpf (except for giant cells,
3–5/hpf); 3=heavy infiltrate; 4=packed. The final average
irritating ranking (as described in ISO 10993-6:2007) was
obtained from the average of overall scores.
 nonirritant (0.0–2.9)
 slight irritant (3.0–8.9)
 moderate irritant (9.0–15.0)
 severe irritant (>15)
The final active inflammatory changes were multiplied by
two to get the final irritation ranking.
Statistical analysis
All statistical analyses were performed and graphs pro-
cessed with GraphPad Prism 5 (GraphPad Software, Inc.).
Samples were subjected to one-way analysis of variance
followed by appropriate post-tests; for the capillary forma-
tion and adipose tissue formation, Tukey’s and Dunnett’s
post-tests, and for tissue thicknesses, Tukey’s post-test. The
results were considered significant when *p< 0.05, **p< 0.01,
and ***p < 0.001.
Results
Protein release from the implants
The protein release of the designed implants was tested by
incubating the implants with PBS as well as incubating the
implants with ASCs. The ATE-containing implants were
shown to release protein when incubated in PBS up to 3
weeks, whereas control implants did not show any protein
release. The results are seen in Figure 1A. The protein re-
leased from the implants was able to induce adipogenesis in
hASC culture as stained with ORO after 6 days of culture
(Fig. 1B).
Histological evaluation of the local effects
of implantation in tissue
The effects of implantation were evaluated with local tis-
sue histology after H&E staining. The evaluated time points
were 1, 4, 12, 20, and 40 weeks. The results are shown in
Figure 2.
At 1 week, cell penetration into all of the implants was
seen. Capillary proliferation with small newly formed
capillaries was extensively present with both rATE-HA and
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hATE-HA implants (Fig. 2B, C, respectively) at the implant–
tissue interface. In rATE, also larger arteriole-like and venule-
like vessels were seen next to the implant (Fig. 2B). The vessels
were higher in number as well as in the diameter with rATE-
HA and hATE-HA implants, compared to controls. Very small
adipose tissue deposits, indicating triglyceride accumulation,
were also seen (Fig. 2B). The control implant did not present
any relevant tissue changes (Fig. 2A).
At 4 weeks, the tissue histology resembled that of 1 week.
Vast capillary infiltration was seen with both rATE-HA and
hATE-HA implants at the implant–tissue interface, close to the
degrading hydrogel, and several arteriole-like and venule-like
structures and a lot of small fat deposits were seen. Close to
the implant, large vessels were also present. Only few larger
capillaries were detected in the control implant (Fig. 2D).
At 12 weeks, few larger vessels and small fat deposits
were seen in the control HA implant (Fig. 2G). In rATE-HA
implant, dense, large, well-vascularized fat pads were al-
ready seen (Fig. 2H). Capillaries were evenly distributed
throughout the fat tissue. The newly formed fat pads were
often seen to be located apart from the native fat tissue, at the
initial implant injection site. Inside the fat pads, vasculari-
zation and nerve bundles were visible. The hATE-HA im-
plant (Fig. 2I) was histologically similar to the rATE-HA
implant; however, the amount of fat was more extensive in
the rATE-HA implant than in the hATE-HA implant.
At 20 weeks, the tissue histology was similar to 12 weeks,
except that more adipose tissue had accumulated in the
rATE-HA (Fig. 2K) and hATE-HA (Fig. 2L) implants. More
adipose tissue was seen in the rATE (Fig. 2K) than in the
hATE (Fig. 2L). The rATE-HA implants had induced large fat
pad formations, seen as several layers of adipose tissue. All
implants, the rATE-HA implant, hATE-HA implant, and
control implant, were still present in tissue, and they were
equally degraded.
At 40 weeks, the control implants were completely de-
graded. These implants had induced some adipogenesis, more
than was seen in the control tissue. Two of the rATE-HA
implants (out of three animals) were degraded completely.
The degradation of the control implant was faster than the
rATE-HA and hATE-HA implants. The hATE-HA implant
degradation rate was decreased compared to other implants,
as all of the implants still partly remained in tissue at 40
weeks. However, no capsule formation was seen, only a
narrow layer of fibrosis occasionally. The large fat pad for-
mations, seen also already at 20 weeks, and induced especially
by rATE-HA implants, were present at 40 weeks, and the
adipose tissue seen was well vascularized. The histology of
the newly formed mature adipose tissue was similar to normal
tissue in all implants at 40 weeks, when tissue histology was
compared between the control implant (Fig. 3A), rATE-HA
implant (Fig. 3B), and hATE-HA implant (Fig. 3C). The ac-
cumulated adipose tissue in the implants resembled that of the
endogenous tissue with a densely packed structure and hex-
agonal-shaped cells, accompanied with blood vessels.
When tissue thicknesses were microscopically evaluated,
the HA implant (Fig. 3D, rATE-HA implant) was shown to
induce increase in thickness of subcutis at 20 weeks com-
pared to control implant (Fig. 3E) and control tissue (Fig. 3F).
The change in tissue thickness was evaluated by measuring
the thickness of the subcutis from histological samples at 40
weeks. The results are shown in Figure 3G. As statistically
evaluated, all implants induced a significant increase in tis-
sue thickness at 40 weeks compared to control tissue (control
implant **p< 0.01; hATE-implant ***p< 0.001; rATE-implant
***p< 0.001). At 40 weeks, the tissue thickness was signifi-
cantly higher in the rATE implant and the hATE implant
(both ***p< 0.0 = 1), compared to the control implant.
The capillary proliferation was confirmed with anti-von
Willebrand factor staining at 4 weeks (Fig. 4A), and tissue
innervation, seen often from 12 weeks onward as nerve
bundles, was confirmed with antineurofilament 68 staining
(Fig. 4B). Nerve bundles were not detected at earlier time
points, but often at 12 to 40 weeks.
Quantification of angiogenesis
and adipogenesis in vivo
Capillary density was evaluated from five different mi-
croscopic hpf (400 · magnification) at 1 and 4 weeks (e.g.,
before adipose tissue accumulation) by calculating the
capillaries manually under microscope. The results are
shown in Figure 5A. The statistical analysis was performed
at both time points between different implants (significancy
FIG. 1. The HA hydrogel protein release. (A) The protein
release from the hATE-HA implant as measured with BCA
protein assay kit. (B) The image of Oil-red-O-stained triglyc-
eride accumulation in hASCs after being cultured with the
HA implant for 6 days. Scale bar: 100mm. ATE, adipose tissue
extract; HA, hyaluronan; hASC, human adipose stem cell.
Color images available online at www.liebertpub.com/tea
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shown in Fig. 5A as asterisks) as well as by comparing
each implant to their 1-week control (significancy shown in
Fig. 5A as hash signs). Both capillary proliferation and larger
arteriole-like and venule-like vessels were counted. The
overall number of vessels was highest at 1 week. The control
implant blood vessel number was very similar at both time
points. The hATE-HA implant induced significantly higher
capillary proliferation at 1 week (p < 0.05) and at 4 weeks
(p< 0.001), compared to the respective control implants.
The adipose tissue was quantified with a specific analysis
tool designed for the purpose and published previously.44 The
statistical analysis was performed at each time point between
different implants (shown in Fig. 5B as asterisks) as well as by
comparing each implant to their 1-week control (shown in
FIG. 2. The rat subcutaneous tissue histology at 1, 4, 12, 20, and 40 weeks after implantation of the rATE-HA implant,
hATE-HA implant, or control (plain HA) implant. (A)–(C) implants at 1 week, (D)–(F) implants at 4 weeks, (G)–(I) implants
at 12 weeks, (J)–(L) implants at 20 weeks and (M)–(O) implants at 40 weeks. The samples were H&E stained. Scale bar:
250 mm, except for (B) and (C); scale bar: 100mm. i = implant, adipose tissue is shown with asterisks (*) and blood vessels with
arrowheads (>). H&E, hematoxylin-eosin. Color images available online at www.liebertpub.com/tea
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Fig. 5B as hash signs). The number of adipose tissue (% from
microscopic image, 40· magnification) was increased during
the time; however, until 12 weeks, there was no significant
increase in adipose tissue accumulation. At 12 weeks, the
rATE-HA implant contained significantly more adipose tissue
than the rATE-HA implant at 1 week (p<0.05). At 20 weeks, all
(control implant, rATE-HA implant, and hATE-HA implant)
had more adipose tissue than respective treatments at 1 week
(p<0.05, p<0.001, and p<0.001, respectively). Moreover, at 20
weeks, the rATE-HA implant and the hATE-HA implant had
induced more adipose tissue accumulation than control tissue
(p<0.05 and p<0.01, respectively). At 40 weeks, all implants, as
FIG. 3. The comparison of adipose tissue histology in H&E-stained images between rATE-HA implant (A), hATE-HA
implant (B), and normal tissue (C) at 40 weeks. The comparison of the tissue thicknesses between rATE implant (D), control
implant (E), and control tissue (F) at 20 weeks, as well as comparison of measured tissue thicknesses between implants at 40
weeks (G). The results in (G) represent individual observations and mean. Differences were considered significant when
**p < 0.01 and ***p< 0.001. Scale bar for (A), (B), and (C) 20mm, and for (D), (E), and (F), scale bar: 200mm. Color images
available online at www.liebertpub.com/tea
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well as control tissue, contained more adipose tissue than re-
spective treatments at 1 week (all highly significant, p<0.001).
However, at 40 weeks, the rATE-HA and hATE-HA implants
had induced significantly more adipose tissue accumulation
than the control implant (p<0.001 with both implants) or con-
trol tissue (p<0.001 and p<0.01, respectively).
Immunological effects of implantation
The evaluation of immunological effects of implantation
was modified from ISO-10993:6-2007. The results are scored
and summarized in Table 1. To be able to perform irritating
ranking as described in ISO 10993-6:2007, the active in-
flammatory changes were multiplied by two. Similar in-
flammatory scoring is also described previously.45,46 The
irritation ranking was evaluated solely by immunological
effects, not with induction of vascularization or fatty infil-
trate, as these were the desired effects of implantation. No
serious adverse tissue effects occurred. Some inflammatory
cell infiltration was seen in earlier time points. At week 1,
the control implant showed moderate B-cell and mild
macrophage infiltration, as well as the rATE-HA and hATE-
HA implants showed mild infiltration of B-cells and mac-
rophages. The polymorphonuclear cell infiltration was
minimal throughout the study. During the time course, the
control implant inflammatory effects were decreased and
were completely disappeared at 40 weeks, when also the
implant had degraded completely. The rATE-HA and
hATE-HA implants were both present at 40 weeks, hATE-
HA in each sample and rATE-HA occasionally, and they
still showed some inflammatory cell infiltration at the time.
No granuloma, fibrous capsule formation, giant cells, or
necrosis were seen in any of the samples. Implants were
seen to be often surrounded by a narrow band of fibro-
blasts, but after implant was degraded, no signs of fibrous
bands were seen. Normal fibroblast proliferation was often
FIG. 4. (A)Anti-von Willebrand factor (anti-vWf) staining
of capillaries) at 4 weeks and (B) anti-neurofilament - 68
(anti-NF-68) staining of nerve bundles at 12 weeks in rat
subcutaneous tissue after implantation of rATE-HA implant.
Scale bar: 100mm. Color images available online at www
.liebertpub.com/tea
FIG. 5. The quantification of angiogenesis and adipogen-
esis after implantation of ATE-HA implants. (A) The capil-
lary count in tissue at 1 week and at 4 weeks. The results
were evaluated from five different high-powered fields (hpf,
400 · ) surrounding the implant and from three different
animals in each time point. Differences were considered
significant when *p < 0.05, **p< 0.01, and ***p< 0.001. (B) The
adipose tissue accumulation during time. The results were
evaluated from 20 different images per each implant in each
time point. The results are given as mean – SD. The implants
were compared to each other in each time point (differences
were considered significant when *p< 0.05, **p< 0.01, and
***p < 0.001). Each implant was also compared to their one
week control (differences were considered significant when
#p< 0.05, ##p< 0.01, and ###p< 0.001).
8 SARKANEN ET AL.
seen, and it was accompanied with capillary proliferation.
According to the evaluation of local immunological effects,
the implant was considered to be nonirritant compared to
the control implant.
When statistically evaluated, none of the implants were
found to be more irritating than others. The CD3- (T-cell)
positive cell count was significantly higher in the rATE-HA
implant at 1 week than with any other implant and in any
other time point ( p< 0.001) as well as in the hATE-HA implant
at 1 week compared to implants at 20 weeks ( p< 0.05) and 40
weeks ( p< 0.01). The CD68- (macrophage) positive cell infil-
tration was significantly higher in the control implant at
1 week and at 20 weeks compared to the control implant at
40 weeks ( p< 0.01 and p< 0.001, respectively). Moreover,
the rATE-HA and hATE-HA implants had significantly more
macrophage infiltration at 1 week compared to the respective
implants at week 40 ( p< 0.05 and p< 0.01, respectively).
The control implant had significantly more CD79a-positive
cells at week 1 than at week 20. The polymorphonuclear cell
count remained low in all implants throughout the study.
Discussion
Soft tissue engineering is a prominent research area, as soft
tissue defects and chronic wounds are a medical and eco-
nomic challenge to the healthcare system, and the demand is
increasing every year.4,5 The ideal soft tissue replacement
should induce rapid vascularization, induction of adipo-
genesis, and induce a permanent effect in tissue.2 However,
the current applications have shown only modest success, for
example, some vascularization, but hardly any adipose tis-
sue formation,14 and the optimal adipose tissue substitute
remains to be discovered.
Our approach for the induction of capillary proliferation
and adipose tissue accumulation was to create an in vivo-like
environment for soft tissue formation as possible. In our
previous work, we demonstrated that extracted factors from
adipose tissue (ATE) induce angiogenesis and adipogenesis
in vitro.34 ATE is able to induce adipogenesis at ‡ 200mg/mL
protein and angiogenesis at ‡ 450mg/mL protein.34 ATE is a
mixture of a wide variety of components of mature adipose
tissue, of which the most abundant are, for example, vascular
endothelial growth factor, fibroblast growth factor 2, adipo-
nectin, angiogenin, interleukin 6, leptin, and insulin-like
growth factor-binding protein 6.34 These factors are known
to have an inductive role on adipogenesis and/or angio-
genesis (reviewed in Szasz and Webb).47 In the present
study, we demonstrate that both the induction of micro-
vessels and adipose tissue can be effectively and perma-
nently induced with these adipose tissue-derived factors
in vivo. The key requirements for soft tissue replacement, as
listed by Choi et al,2 are host compatibility, bioactivity, and
sustainability, all of which were achieved with the novel
ATE-HA implant.
The ATE-HA implant induced extensive capillary prolif-
eration early after implantation, and the induction was
Table 1. Histological Semiquantitative Evaluation of the Local Effects of Implantation
Implant response (average score)a
1 week 20 weeks 40 weeks
Inflammatory cell type ctrl HA rATE +HA hATE +HA ctrl HA rATE +HA hATE +HA ctrl HA rATE +HA hATE +HA
Polymorphonuclear cells
(H&E)
0.4 0.3 0.3 0.3 0.4 0.3 0.2 0.1 0.2
Lymphocytes (T-cells CD3) 1.2 2.2 1.9 1.1 0.5 0.7 0.7 0.5 0.6
Plasma cells (B-cells and
plasma B-cells CD79a)
3.6 2.7 2.6 2.5 2.1 1.7 1.1 1.6 2
Macrophages (CD 68) 2.8 2.7 2.8 2.5 2.3 2.3 1.4 1.7 1.6
Giant cells (H&E, CD68) 0 0 0 0 0 0 0 0 0
Necrosis (H&E) 0 0 0 0 0 0 0 0 0
Total 8 7.9 7.6 6.3 5.3 5.1 3.4 3.9 4.4
Average total 1.3 1.3 1.3 1 0.9 0.8 0.6 0.7 0.7
Total · 2 16 15.8 15.2 12.5 10.5 10.1 6.8 7.9 8.8
Average (test sample-
control HA)b
— 0c 0c — 0c 0c — 1.1 2
aThe response has been evaluated per high-powered field (hpf, 400· ) from five different fields surrounding the implant and from three
different animals in each time point.
The inflammation score criteria were (as modified from ISO 10993-6:2007)
0=no cell type detected,
1= rare, 1–5/hpf (except for giant cells, 1–2/hpf),
2= 5–10/hpf (except for giant cells, 3–5/hpf),
3=heavy infiltrate,
4=packed
bThe average irritating ranking (as described in ISO 10993-6:2007) was as follows:
 nonirritant (0.0–2.9)
 slight irritant (3.0–8.9)
 moderate irritant (9.0–15.0)
 severe irritant ( > 15)
cNegative difference was recorded as zero.
ATE, adipose tissue extract; HA, hyaluronan; ISO, International Organization of Standardization.
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significantly higher than the control implant. The induction
of vascularization during the first 4 weeks was well in line
with the protein release rate of the implants detected in vitro.
The human ATE induced slightly more capillary formation
than rat ATE in rat subcutaneous tissue. This may have been
due to the higher concentration of hATE in the implant
compared to rATE (rATE implant contained 75mg protein
and hATE implant 148 mg protein). However, as the rat ATE
was overall slightly more efficient in adipose tissue accu-
mulation in rat tissue than human ATE, one explanation may
be that human factors act differently in rat adipose tissue
remodeling than allogenic (rat) factors. In fact, it is known
that there are differences between rodent and human adi-
pose tissue.48 In adipose tissue, key adipokines have differ-
ences in function in humans and rodents, as reviewed in
Wang et al.49 From 12 weeks upward, when also adipose
tissue started to accumulate, the histology of the newly
formed tissue vasculature resembled that of endogenous
adipose tissue. The growth factor-induced neovasculariza-
tion was extensive early after implantation compared to
endogenous tissue, but during adipogenesis, the vessels
were remodeled. During angiogenesis stimulus in tissue, the
endothelial cells start to proliferate toward the stimulus, and
a number of immature capillaries are formed. During vessel
remodeling, the vessels that cannot become perfused are
regressed,50 resulting in normal tissue restoration. Similarly,
the ATE-implant induced formation of adipose tissue with
vasculature that was histologically comparable to the en-
dogenous fat tissue. It is an important finding that ATE is
able to induce efficient tissue restoration with normal vas-
cular remodeling.
The adipose tissue deposition was abundant and micro-
scopically observed as dense fat pads from 12 weeks onward
with ATE-HA implants (significant increase compared to
control tissue), and also, the subcutaneous tissue volume was
increased. However, due to variation between animals, the
adipose tissue increase was not statistically significant com-
pared to the control implant, until at 40 weeks. The timing of
adipose tissue appearance in ATE implants most likely re-
flects the release properties of the biomaterial used in the
study. The inductive factors are first released by diffusion
from the implant; however, later on, the factors are released
simultaneously with the degradation of the material. The
inductive effect could be possibly reached sooner, if a higher
concentration of ATE was used, or moreover, different type
of hyaluronic acid or other biomaterial was used. However,
this remains to be further tested.
The rat ATE was overall slightly more efficient in adipose
tissue induction in rat tissue than human ATE. However,
both the rATE-HA implant and the hATE-HA implant were
replaced by newly formed adipose tissue that had histolog-
ical features of normal adipose tissue; capillaries, nerve
bundles and normal connective tissue, and the fat pads re-
mained in tissue until the follow-up time (9 months). Al-
ready at a 20-week time point, the 100 mL rat ATE implant
had induced even a sevenfold increase in fat accumulation
compared to control tissue (*0.4-mm fat layer in control
tissue vs. even 2.8-mm fat layer in the rat ATE implant), and
almost 2.5-fold induction compared to the control implant
(*1.2-mm fat layer in the implant). Both ATE implants in-
duced significantly thicker tissue than the control implant at
40 weeks. The sustained effect in this extent has not been
demonstrated previously by any of the applications tested,
neither with hASC-seeded scaffolds nor with acellular scaf-
folds. For example, in a previous study by Hemmrich et al.,37
blood vessels were formed, but hardly any mature fat was
seen by 12 weeks postimplantation. In a 24-week study by
Tsuji et al,51 only modest de novo adipogenesis was seen.
Overall, previous studies show some adipose tissue forma-
tion, but no vascularization,52 or limited longevity of the
adipose tissue20 and not enough information on long-lasting
(over 3-month) effects.52–54
Tissue fillers like hyaluronic acid are known to contribute
to angiogenesis and adipogenesis,36–38 and this was also seen
in our study, as the control implant did increase both capil-
lary and adipose tissue formation in some extent. However,
at 40 weeks, when the control implant had degraded, the
control implant had not induced any more adipose tissue
than what was seen in control tissue. There was an increase
in the tissue thickness in the control implant, which was
however often contributed by the connective tissue forma-
tion induced by the control implant. Therefore, the control
implant did not induce mature adipose tissue formation,
although mild adipose tissue induction compared to normal
tissue. The control tissue also represented a significant
change in adipose tissue accumulation between week 1 and
20 and/or 40 weeks. It is a well-known phenomenon and a
normal feature presented in laboratory animals that labora-
tory animals gain weight during time when they get older.
The key feature of a soft tissue substitute, the good bio-
compatibility,2 was achieved with the ATE-HA implant. No
adverse reactions or fibrous capsule formation occurred, and
when the local inflammatory cell response of the implants
was observed, ATE-HA implants did not show increase in
irritating effects over the control HA implant. At 1 week
postimplantation, the T-cell marker CD3 was increased in the
rATE-HA and hATE-HA implants, and on the other hand,
the B-cell marker CD79a in the control implant and macro-
phage infiltration in all implants. This is most probably due
to the tissue damage caused by the injection of the implant
into the subcutaneous space. We cannot exclude the possi-
bility that hyaluronic acid itself induces inflammatory cell
infiltration; however, ATE does not have any additional ef-
fect on the number of inflammatory cells, and therefore can
be considered to be biocompatible and safe. In fact, macro-
phage infiltration is reported to be intrinsic for adipose tissue
formation.55–57 Macrophages are known promote angiogen-
esis,36,58 hASC differentiation into endothelial cells,45 and
even to transdifferentiate into adipocytes.55 It is also note-
worthy that there was no difference with the immunological
reaction between allogenic (rat ATE in rat) and xenogenic
(human ATE in rat) implants, indicating that the ATE is well
tolerated.
The angiogenesis-/adipogenesis-inducing effect in rats was
demonstrated with quite low doses of ATE. Each rATE im-
plant contained 75mg protein and each hATE implant 148mg
protein. In the current study, the injectable implant was ad-
ministered only once, at the onset of the study. Repeated
administration and increased dose of ATE could even enhance
the inductive effect. As the potential cytokines are injected
locally, the overall doses of adipogenic and angiogenic factors
required are reduced. However, the optimal dose and efficacy,
and administration schedule of ATE, are currently under
further investigation, as the right combination of factors is
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known to be crucial,28,30 rather than the maximal dose. The
effects of simple ATE substance, if used without incorporation
into scaffold, are currently under study, as well as the sys-
temic toxicity of high concentrations of ATE. It also remains to
be resolved whether the range of indications of ATE could be
broadened, that is, whether the inductive effect of ATE applies
to other tissues than soft tissue.
We have developed a new acellular approach to soft tissue
engineering. ATE combined with HA hydrogel is able to
induce vascularization and soft tissue formation in tissue.
The key requirements for soft tissue replacement—host
compatibility, bioactivity, and sustainability—are all
achieved with the novel ATE-HA implant. The blood vessel
induction in tissue is rapid, and the newly formed adipose
tissue remains at least for 40 weeks and is histologically
comparable to the native mature adipose tissue. The implant
presents no immunological risks even when used in a xe-
nogenic manner, and therefore is an important tool in cre-
ating an allogenic soft tissue substitute for patients. This
bioactive implant is a potential replacement for the current
soft tissue products to overcome the challenge of vasculari-
zation and to restore soft tissue permanently.
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both cell populations – hASC and HUVEC. hASC monocul-
ture had passage- and donor-dependent ability to form tu-
bular networks, with half of the cultures presenting tubule 
structures and basement membrane formation. Pericytic 
and smooth muscle cell markers were expressed in hASC 
monoculture even when tubules were absent. By combining 
the potential properties of hASC and features from the pres-
ent angiogenesis assays, we generated a natural-like, xeno-
free, prevascular-like network in vitro model with excellent 
reproducibility and minimal limitations in technical perfor-
mance. This tubular network model is an excellent tool for 
studying cell interactions during vascular development, for 
chemical and drug testing and for developing natural-like, 
multilayered, vascularized, scaffold-free tissue models. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 The current major limitation in designing three-di-
mensional vascularized tissue models and implantable 
tissue constructs is the lack of adequate vascularization in 
the construct and especially the maturation and stabiliza-
tion of the vasculature [Moon and West, 2008; Rivron et 
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 Abstract 
 The current limitation in designing three-dimensional tissue 
models is the lack of adequate vascularization with mature 
and stable vessels. Adipose tissue is known to secrete sev-
eral angiogenic factors, and human adipose stromal cells 
(hASC) are known to promote vessel growth, maturation and 
stabilization. In this study, hASC were induced to angiogen-
esis with growth factor-enriched medium either in monocul-
ture or in coculture with human umbilical vein endothelial 
cells (HUVEC) and analyzed for vascular, pericytic and smooth 
muscle cell markers. hASC and HUVEC cocultures showed an 
accelerated proliferation rate and the cells self-assembled, 
independent of the cell passage number, into multilayered 
three-dimensional tubular networks. The networks of hASC 
and HUVEC expressed endothelial markers, a complete base-
ment membrane and vessel-supporting cells with contrac-
tile properties. A hASC and green fluorescence protein-HU-
VEC-infection model revealed that cocultures consisted of a 
mosaic of von Willebrand factor-positive cells derived from 
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al., 2008]. The vascular network with stable and function-
al vessels [Abramsson et al., 2002] is essentially needed to 
meet the nutritional and functional demands of the organ 
[Gerhardt and Betsholtz, 2003]. The vessel engineering 
should optimally produce natural-like and xeno-free vas-
cular constructs. Preferably, no animal components or 
unnatural scaffold materials should be allowed in the tis-
sue culture, the cultures should contain only growth fac-
tors and proteins that occur in tissue naturally, and vessels 
forming in culture should have features of maturing ves-
sels, i.e. in addition to tubule structures, the pericyte re-
cruitment, basement membrane formation and vessel-
supporting layer of smooth muscle cells should appear. 
 Adipose tissue, an active endocrine organ, is known to 
secrete several angiogenic and adipogenic cytokines and 
growth factors such as vascular endothelial growth factor 
(VEGF), basic fibroblast growth factor (bFGF) and insu-
lin-like growth factor-I (IGF-I) [Gimeno and Klaman, 
2005; Rehman et al., 2004; Rubina et al., 2009; Sadat et al., 
2007; Verseijden et al., 2009]. Moreover, human adipose 
stromal cells (hASC), isolated as a stromal-vascular frac-
tion from the adipose tissue specimens, are known to 
have developmental plasticity both in vitro and in vivo 
[Planat-Benard et al., 2004; Rehman et al., 2004] and have 
the capacity to differentiate into multiple cell phenotypes 
such as adipose [Gimble and Guilak, 2003b; Zuk et al., 
2001], smooth muscle [Traktuev et al., 2008] and endo-
thelial cells [Miranville et al., 2004; Oswald et al., 2004; 
Pittenger et al., 1999; Planat-Benard et al., 2004; Wosnit-
za et al., 2007; Wu et al., 2007]. hASC are known to pro-
mote vessel growth, maturation and stabilization in vivo 
[Amos et al., 2008; Cai et al., 2009; Covas et al., 2008; 
Traktuev et al., 2008; Zannettino et al., 2007] by secreting 
angiogenic factors and by differentiating into vessel lin-
ing supporting cells with pericytic properties [Amos et 
al., 2008; Kilroy et al., 2007; Traktuev et al., 2008]. The 
high proliferation and differentiation capacity of hASC 
makes them an ideal component for angiogenesis model-
ing, and the use of abundant adipose tissue as a source of 
endothelial cells would also be attractive for vessel engi-
neering [Merfeld-Clauss et al., 2010; Miranville et al., 
2004; Planat-Benard et al., 2004; Wu et al., 2007]. More-
over, understanding the role of angiogenesis in adipose 
tissue is important, as vasculature regulates both the ad-
ipose tissue mass development and adipose tissue reduc-
tion, and is also suggested to have an impact on regulat-
ing the mass of other adult tissues [Rupnick et al., 2002]. 
 The angiogenic potential of hASC has widely been 
studied [Cao et al., 2005; Planat-Benard et al., 2004; Trak-
tuev et al., 2008; Verseijden et al., 2009], alone or in co-
culture with endothelial cells, in the presence of a sup-
porting scaffold, e.g. collagen I, Matrigel or fibrin [Diet-
rich and Lelkes, 2006; Lai et al., 2009; Miranville et al., 
2004; Oswald et al., 2004; Pittenger et al., 1999; Planat-
Benard et al., 2004; Rubina et al., 2009; Verseijden et al., 
2010; Wosnitza et al., 2007]. However, in general, in the 
previous methods, the capillary tubule formation has 
been quite modest or the test has contained animal-de-
rived components. Moreover, several previous methods 
have focused only on the role of endothelial cell migra-
tion and proliferation during angiogenesis, i.e. tubule for-
mation. However, as pericytes have a crucial role in the 
regulation of the microvessel growth, maturation and 
stabilization during angiogenesis [Amos et al., 2008; Ben-
jamin et al., 1998], the endothelial tubule formation alone 
is not a sufficient measure of vascular growth and differ-
entiation. The recruitment of pericytes along vascular tu-
bules is an essential step in vessel maturation, needed to 
induce basement membrane formation and to prevent 
vessel regression [Gerhardt and Betsholtz, 2003]. The fail-
ure of the endothelial cells to establish mature structures 
in vitro is often due to an absence of stabilizing mural 
cells [Merfeld-Clauss et al., 2010]. Coculture models that 
have been used in several studies [Bishop et al., 1999; 
Donovan et al., 2001; Friis et al., 2003, 2005; Merfeld-
Clauss et al., 2010; Montesano et al., 1993; Nicosia and 
Ottinetti, 1990] provide a useful method for studying an-
giogenesis in controlled conditions in vitro, with the ad-
vantage of being able to replicate some tissue-derived sig-
naling [Rubina et al., 2009]. However, only a few studies 
[Merfeld-Clauss et al., 2010; Traktuev et al., 2008] have 
Abbreviations used in this paper
bFGF basic fibroblast growth factor
COLIV collagen IV
EGM-2 endothelial cell growth medium-2
GFP green fluorescence protein
hASC human adipose stromal cells
HS human serum
HUVEC human umbilical vein endothelial cells
IGF-I insulin-like growth factor-I
PDGFR platelet-derived growth factor receptor-
PECAM-1 platelet/endothelial cell adhesion molecule-1
RPLP0 ribosomal protein large P0
SMA -smooth muscle actin
SMMHC smooth muscle myosin heavy chain
VEGF vascular endothelial growth factor
vWf von Willebrand factor
 Adipose Stromal Cell Tubule Network 
Model 
Cells Tissues Organs 3
characterized hASC and human umbilical vein endothe-
lial cells (HUVEC) scaffold-free cocultures and their an-
giogenic properties or hASC monoculture angiogenic 
properties [Miranville et al., 2004].
 Our specific aim was to develop a completely human-
based, simplified and improved angiogenesis model, a 
prevascular-like network with properties of maturing 
vessels, that could be used for studying angiogenesis in 
vitro, and that would aid in the development of tissue 
models by improving target cell proliferation, survival 
and differentiation. In this prevascular-like network 
model, cells are induced with natural growth factors and 
allowed to self-assemble into tubular network and vascu-
lar supporting structures. We studied the hASC+HUVEC 
coculture model by combining some properties and anal-
yses from previous studies [Friis et al., 2003; Merfeld-
Clauss et al., 2010] and the fibroblast-HUVEC coculture 
angiogenesis assay previously validated in our laboratory 
[Sarkanen et al., 2011]. We induced the hASC+HUVEC 
coculture or hASC monoculture with naturally occur-
ring angiogenic growth factors; epidermal growth factor, 
VEGF, bFGF and IGF-I [Mehta and Besner, 2007]. We 
evaluated the cultures for expression of vascular, peri-
cytic and smooth muscle cell markers by immunocy-
tochemistry and quantitative RT-PCR. We also studied 
the endothelial differentiation capacity of hASC in both 
hASC monoculture and a hASC and green fluorescence 
protein (GFP)-HUVEC-infection model. We produced 
an improved assay that, due to growth factor addition, 
induces a multilayered prevascular-like network with 
properties of maturing vessels that do not regress over 
time. We also showed that hASC, at low passages, are able 
to differentiate into endothelial-like cells alone and in 
hASC+HUVEC coculture. This improved and easy tubu-
lar network model is an excellent tool for studying cell 
interactions during vascular development, in drug and 
chemical screening, and most significantly, in designing 
vascularized tissue models in vitro or, as it is xeno-free, 
for creating vascularized tissue constructs for implanta-
tion. 
 Materials and Methods 
 The study was conducted in accordance with the Ethics Com-
mittee of the Pirkanmaa Hospital District, Tampere, Finland 
(R03058, R08028). The adipose tissue samples were obtained from 
surgical operations and the human umbilical cords from sched-
uled cesarean sections with informed consents at the Tampere 
University Hospital, Tampere, Finland. The experiments com-
plied with the current laws of Finland. 
 Isolation and Culture of hASCs 
 Stem cell isolation procedure was performed as described pre-
viously [Gimble and Guilak, 2003a; Hong et al., 2005; Niemela et 
al., 2007]. Briefly, human adipose tissue specimens were cut into 
small pieces, enzymatically digested with 0.05% collagenase I (In-
vitrogen, Paisley, UK) in Dulbecco’s Modified Eagle’s Medium 
Nutrient Mixture F-12 (Gibco, Invitrogen, Carlsbad, Calif., USA) 
for 60 min at 37   °   C in a gyratory water bath. The digested tissue 
was centrifuged at 600  g for 10 min at room temperature. The di-
gested tissue was filtered through a 100-  m filter (Sarstedt, Nüm-
brecht, Germany), centrifuged and filtered again through a 40-
  m filter (Sarstedt). Cells were seeded into 75-cm 2 flasks (Nunc 
EasyFlask TM , Nunc, Roskilde, Denmark) in Dulbecco’s Modified 
Eagle’s Medium Nutrient Mixture F-12 supplemented with 1%  L -
glutamine (Gibco), 1% antibiotic-antimycotic mixture (Gibco) 
and 15% human serum (HS; Cambrex, East Rutherford, N.J., 
USA). The next day, cells were washed several times with PBS. The 
cells were maintained at 37  °  C under a 5% CO 2 air atmosphere at 
a constant humidity and medium was changed every 2–3 days. 
After having grown to confluency, cells were divided in a ratio of 
1: 2 to 1: 3, or further used for cell culture studies. 
 Isolation and Culture of HUVEC 
 The HUVEC were isolated from human umbilical cord veins 
as described previously [Jaffe et al., 1973; Sarkanen et al., 2011]. 
 Briefly, the cord was separated from the placenta and the umbili-
cal vein was cannulated with a 20G needle and the needle was 
secured by clamping the cord over the needle with a surgical 
clamp. The vein was perfused with PBS to wash out blood and 
then the opposing end of the umbilical vein was clamped with a 
surgical clamp. Subsequently, the vein was infused with 0.05% 
collagenase I. The umbilical cord was incubated in a water bath at 
37  °  C for 15 min. After incubation, the collagenase I solution con-
taining HUVEC was flushed from the cord by perfusion with PBS 
into a 50 ml polypropylene tube (Sarstedt). The cells were centri-
fuged at 200  g for 10 min, washed once with medium, centrifuged 
again and resuspended in endothelial growth cell medium-2 
(EGM-2), BulletKit medium (Lonza Group Ltd., Basel, Switzer-
land) and seeded into 75 cm 2 flasks. Medium was changed every 
2–3 days and cells were divided when confluent. For assay con-
trols, HUVEC were plated at 4,000 cells/cm 2 and cultured in 
EGM-2 BulletKit medium.
 Flow Cytometric Surface Marker Expression Analysis of 
HUVEC 
 The HUVEC were harvested at passage 3 and analyzed with a 
fluorescence-activated cell sorter (FACSAria, BD Biosciences, 
 Erembodegem, Belgium). Monoclonal antibodies against CD13-
PE (BD Biosciences), CD31-FITC, CD34-APC and CD44-FITC 
(Immunotools GmbH Friesoythe, Germany), CD117-APC and 
CD133-PE (Miltenyi Biotech, Bergisch Gladbach, Germany), 
CD144-PE, CD202b and VEGFR2 (R&D Systems Inc., Minn., 
USA) and CD63-PE (Abcam, Cambridge, UK) were used. Mono-
clonal antibodies against von Willebrand factor (vWF, Abcam) 
were conjugated with IgG-PE (CalTag Laboratories, Calif., USA). 
Ten thousand cells were analyzed per sample and the positive ex-
pression was defined as the level of fluorescence greater than 99% 
of the corresponding unstained cell sample.
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 Lentivirus Infection  
 Lentiviral construct pLKO-MISSION-Bright-GFP was pur-
chased from Biomedicum Genomics (BMGen, Biomedicum Hel-
sinki, Helsinki, Finland). The infection was carried out with HU-
VEC at low passages with 300   l of pLKO-MISSION-Bright-GFP 
in 1 ml EGM-2 BulletKit medium (1 U/ml). Virus infection was 
accelerated with 8   g/ml hexadimethrine bromide (Sigma). After 
24 h of incubation, medium was replaced with fresh EGM-2 me-
dium. Highly fluorescent clones were selected with cloning rings 
and further selected with dilution cloning to obtain pure GFP-
HUVEC culture. After expanding the infected HUVEC, they were 
used for hASC and HUVEC coculture assay as described below.
 hASC Monoculture Assay 
 hASC (six different cell lines derived from different donors, 
passages 1–7 used) were seeded in EGM-2 BulletKit medium into 
48-well plates (Nunclon TM Multidishes, Nunc, Roskilde, Den-
mark) at a density of 20,000 cells/cm 2 . Cells were induced for 
either 3 or 6 days in EGM-2 BulletKit medium, a commercially 
available growth factor-enriched medium containing epidermal 
growth factor, VEGF, bFGF, IGF-I, ascorbic acid, heparin, 0.1% 
gentamicin/amphotericin-B and 2% FBS, or in DMEM/F-12 
 medium supplemented with 15% HS, 1 m M  L -glutamine and 1% 
antibiotic-antimycotic mixture. Medium was changed and the 
treatments applied once to cells cultured for 3 days and twice to 
cells cultured for 6 days. 
 hASC and HUVEC Coculture Assay 
 hASC (21 different cell lines derived from different donors, 
passages 1–7 used) were seeded in EGM-2 BulletKit (Lonza) cul-
ture medium into 48-well plates (Nunclon TM Multidishes, Nunc, 
Roskilde, Denmark) or for confocal imaging into 8-well slides 
(IbiTreat, Ibidi Gmbh, Martinsried, Germany) at a density of 
20,000 cells/cm 2 . HUVEC, cultured as above (24 different cell 
lines derived from different donors, passages 1–6 used), were im-
mediately carefully seeded on top of hASC at a density of 4,000 
cells/cm 2 . The seeding densities of hASC and HUVEC were cho-
sen according to previous studies by us and others [Donovan 
et al., 2001; Friis et al., 2003; Sarkanen et al., 2011]. The day 
after plating, the differentiation treatments were applied to 
hASC+HUVEC coculture. Treatments were (all in duplicate 
wells): (1) EGM-2 BulletKit medium (composition as described 
above in hASC monoculture assay); (2) EGM-2 BulletKit – me-
dium in which 2% FBS was replaced with 2% HS; (3) EGM-2 Bul-
letKit – medium without serum, and (4) endothelial cell basal me-
dium-2 (Lonza) containing no growth factors, supplemented with 
0.1% gentamicin, 2% FBS and 1 m M  L -glutamine. Cells were cul-
tured for either 3 or 6 days prior to immunocytochemistry or 
quantitative RT-PCR. Medium was changed and the treatments 
applied once to cells cultured for 3 days and twice to cells cultured 
for 6 days. 
 Quantitative RT-PCR  
 The primers used for angiogenesis and blood vessel matu-
ration genes – platelet/endothelial cell adhesion molecule-1 
( PECAM-1 , also referred to as CD31); the blood vessel stabilizing 
signal molecule angiopoietin 1  (Angiopoietin 1) ; the smooth mus-
cle cell microfilament protein regulating cell contraction, caldes-
mon  (Caldesmon) ; and reference gene ribosomal protein large P0 
( RPLP0 ; all oligonucleotides from Oligomer Oy, Helsinki, Fin-
land) – are shown in  table  1 . The total RNA from hASC or 
hASC+HUVEC was extracted from 3 or 6 days differentiated 
confluent cultures using TRIzol  (Invitrogen, Carlsbad, Calif., 
USA) following the manufacturer’s protocol. cDNA was synthe-
tized using High Capacity cDNA Reverse Transcriptase Kit (Ap-
plied Biosystems, Foster City, Calif., USA) according to manufac-
turer’s instructions. Quantitative RT-PCR analysis was performed 
in a 96-well optical reaction plate using an ABI Prism 7000 se-
quence detector (Applied Biosystems). As the expression of RPLP0 
gene was stable between experimental conditions, we used this 
gene as the reference for data normalization. hASC grown in 
hASC culture medium were used as controls for gene expression 
for  Angiopoietin 1 and  Caldesmon and HUVEC grown in EGM-2 
for  PECAM-1.  Reactions were performed using SYBR Green PCR 
Master Mix kit (Applied Biosystems), 50 ng cDNA sample and 10 
  M primers. The PCR conditions were as follows: 10 min at 95  °  C, 
followed by 40 cycles of 15 s at 95  °  C and 60 s at 60  °  C. The target 
and reference genes were amplified in separate wells. All reactions 
were performed in duplicate. Relative RNA expression was calcu-
lated in comparison to RPLP0 RNA expression for cell culture 
experiments using the Pfaffl method [Pfaffl, 2001]: 
 ratio of relative expression = (E target )  CP target (control-sample)/
(E ref )  CP ref (control-sample)
Table 1.  Oligonucleotide sequences used for RT-PCR experiments
Gene Primer
Human RPLP0 Forward 5-AATCTCCAGGGGCACCATT-3
Reverse 5-CGCTGGCTCCCACTTTGT-3
Human PECAM-1 (CD31) Forward 5-TCATTTCTGGGATCCATATGCA-3
Reverse 5-TGGGTGTAGAGAAGGATTCCGT-3
Human Angiopoietin 1 Forward 5-AGCTACCACCAACAACAGTG-3
Reverse 5-CAAAGATTGACAAGGTTGTGG-3
Human Caldesmon Forward 5-AAGAATCCTTGGGACAGGTGAC-3
Reverse 5-GTGGTGGTTGTCTTGGCCTC-3
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 Immunocytochemistry 
 The tubule formation was visualized with endothelial cell-
specific antibody to vWf (anti-vWf primary antibody produced in 
rabbit, 1: 500, Sigma). To evaluate human adipose stromal cell dif-
ferentiation, parallel double immunofluorescence staining with 
  -vWf was performed. Primary antibody against either common 
pericytic marker   -smooth muscle actin (monoclonal anti-  SMA 
clone 1A4, 1: 200, Sigma), vascular smooth muscle cell marker 
smooth muscle myosin heavy chain (anti-SMMHC,  1: 800, Sig-
ma), contractile smooth muscle cell marker calponin (anti-cal-
ponin, 1: 800, Sigma), pericytic and smooth muscle cell progenitor 
marker platelet-derived growth factor receptor-  (anti-PDGFR  
1: 800) or basement membrane marker collagen IV (anti-COLIV, 
1: 500, Sigma) was combined with anti-vWf. Cells were washed 
three times with PBS, fixed with ice-cold 70% ethanol for 20 min, 
permeabilized with 0.5% Triton X-100 (JT Baker, Phillipsburg, 
N.J., USA) for 15 min and blocked for unspecific staining with 
10% bovine serum albumin (Sigma) for 30 min. After blocking, 
cells were incubated with the primary antibody pairs for 1 h at 
room temperature. Cells were washed three times with PBS, in-
cubated for 30 min with secondary antibody polyclonal anti-rab-
bit IgG TRITC (1: 100, Sigma) for anti-vWf and polyclonal anti-
mouse IgG FITC (1: 100, Sigma) for anti-  SMA, anti-COLIV, an-
ti-PDGFR  and anti-SMMHC. Cell nuclei were stained with 
Hoechst 33258 (1   g/ml, Sigma) for 5 min and washed 5 times 
with PBS. For anti-GFP staining, the primary antibody pair was 
mouse monoclonal antibody to GFP (1: 100, Abcam, Cambridge, 
UK) and anti-vWf, secondary antibodies being anti-mouse IgG 
TRITC (1: 100, Sigma) and polyclonal antibody to rabbit IgG FITC 
(1: 500, Acris Antibodies GmbH, Hiddenhausen, Germany), re-
spectively. Fluorescence was visualized with a Nikon Eclipse Ti-S 
microscope (Nikon, Tokyo, Japan) or with a confocal laser scan-
ning microscope Zeiss LSM 700 (Zeiss LSM 700 on the Axio Ob-
server, Carl Zeiss Microimaging GmbH, Jena, Germany) and the 
images were processed with Zen2009 (confocal images, Carl 
Zeiss), with Adobe Photoshop software 7.0 (Adobe Systems, San 
Jose, Calif., USA) and Corel Draw software 10.0 (Corel Corpora-
tion, Ottawa, Ont., Canada). 
 Microscopic Analysis of Tubule Formation 
 After immunocytochemical staining, the tubules were ana-
lyzed with Nikon Eclipse TS100 microscope (Nikon, Tokyo, Ja-
pan) from 48-well plate wells with 40 ! magnification. The extent 
of tubules in different cultures was quantified visually by using a 
semiquantitative grading scale from 0 to 10. The grading was 
based on tubule formation, the length and the branches of tubules, 
as described in our previous study [Sarkanen et al., 2011].
 Statistical Analysis 
 Statistical analyses were performed and graphs processed with 
GraphPadPrism 5.0 (GraphPad Software Inc., San Diego, Calif., 
USA). Tubule formation and RT-PCR results were subjected to 
one-way ANOVA followed by Dunnett’s and Bonferroni’s post-
hoc tests when applicable. The results were reported as mean  8 
 SD and differences were considered significant with p  ! 0.05, p  ! 
0.01 and p  ! 0.001.
 Results 
 The Tubule Network Formation Is Induced in hASC 
Monoculture and in hASC+HUVEC Coculture in the 
Presence of Inductive Growth Factors  
 The tubule formation capacity and anti-vWf-positive 
endothelial tubule structures of hASC monoculture or 
hASC+HUVEC coculture were evaluated and compared 
at two different time points (day 3 and day 6) when grown 
in the growth factor-enriched EGM-2 BulletKit medium 
( fig. 1 a). hASC+HUVEC coculture showed an extremely 
accelerated proliferation rate that was shown at day 6 as 
a massive, dense, multilayered prevascular-like network 
formation. hASC+HUVEC coculture tubular network 
formation was very extensive early (day 3) in vitro, always 
reproducible and not dependent on the cell line or pas-
sage number of cells. In hASC monoculture, the induc-
tion towards angiogenesis was not seen repeatedly be-
tween different experiments, only approximately half of 
the cultures showed tubule formation in some degree and 
dense tubular network formation, as seen in  figure 1 a, 
was seen less often. When the tubule formation was 
 semiquantitatively evaluated ( fig. 1 b, tubule formation), 
hASC+HUVEC had significantly more tubules at day 6 
than at day 3 (p  ! 0.001) and significantly more tubules 
than hASC monoculture at day 3 (p  ! 0.01) and at day 6 
(p  ! 0.01). The two controls, hASC+HUVEC grown with-
out growth factors and HUVEC alone, both grown in 
growth factor-enriched EGM-2 medium, showed only 
mild tubule formation or no tubule formation, respec-
tively ( fig.  1 c). The surface marker characterization of 
control HUVEC is shown in  table 2 . We also studied the 
hASC+HUVEC tubule formation in EGM-2 when FBS 
was replaced with 2% human serum (hASC+HUVEC 
EGM-2, 2% HS,  fig.  1 d) or when FBS was completely 
 removed (hASC+HUVEC, without serum,  fig.  1 d). We 
were able to replace FBS without significant effect on the 
tubule formation capacity of hASC+HUVEC coculture 
as tested with one-way ANOVA.
 In order to further evaluate which cells were re-
sponsible for the massive tubule network formation in 
hASC+HUVEC coculture and to see whether hASC in-
duce the proliferation and tubule formation of HUVEC 
or also differentiate into endothelial-like cells, as seemed 
to be the case according to hASC monoculture studies, 
we created a hASC and GFP-infected HUVEC coculture 
(hASC+GFP-HUVEC,  fig. 2 ). The anti-vWf-stained co-
cultures ( fig. 2 , vWf) were mostly mosaic and consisted 
of two different populations of vWf-positive cells, ap-
proximately half of the cells being GFP infected ( fig. 2 , 
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GFP), and the other half of the anti-vWf-positive cells be-
ing GFP negative. Moreover, several GFP-negative and 
vWf-negative cells were surrounding the tubules as seen 
with Hoechst staining ( fig. 2 , merged). 
 Genes That Indicate Differentiation of Cells and 
Maturation of Tubule Structures Are Upregulated in 
hASC Monoculture and in hASC+HUVEC Coculture 
 hASC and hASC+HUVEC, both cultured in EGM-2 
BulletKit medium, were further tested for their matura-
tion stage with several pericytic and smooth muscle 
markers. The relative mRNA expression of  PECAM - 1 , 
 Angiopoietin 1 and Caldesmon were studied both in 
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 Fig. 1. The tubule formation of hASC monoculture and 
hASC+HUVEC coculture. Cells were stained with vWf antibody 
(anti-vWf, 1: 500, Sigma; red fluorescence shown with TRITC-
conjugated secondary antibody, 1: 100, Sigma).  a Comparison of 
tubule formation of hASC monoculture and hASC+HUVEC co-
culture. Cells were cultured and induced to angiogenesis for 3 or 
6 days in growth factor-enriched EGM-2 BulletKit medium.
 b Semi-quantitative analysis of the tubule formation between dif-
ferent treatments. hASC monoculture and hASC+HUVEC cocul-
ture were compared to each other at 3 and 6 days. Semiquantita-
tive scale according to Sarkanen et al. [2011]. The results are re-
ported as mean  8 SD and differences considered significant 
when  * *  p  ! 0.01 and  * * *  p  ! 0.001.  c The controls shown at day 6 
in vitro. HUVEC were plated at 4,000 cells/cm 2 and grown in 
growth factor-enriched EGM-2 and hASC+HUVEC cocultured 
without exogenous addition of growth factors.  d hASC+HUVEC 
were cultured in the growth factor-enriched EGM-2 with human 
serum (EGM-2, 2% HS) or without serum (EGM-2 w/o serum).  
Table 2. S urface protein expression of HUVEC
Antigen Surface protein HUVEC
CD 13 Aminopeptidase N 99.4
CD 31 PECAM 94.5
CD 34 Glycoprotein 3.9
CD 44 Hyaluronate, HCAM 44.5
CD 63 Tetraspanin 8.5
CD 117 c-kit, SCFR 8.4
CD 133 AC133 1.1
CD 144 VE-Cadherin 0.9
CD 202b Tie-2/TEK 31.9
VEGFR2 0.4
vWF/factor VIII 14.5
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hASC monoculture and in hASC+HUVEC coculture at 
days 3 and 6 ( fig. 3 ). As a control, hASC, grown in their 
normal culture media, were used. By day 3, only  Caldes-
mon showed significant activity, when compared to the 
control.  Angiopoietin 1 and Caldesmon expressions were 
significantly increased by day 6 with hASC and with 
hASC+HUVEC by days 3 and 6 (p  ! 0.05 and p  ! 0.001, 
respectively) when compared to the control hASC. The 
 PECAM-1 expression was significantly increased with 
hASC grown in growth factor-enriched medium by day 
6 (p  ! 0.05) when compared to the control hASC, and 
moreover, also between days 3 and 6 (p  ! 0.05).  PECAM-1 
expression was also seen to increase with hASC+HU-
VEC, but due to high variation, the result was not
sta tistically significant.  Caldesmon expression was in-
creased between days 3 and 6 with hASC and with 
hASC+HUVEC (p  ! 0.01 and p  ! 0.001, respectively). It 
seemed that the  PECAM-1 expression was lower with 
hASC+HUVEC than with the control hASC monocul-
ture. However, the  PECAM-1 expression was very low at 
day 3 in all treatments, which has probably caused an er-
ror in the normalization of the data.
 Induced Extracellular Matrix Production in Culture 
and Differentiation of hASC into Vessel Lining Cells 
 hASC monoculture and hASC+HUVEC coculture 
were also subjected to immunocytochemical staining. 
The results from day 6 are shown in  figure 4 , except for 
PDGFR  expression in hASC+HUVEC which is shown 
from day 3. PDGFR  expression was most intense in 
hASC+HUVEC at day 3, seen as dot-like structures 
 evenly surrounding the developing tubules. At day 6, 
PDGFR  was seen in some extent in both hASC and 
hASC+HUVEC, but the expression was not changed 
with hASC+HUVEC between days. COLIV, showing the 
development of a basement membrane, was remarkably 
widely expressed in hASC+HUVEC. The expression was 
colocalized with the developing tubules covering the tu-
bules.   SMA- and SMMHC-positive cells were expressed 
quite often in hASC and widely in hASC+HUVEC at day 
6, often localized in the branching points of tubular 
structures and between the tubules. SMMHC expression 
was increased between days 3 and 6, especially in 
hASC+HUVEC. In hASC monoculture, vessel-support-
ing pericytic and smooth muscle cell markers were ex-
pressed, even despite the lack of capillary formation at the 
area. COLIV was also expressed in hASC monoculture at 
the sites of tubule formation, but not elsewhere. The con-
focal laser scanning microscopy of basement membrane 
(COLIV) and tubule network (vWf) staining showed the 
multilayered nature of the tubule network ( fig.  5 ). The 
transparent three-dimensional projection of the Z-stack 
shown in  figure 5 a was merged from 28 single layers, the 
distance between layers being 7   m. Therefore, the thick-
ness of the tubule network was 196   m. The close-up of 
the tubule network ( fig. 5 b) shows multilayered tubules 
crossing each other. Some of the crossing points are indi-
cated with arrows.
 Discussion  
 We developed an inductive prevascular-like network 
support based on adipose stromal cells and endothelial 
cells for in vitro tissue models and for tissue engineering 
constructs. Our specific aim was to develop a completely 
 Fig. 2. hASC+GFP-HUVEC coculture model. Cells were cultured for 6 days in the growth factor-enriched 
EGM-2 medium and immunostained with anti-GFP (GFP, 1: 100, Abcam; TRITC-conjugated secondary anti-
body, 1: 100, Sigma) and anti-vWf (1: 100, Sigma; FITC-conjugated secondary antibody, 1: 500, Acris Antibodies). 
Cell nuclei were visualized with Hoechst staining (shown in the merged image, 1   g/ml, Sigma).  
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human-based, simplified and improved angiogenesis 
model, a tubular network with properties of maturing 
vessels, which could be used for studying angiogenesis in 
vitro, and that would aid in the development of tissue 
models by improving target cell proliferation, survival 
and differentiation. In this tubular network model cells 
are induced with natural growth factors and allowed to 
self-assemble into a prevascular-like network and vascu-
lar supporting structures. We studied a hASC+HUVEC 
coculture model by combining some properties and anal-
yses from the previously described model [Merfeld-
Clauss et al., 2010] and the fibroblast-HUVEC coculture 
angiogenesis assay previously validated in our laboratory 
[Sarkanen et al., 2011]. The maturity of the developed 
model was evaluated with markers that indicated the 
maturation of the tubules by quantitative RT-PCR and 
immunocytochemical staining. We also studied whether 
hASC alone could be induced to endothelial cell differen-
tiation and tubule formation with the addition of these 
naturally occurring stimulating growth factors.
 Merfeld-Clauss et al. [2010] created a similar hASC+
HUVEC coculture model with no exogenous growth fac-
tors added in cell culture. Contrary to their study, we spe-
cifically wanted to investigate tubule formation in a sim-
ilar coculture system by adding growth factors that are 
secreted in vivo and that naturally stimulate angiogene-
sis, e.g. in adipose tissue [Hausman and Richardson, 
2004; Mehta and Besner, 2007]. This selection of growth 
factors would provide a close to natural-like cell culture 
environment and presumably therefore favor the tubule 
network induction and allow sustained vessel formation 
and long-term stability of the tubular network, a feature 
that is often required in the development of complex tis-
sue or organ models. 
 When hASC were combined with HUVEC (hASC+
HUVEC) and cultured in EGM-2, a remarkable enhance-
ment in cell proliferation, capillary formation and induc-
tion of maturation was seen with both cells. However, if 
the hASC were allowed to attach and proliferate in cul-
ture for a prolonged time period prior to HUVEC seed-
ing, only modest tubule formation was seen (data not 
shown). Therefore, only simultaneous plating of cells ef-
fectively induced the self-assembly of the multilayered tu-
bule network. The growth factor stimulation induced tu-
bule formation that seemed not to be passage dependent 
(up to passage 7 tested) with either HUVEC or hASC, a 
result contrary to previous studies on these cell types cul-
tured alone by us [Sarkanen et al., 2011] and others [Hey-
darkhan-Hagvall et al., 2008] that have shown that the 
differentiation capability is passage dependent.
 hASC monoculture, on its behalf, had clearly passage 
and donor-dependent differentiation capacity towards 
endothelial-like cells despite the use of the growth factor-
enriched medium. hASC alone often formed short cords 
in culture, but only occasionally massive tubule network 
formation. In addition to the current study, the tubule for-
mation in hASC monoculture has only been shown previ-
ously by Miranville et al. [2004] and Heydarkhan-Hagvall 
et al. [2008]. Several groups have reported cord formation 
of hASC in Matrigel for example, but it has also been re-
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 Fig. 3. The relative mRNA expression of  PECAM-1 ,  Caldesmon 
and  Angiopoietin 1 in hASC monoculture or hASC-HUVEC co-
culture at 3 and 6 days after angiogenesis induction with growth 
factor-enriched EGM-2 medium. The expressions were compared 
to their respective control (hASC, plated at 20,000 cells/cm 2 , 
grown in hASC culture medium). The statistical analysis was per-
formed with one-way ANOVA. The results are reported as mean 
 8  SD and differences considered significant when  *  p  ! 0.05, 
 * *  p  ! 0.01 and  * * *  p  ! 0.001.  
 Adipose Stromal Cell Tubule Network 
Model 
Cells Tissues Organs 9
PD
G
FR


SM
A
SM
M
H
C
C
O
LI
V
C
al
p
on
in
hASC alone EGM-2 hASC+HUVEC EGM-2
500 μm
100 μm
 Fig. 4. The expression of pericytic and 
smooth muscle cell differentiation mark-
ers in tubule structures after angiogenic 
induction with growth factor-enriched 
EGM-2 medium. For detection of tubule 
formation, cell cultures were immuno-
stained with vWf  antibody (anti-vWf,
1: 500, Sigma; red fluorescence shown with 
TRITC-conjugated secondary antibody,
1: 100, Sigma). For detection of tubule mat-
uration, cultures were immunostained 
with  either anti-  SMA (1: 200, Sigma), an-
ti-COLIV (1: 500, Sigma),  anti-PDGFR  
(1: 500, Sigma), anti-SMMHC (1: 800, Sig-
ma) or  anti-calponin (1: 800, Sigma), all of 
these green fluorescence, FITC-conjugat-
ed secondary antibody (1: 100, Sigma). The 
images shown are merged images of dou-
ble immunofluoresence at day 6, except for 
anti-PDGFR  , which is at day 3, and ex-
cept for anti-COLIV and anti-calponin for 
which both the merged image of staining 
( insets ) and the FITC-conjugated second-
ary antibody – anti-COLIV/anti-calponin 
staining – are shown. 
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ported that the cord formation observed by different cells 
in Matrigel is an unspecific phenomenon [Donovan et al., 
2001] and, therefore, not a reliable or comparable endo-
thelial tubule formation assay to coculture assays. 
 To further evaluate which cells contribute to the tu-
bule formation and whether the hASC mainly stimulate 
endothelial cell proliferation or take part in the endothe-
lial cell differentiation itself, we created a GFP-infection 
model. In the hASC+GFP-HUVEC coculture, the tu-
bules were seen to consist of a mosaic of GFP-HUVEC 
and of other cells that were GFP-negative, although vWf-
positive. This finding, with our other result that hASC 
monoculture is able to form tubular networks, suggests 
that hASC not only stimulate the tubule formation and 
maturation, but also differentiate into endothelial-like 
cells in this system. Moreover, the significant increase in 
the expression of the endothelial marker  PECAM-1 in 
hASC monoculture between days 3 and 6 supports this 
finding. 
 Although freshly isolated hASC, or more precisely, 
stromal-vascular fraction cells, may contain microvascu-
lar endothelial cells [Rehman et al., 2004; Wosnitza et
al., 2007], we have previously thoroughly characterized 
hASC [Lindroos et al., 2009, 2010] and shown that hASC, 
cultured in several different proliferation media, lack the 
expression of hematopoietic and angiogenic markers 
such as CD31, CD106 and CD146 (surface marker expres-
sion 0.6  8 0.7, 0.7  8 0.7 and 0.4  8 0.2, respectively). 
However, the extent whereby hASC differentiate into en-
dothelial-like cells in this model, especially in higher pas-
sages, and the functional and metabolic competency of 
these differentiated endothelial-like cells need careful 
further evaluation and characterization. In our opinion, 
the advantage of this current coculture model is, in fact, 
the heterogeneity of the hASC, creating and inducing a 
natural-like environment for the formation of a self-as-
sembling tubule network. 
 The HUVEC isolated from umbilical cords and used 
in the assay were previously carefully quality controlled 
for their tubule formation capacity with low variation be-
tween cell batches [Sarkanen et al., 2011], and the surface 
marker expression profile of HUVEC that has been char-
acterized here corresponds with previous reports [Fuka-
sawa et al., 2006; Ichikawa et al., 2006; Korbling et al., 
2006; Schmidt et al., 2006]. However, the flow cytometry 
results indicate low expression of VE-cadherin (0.9%) 
and relatively low expression of vWf (14.5%). VE-cad-
herin is reported to be low in HUVEC in normal cell cul-
ture, whereas significantly upregulated in HUVEC dur-
ing tubule network formation [Kiran et al., 2011]. vWf 
expression, on its behalf, is reported to be heterogeneous 
in endothelial cells and to show regional variations in 
mRNA levels [Zanetta et al., 2000]. Expression of vWf is 
reported to be upregulated by the angiogenic growth fac-
a b
 Fig. 5. The confocal laser scanning microscopy of a multilayered 
precapillary-like tubule network. For detection of the tubule for-
mation, the hASC+HUVEC cocultures were immunostained 
with vWf antibody (anti-vWf, 1: 500, red fluorescence, shown with 
TRITC-conjugated secondary antibody, 1: 100, Sigma). For detec-
tion of basement membrane, cultures were immunostained with 
anti-COLIV (1: 500, Sigma green fluorescence, FITC-conjugated 
secondary antibody, 1: 100, Sigma). The images shown are merged 
images of double immunofluoresence at day 6.  a Transparent 
three-dimensional projection of the Z-stack built from 28 layers 
with a threshold of 13; distance between layers: 7 um; scale bar = 
200   m.  b A close-up of the tubule network, multilayered tubule 
formation seen in several areas, some of the crossing points of the 
tubules are indicated with arrows. 
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tors bFGF and VEGF [Zanetta et al., 2000], which may 
explain the difference in our flow cytometry and immu-
nofluoresence results.  
 Blood vessel formation involves not only endothelial 
tubule formation, but also the maturation of vessels by 
basement membrane formation and pericyte and vascu-
lar smooth muscle cell recruitment and differentiation 
[Kalluri, 2003]. Therefore, the maturation stage of hASC-
induced vascular structures was evaluated. Our study 
supports the earlier studies [Merfeld-Clauss et al., 2010; 
Planat-Benard et al., 2004; Rubina et al., 2009; Traktuev 
et al., 2008] and demonstrates that hASC are able to con-
tribute to vessel formation maturation in vitro by differ-
entiating into vessel supporting structures with pericyt-
ic and smooth muscle cell properties. PDGFR  , an
important receptor in pericytic cell recruitment to
developing tubules [Nishishita and Lin, 2004], was al-
ready extensively seen at 3 days in hASC+HUVEC. In 
contrast to a previous study [Merfeld-Clauss et al., 2010], 
we detected  that hASC monoculture expressed COLIV 
colocalized with the tubules expressing vWf. hASC also 
widely expressed   SMA and occasionally other markers, 
even when capillaries were not present, which is well in 
line with the known vessel supporting role of hASC [Ver-
seijden et al., 2010]. COLIV, an important basement 
membrane component defining integrity, stability and 
functionality of the basement membrane [Bonanno et 
al., 2000; Poschl et al., 2004], was intensively expressed 
in hASC+HUVEC, both at days 3 and 6, and surrounded 
all of the tubules completely, indicating well-formed 
basement membrane. COLIV staining also revealed the 
multilayered structures where the tubules were orga-
nized into three-dimensional networks ( fig. 4 and  fig. 5 ). 
hASC+HUVEC also expressed widely   SMA and 
SMMHC, the major contractile proteins in smooth mus-
cle cells [Frid et al., 1992].  Angiopoietin 1 , a molecule reg-
ulating blood vessel stabilization [Nishishita and Lin, 
2004] and indicating late stages of tubule maturation and 
stabilization, as well as  Caldesmon, a smooth muscle cell 
contraction regulator indicating higher differentiation 
of smooth muscle cells [Frid et al., 1992], were signifi-
cantly expressed in both hASC and hASC+HUVEC at 
day 6. Another regulator of muscle cell contraction, cal-
ponin, was rarely seen in hASC monoculture, but often 
in hASC+HUVEC at the sites of the tubule formation. 
However, the maturation stage of the tubule networks 
needs further study, especially with endothelial nitric 
oxide synthase, an important regulator of angiogenesis, 
as well as by testing the VEGF independency of the 
formed tubule network.
 Most tissue-engineered constructs are limited in 
thickness to 1–2 mm due to inadequate vascularization 
[Norotte et al., 2009]. However, scaffolds, which are often 
used to create multilayered tissue constructs, may inter-
fere with the cell-to-cell interactions and the cell assem-
bly [Norotte et al., 2009]. The growth factor induction 
induced a high proliferation of both cell types in 
hASC+HUVEC coculture. Therefore, this supporting 
prevascular-like network model could allow for the cre-
ation of multilayered, yet scaffold-free, soft tissue con-
structs. The three-dimensional nature of hASC+
HUVEC coculture could be seen in confocal scanning 
microscopy three-dimensional projection, where the to-
tal thickness of the tubule network was nearly 200   m. 
This network model would be especially suitable for en-
gineering tissue constructs that need an intense tubular 
network. Moreover, due to a high proliferation rate, the 
cell number used in our study was only one fourth of the 
number used by Merfeld-Clauss et al. [2010], for example. 
A lower cell number provides a higher capacity, e.g. for in 
vitro drug screening studies. The xeno-free modification 
of hASC+HUVEC coculture allows the use of this tubu-
lar network culture model in tissue engineering applica-
tions. As suggested by Merfeld-Clauss et al. [2010], the 
endothelial cells could possibly be replaced with any tis-
sue-specific endothelial cells (e.g. microvascular endo-
thelial cells in adipose tissue) with no effect on tubule 
formation capability. Therefore, we can suspect that this 
developed tubular network platform is easily modified to 
be suitable in several different tissue model applications 
where a dense tubular network is needed. However, when 
this coculture system is aimed at human use in tissue 
constructs, the origin of endothelial cells must meet the 
need of the target tissue. Moreover, if hASC monoculture 
tubule network induction could be improved to be re-
peatable, this would allow an even more simplified tubu-
lar network model. However, the tubule formation of 
hASC alone in growth factor-enriched medium needs 
further study and more optimization, e.g. through an in-
crease in cell seeding density.
 By combining the present knowledge of potential 
properties of hASC in angiogenesis induction and fea-
tures from the presently available tubule network assays, 
we could generate a natural-like angiogenesis in vitro 
with an excellent prevascular-like network formation ca-
pability, reproducibility and stability, and minimal limi-
tations in technical performance (i.e. passaging and cul-
ture conditions). The tubule network had morphological 
and genetic features of maturing capillaries. This tubular 
network model mimics especially well the naturally oc-
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curring angiogenesis in adipose tissue. The hASC mono-
culture or hASC+HUVEC coculture model provides an 
ideal platform for tissue engineering applications, both 
for developing tissue models in vitro or for the develop-
ment of implantable tissue structures. Clinically relevant 
in vitro angiogenesis models are also valuable tools for 
investigating the in vivo angiogenesis process [Lai et al., 
2009; Ucuzian and Greisler, 2007], e.g. for the treatment 
of cancer, macular degeneration or peripheral and coro-
nary vascular diseases [Nillesen et al., 2007; Ucuzian and 
Greisler, 2007].
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and Tuula Heinonen1
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The developed standardized human cell based in vitro angiogenesis assay was intra-laboratory 
pre-validated to verify that the method is reliable and relevant for routine testing of modulators 
of angiogenesis, e.g., pharmaceuticals and industrial chemicals. This assay is based on the 
earlier published method but it was improved and shown to be more sensitive and rapid 
than the previous assay. The performance of the assay was assessed by using six reference 
chemicals, which are widely used pharmaceuticals that inhibit angiogenesis: acetyl salicylic 
acid, erlotinib, 2-methoxyestradiol, levamisole, thalidomide, and anti-vascular endothelial growth 
factor. In the intra-laboratory pre-validation, the sensitivity of the assay (upper and lower limits 
of detection and linearity of response in tubule formation), batch to batch variation in tubule 
formation between different Master cell bank batches, and precision as well as the reliability 
of the assay (reproducibility and repeatability) were tested. The pre-set acceptance criteria 
for the intra-laboratory pre-validation study were met. The relevance of the assay in man was 
investigated by comparing the effects of reference chemicals and their concentrations to the 
published human data. The comparison showed a good concordance, which indicates that this 
human cell based angiogenesis model predicts well the effects in man and has the potential 
to be used to supplement and/or replace of animal tests.
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angiogenesis (Auerbach et al., 2003; Norrby, 2006) or embryonic, 
and organogenic angiogenesis (Norrby, 2006). Despite the advantage 
of providing more information on complex cellular and molecular 
interactions compared to in vitro models (Norrby, 2006), animal 
models are burdened by several disadvantages such as variability, 
animal-specificity, and unethical procedures (Norrby, 2006; Ishikane 
et al., 2008). The current in vivo assays are not pertinent to human 
diseases as regards both efficacy and relevance (Norrby, 2006). 
Therefore, human cell based (in vitro) assays would have potential 
to be more predictive than animal models when investigating the 
effects in man.
Current in vitro angiogenesis assays include cell proliferation 
and cell migration assays, tubule formation assays, and organ 
culture assays (Auerbach et al., 2003; Ucuzian and Greisler, 2007). 
Three-dimensional in vitro assays permit cell-to-cell interactions, 
but responses are often difficult to evaluate and quantitate. Most 
cell culture assays (e.g., tubule formation assays in collagen or 
Matrigel, cell motility assays, trans-membrane assays, or cell 
proliferation assays) only reflect one single step of angiogenesis 
(Auerbach et al., 2003). An ideal in vitro assay would measure 
both stimulation and inhibition (Bishop et al., 1999; Norrby, 
2006) and provide quantitative measurement of the tubule for-
mation (Norrby, 2006). Although tubule formation in vitro does 
not cover the whole angiogenesis process, it effectively mimics 
the key steps, i.e., migration and differentiation of endothelial 
cells (Donovan et al., 2001).
IntroductIon
Angiogenesis, the formation of new blood vessels, is a multistep 
process regulated by an interplay of pro- and anti-angiogenic fac-
tors. The steps involved are: endothelial cell proliferation, migra-
tion, differentiation, and tubule formation, as well as stabilization 
of newly formed blood vessels by a layer of pericytes and smooth 
muscle cells (Beilmann et al., 2004; Folkman, 2006; Nillesen et al., 
2007). Angiogenesis is involved in critical physiological processes 
such as in embryonic development, wound healing, and female 
reproductive cycle (Friis et al., 2003; Berthod et al., 2006; Norrby, 
2006), as well as in pathologic processes such as in tumor develop-
ment and macular degeneration (Friis et al., 2003), rheumatoid 
arthritis (Friis et al., 2003; Middleton et al., 2004), ischemic diseases 
(van Weel et al., 2008; Cao, 2009), endometriosis (Rogers et al., 
2009), and psoriasis (Folkman, 2006).
Due to complex interactions during angiogenesis, the evalua-
tion of factors that affect angiogenesis would optimally be studied 
in vivo (Auerbach et al., 2003). The most commonly used in vivo 
angiogenesis assays include chick chorioallantoic membrane (CAM) 
assay, Matrigel plug assay, zebrafish embryo system, corneal micro-
pocket assay, rat/mouse hind limb ischemia model, rat aortic ring 
assay, intradermal angiogenesis assays, and Xenopus tadpole assay 
(Auerbach et al., 2003). These in vivo assays are used to measure 
new blood vessel formation by pro- and anti-angiogenic factors and 
compounds (Akhtar et al., 2002; Auerbach et al., 2003; Norrby, 2006; 
Ishikane et al., 2008; Ziche and Morbidelli, 2009), and to study tumor 
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The objective of the study was to intra-laboratory pre-validate 
the optimized test method for testing of angiogenesis modula-
tors in routine use to replace and/or supplement animal experi-
ments. The co-culture assay published by Bishop et al. (1999) 
and Donovan et al. (2001) was further developed, optimized and 
finally pre- validated in the laboratory. All critical steps including 
cell isolation procedure, cell number, cell passage, culture time, and 
tubule formation procedure as well as microscopic analysis were 
thoroughly investigated and optimized before the intra-laboratory 
pre-validation. During the intra-laboratory pre-validation, the per-
formance of the assay was assessed by using six reference chemicals, 
inhibitors of angiogenesis, with animal and human data available; 
levamisole hydrochloride (levamisole), acetyl salicylic acid (ASA), 
thalidomide, erlotinib hydrochloride (erlotinib), anti-vascular 
endothelial growth factor (anti-VEGF), and 2-methoxyestradiol 
(2-ME). The relevance of the method to man was shown by com-
paring the obtained results to the literature data from the clinical 
studies with the same compounds. We here show that through 
thorough optimization and intra-laboratory pre-validation, it is 
possible to develop cell a culture assay into a reproducible and 
repeatable routine method with minimal variation and easy and 
fast semi-quantitative analysis of the effects.
MaterIals and Methods
MaterIals and cheMIcals
The BJ human foreskin fibroblasts were purchased from 
American Type Culture Collection (ATCC, LGC Promochem 
AB, Boras, Sweden, Cat. No. CRL-2522, Lot No. 57632920). 
Fetal bovine serum (FBS, Cat. No. 10106), l-glutamine (Glu, 
Cat. No. 25030), non-essential amino acids (NEAA, Cat. No. 
11140), and TrypLE Express (Cat. No. 12604) were obtained 
from Gibco, Invitrogen, Carlsbad, CA, USA. DAB Substrate Kit 
(Cat. No. 00-2014) was from Zymed Laboratories Inc, Invitrogen, 
Carlsbad, CA, USA. EGM-2 bullet kit including SingleQuots-
supplements (Cat. No. CC-3162), endothelial basal medium 
(EBM; Cat. No. CC-3156), EGM-2 SingleQuots-supplements 
(Cat. No. CC-4176), Gentamicin sulfate 50 mg/ml (Cat. No. 
17-518Z), and Amphotericin B 250 μg/ml (Cat. No. 17-836E) 
were obtained from Lonza Group Ltd., Basel, Switzerland. 
Recombinant Human Fibroblast Growth Factor-basic 146 AA 
(FGF-2, Cat. No. 233-FB, Lot. No. HKW3809032, ED
50
 for induc-
ing proliferation of NR6R-3T3 mouse fibroblasts is typically 0.1–
0.6 ng/ml) and Recombinant human vascular endothelial growth 
factor 165 (VEGF, Cat. No. 293-VE, Lot. No. II2209012, ED
50
 for 
inducing proliferation of human umbilical vein endothelial cells 
(HUVEC) is typically 2.0–6.0 ng/ml) were obtained from R&D 
Systems, Abingdon, UK. 1,4-Ditiotreitol (DTT, Cat. No. 233156, 
Molecular Biology Grade) was obtained from Calbiochem, San 
Diego, CA, USA. Bovine serum albumin fraction V (BSA, Cat. No. 
107350940019) was from Roche, Indianapolis, IN, USA. Erlotinib 
(Lot. No. BS06110030) was a kind gift from Roche Diagnostics 
GmbH, Mannheim, Germany. Anti-von Willebrand Factor (Anti-
vWf) antibody produced in rabbit (Cat. No. F-3520), Neutral 
Red (NR) Solution (Cat. No. N2889), anti-VEGF (Cat. No. 
V6627, Lot. No. 088K1260), thalidomide (Cat No. T144, Lot. 
No. 097K4601), levamisole (tetramisole hydrochloride, Cat. No. 
L9756, Lot. No. 088K0753), 2-ME (Cat. No. M6383, Lot. No. 
108K4087), and ASA (Cat. No. A5376, Lot. No. 048K0015) were 
from Sigma Aldrich, Manassas, VA, USA. Biotinylated anti-rabbit 
IgG (H + L) made in goat (Cat. No. BA-1000) and Vectastain Elite 
ABC Kit, Standard (Cat. No. PK-6100) were purchased from 
Vector laboratories Inc, Burlingame, CA, USA. Triton X-100 was 
from JT Baker, Phillipsburg, NJ, USA. Collagenase I was pur-
chased from Invitrogen, Paisley, Scotland, UK. A 75-cm2 filtered 
cell culture flasks (Nunc EasyFlask™) were from Nunc, Roskilde, 
Denmark. MycoAlert® Mycoplasma Detection Kit (LT07-118) was 
purchased from Lonza Group Ltd., Basel, Switzerland.
PosItIve and negatIve controls
The tubule formation potency of each reference chemical was 
quantified based on the tubule formation potency of the posi-
tive control. The negative control compound induced no tubule 
formation. The positive control was a cocktail of commercial, 
well known angiogenic factors, VEGF, and fibroblast growth 
factor 2 (FGFβ or FGF-2), that are widely used to mimic the 
human tubule formation in vitro (Bishop et al., 1999; Cross 
and Claesson-Welsh, 2001; Donovan et al., 2001; Friis et al., 
2003; Ai et al., 2007). The positive control medium consisted of 
10 ng/ml VEGF and 1 ng/ml FGF-2 dissolved in endothelial basal 
medium (EBM). The optimal positive control was chosen by 
testing  different concentrations of VEGF and FGF-2 (Table 1). 
As the negative control compound, which induced no tubule for-
mation, endothelial basal medium (EBM) without any growth 
factors was used. Negative control gave the same response as 
the solvent. Positive control was used in four parallels and 
negative control in two parallels throughout the procedure in 
each 48-well plate to ensure the technical validity of the tests. 
Additionally, the dimethyl sulfoxide (DMSO) control was used 
in three of the reference chemicals (thalidomide, erlotinib, and 
2-ME) as they were dissolved in DMSO. DMSO concentration 
never exceeded 0.5%.
reference cheMIcals
The six reference chemicals and their concentrations used for 
pre-validation of an in vitro angiogenesis assay are shown in Table 2. 
The rationale behind selection of the reference chemicals were 
that they are consistent with the defined objectives of the study 
(known inhibitors of angiogenesis), they represent different types 
Table 1 | The growth factor cocktails used in investigation of the optimal 
positive control, linearity, upper and lower limits and batch to batch 
variation.
Growth factor cocktail no. VEGF/FGF-2  
 concentration (ng/ml)
1 75/7.5
2 50/5.0
3 25/2.5
4 10/1.0
5 7.5/0.75
6 5.0/0.5
7 2.5/.25
8 1.0/0.1
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Methods
Setting up Master cell banks
Quality control (QC) criteria for setting up Master cell banks were 
as follows: cell cultures were pure with high proliferation capacity 
and contained no mycoplasma. Cell viability was over 90%. Cell 
culture was quality-controlled microscopically and always prior 
to Master cell bank establishment. The cells were tested for myco-
plasma contamination with MycoAlert® Mycoplasma Detection Kit 
according to manufacturer’s instructions. The cell lines (human 
foreskin fibroblasts) were not passaged over 10 times and the pas-
saging of primary cells (HUVEC) was investigated and optimized. 
No antibiotics were used in cell culture.
Human foreskin fibroblasts. Human foreskin fibroblasts were 
obtained from ATCC and cultured in Minimum Essential Medium 
with Earle’s salts, w/o l-Glutamine supplemented with 10% FBS, 
1% l-glutamine, 1% NEAA, and 1% antibiotic–antimycotic mix-
ture in 75 cm2 cell culture flasks in 10 ml of medium at 37°C in 5% 
CO
2
 incubator. The medium was changed and the cells observed 
microscopically for their morphology and cell proliferation every 
3 days. When confluent, the cells were detached with Tryple Express 
and subcultured in a ratio of 1:9. The cells were cryopreserved in liq-
uid nitrogen, 500 000 cells per vial to create the Master cell bank.
Human umbilical vein endothelial cells. The human umbili-
cal cords were obtained from scheduled cesarean sections with 
informed consent from Tampere University Hospital (permis-
sion No. R08028 from the Ethics Committee of the Pirkanmaa 
Hospital District, Tampere, Finland). The isolation of umbilical 
vein endothelial cells (HUVEC) from human umbilical cord veins 
was performed as described by Jaffe et al. (1973) but the process 
was further optimized. The umbilical cord was separated from the 
placenta and the umbilical vein was cannulated with a 20G  needle. 
The needle was secured by clamping the cord over the needle with 
of  chemicals and reliable and relevant reference data in animals 
and man is available. No other inducers of angiogenesis than the 
positive control were included. The concentration range for each 
chemical was selected prior to the angiogenesis assay. The criteria 
for the selection of the chemical were non-toxicity, solubility in 
the test system, and that DMSO concentration not exceeding 0.5% 
in the test system. Reference chemicals were dissolved according 
to manufacturer’s instructions and further diluted in stimulation 
medium (=endothelial basal medium supplemented with 10 ng/ml 
VEGF and 1 ng/ml FGF-2) prior to use.
These reference chemicals are widely studied angiogenesis 
inhibitors and pharmaceuticals. Anti-VEGF is the first angio-
genesis inhibitor that has been approved by the U.S. Food and 
Drug Administration under trade name Avastin (bevacizumab) 
for the treatment of colon cancer (Folkman, 2006). According 
to Folkman (2006) VEGF antibody (trade name Lucentis) and 
aptamer of VEGF (trade name Macugen) are used for the treat-
ment of macular degeneration; erlotinib (trade name Tarceva), an 
epidermal growth factor receptor (EGFR) tyrose kinase inhibitor 
is used for the treatment of lung cancer; thalidomide is used for 
the treatment of multiple myeloma. ASA has protective effects 
against colon cancer and cardiovascular disease (Yan et al., 2010). 
2-ME is approved by FDA for the treatment of ovarian cancer 
under trade name Panzem. 2-ME has also been studied in the 
treatment of rheumatoid arthritis (Brahn et al., 2008), cardio-
vascular diseases (Dubey and Jackson, 2009), multiple myeloma 
(Rajkumar et al., 2007), breast cancer (Greenberg and Rugo, 
2010), and prostate cancer (Harrison et al., 2010). Levamisole 
(trade name Ergamisol) has been used to treat worm infesta-
tions in both humans and animals and it is tested in clinical trials 
for the treatment of chronic idiopathic urticaria (Zhang et al., 
2009), for colorectal cancer (Quasar Collaborative et al., 2007; 
Dahl et al., 2009), for malignant melanoma (Verma et al., 2006), 
and for malaria (Dondorp et al., 2007).
Table 2 | Reference chemicals tested in the intra-laboratory pre-validation of an in vitro angiogenesis assay.
Chemical name CAS-RN Chemical class Product class Concentrations tested Purity Supplier Physical and 
       chemical 
       characteristics
Acetyl 50-78-2 Salicylate Non-steroidal anti- 10, 100, 500, 1000,   99.9% Sigma Aldrich Powder 
salicylic acid   inflammatory 1500, and 2000 μM 
   drug (NSAID)
Erlotinib 183319- Quinazoline HER1/EGFR tyrosine  0.0005, 0.001, 0.01, 0.1,  99.9% Roche Powder 
 69-9  kinase inhibitor 1, 10, 25, and 50 μM  Diagnostics
Levamisole 16595-80-5 Imidazothiazole Alkaline phosphatase 0.01, 0.1, 1, 10, 50,  99% Sigma Aldrich Powder 
   inhibitor 100, 250, 500, 750, 
    1000, and 2000 μM 
2-Methoxyestradiol 363-07-2 Estradiol metabolite Tubulin inhibitor 0.01, 0.1, 0.2, 0.4, 0.6 99.5% Sigma Aldrich Powder 
    0.8, 1, and 2 μM
Thalidomide 50-35-1 Phthalimide Immunomodulator,  10, 100, 200, 300, 400, >99% Sigma Aldrich Powder 
   TNF-α inhibitor and 500 μM
Anti-VEGF n/a Human VEGF165  Growth factor antibody 0.5, 1, 2.5, 5, 7.5, 10, 25,  n/a Sigma Aldrich Lyophilized 
  and VEGF121  and 50 μg/ml   powder 
  antibody, IgG fraction      
  of antiserum
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Angiogenesis assay
The angiogenesis assay was performed independently by two tech-
nicians and two analysts. The technicians performed the whole 
assay independently, except that the microscopic analysis was per-
formed independently and blinded by two analysts. For microscopic 
analysis the samples were coded by a person not directly involved 
in the study.
The co-culture of fibroblasts and HUVEC was first established 
as described above (see Co-Culture Establishment). The day after 
co-culture creation, the co-culture was exposed to the positive or 
negative controls (see Positive and Negative Controls), the refer-
ence chemical treatments (see Table 1) or growth factor cocktails 
(see Table 2). The cells were cultured at 37°C for 6 days prior 
to immunocytochemical staining. The media containing either 
reference chemicals, or growth factor cocktail, or positive control 
or negative control, were changed once during the assay, on the 
third day.
Immunocytochemical staining. At day 6 from the onset of the 
experiment, the tubules were immunostained with anti-vWF. 
The media were removed and the cells were washed three times 
with PBS, fixed with ice-cold 70% ethanol for 20 min, permeabi-
lized with 0.5% Triton X-100 (JT Baker, Phillipsburg, NJ, USA) 
for 15 min and blocked for unspecific staining with 10% BSA 
(Roche Diagnostics Corporation, Indianapolis, IN, USA) for 
30 min. After blocking, the cells were incubated with primary 
antibody (anti-vWf, 1:5000) at 4°C overnight or for 1–2 h in 
room temperature (RT). Cells were then washed three times 
with PBS, incubated for 30 min with the secondary antibody 
(biotinylated anti-rabbit IgG, H + L made in goat) and washed 
again three times with PBS. The cells were then incubated with 
enzyme conjugate solution (Vectastain Elite ABC Kit) for 30 min, 
after which substrate was added (DAB Substrate Kit). The color 
development was followed under microscope for 5–10 min and 
the reaction was stopped with 0.5 M Tris buffer. After staining, 
500 μl of Tris buffer was pipetted into each cell culture well 
and the plates were sealed with parafilm for storage at 4°C until 
microscopic analysis.
Microscopic analysis. After immunocytochemical staining, the 
tubules were analyzed with Nikon Eclipse TS100 microscope 
(Nikon, Tokyo, Japan). The extent of tubules and their branch-
ing was quantified using predetermined visually inspected semi-
quantitative grading scale from 0 to 8. The analysis and grading 
required expertise and therefore were performed by scientists. As 
the microscopic analysis was based on semi-quantitative visual 
analysis, we especially wanted to test the repeatability of the analysis. 
Therefore all plates and wells were coded and analyzed individually 
by two scientists. Figure 1 shows the tubule network formation 
from negative and positive control.
Statistics. One-way analysis of variance with Dunnett’s post 
test was used for the statistical analysis of the reference chemi-
cal results. The linearity of tubule formation was tested with 
 linear regression and precision with coefficient of variation (CV). 
The day to day variation of technicians was tested with one-way 
analysis of variance, person to person variation between techni-
cians with unpaired t-test and person to person variation between 
a surgical clamp. The vein was perfused with Umbilical cord buffer 
solution (UBS; 0.1 M phosphate buffer solution containing 0.14 M 
NaCl, 0.004 M KCl, and 0.011 M glucose) to wash out blood after 
which the other end of the umbilical vein was clamped with a 
surgical clamp. The vein was infused with 0.05% collagenase I. 
The umbilical cord was incubated in a water bath at 37°C for up 
to 20 min. After incubation, the collagenase solution containing 
HUVEC was flushed from the cord by infusing the vein with UBS. 
The suspension was flushed out into a 50-ml polypropylene tube. 
The cells were centrifuged at 250×g for 10 min, resuspended in 
EGM-2 BulletKit medium, seeded into 75 cm2 filtered cell culture 
flasks, and cultured at 37°C in 5% CO
2
 incubator.
The isolated HUVEC were daily observed microscopically for 
their morphology, cell culture purity, and cell proliferation. The 
medium was changed every 2–3 days. When confluent, the cells 
were detached with Tryple Express. Pure HUVEC cultures with 
good proliferation capacity were subcultured at primary culture 
(p0) in the ratio of 1:2–1:4 and at passages 1 (p1) upward in a ratio 
of 1:3–1:5. The isolated HUVEC were tested for their tubule forma-
tion capacity in the angiogenesis assay up to passage 10. At passage 
2 (p2), the cells were cryopreserved in liquid nitrogen, 500 000 cells 
per vial to create the Master cell bank. The donor-specific batch 
number was given to each batch stored in the Master cell bank.
Co-culture establishment
BJ fibroblasts were taken from the Master cell bank, thawed, and 
cultured as above (see Human Foreskin Fibroblasts) for 3 days. On 
day 3, the BJ fibroblasts were plated into 48-well plates at a cell den-
sity of 20 000 cells/cm2, and grown for an additional 3 days. On day 
3, the HUVEC were taken from the Master cell bank, thawed, and 
cultured as above (see Human Umbilical Vein Endothelial Cells), 
separately from BJ fibroblasts, for 3 days. On day 6, the HUVEC 
cells were carefully seeded on the top of BJ fibroblasts into 48-well 
plates at a cell density of 4000 cells/cm2. The co-culture was then 
further used for cytotoxicity test and for angiogenesis assay.
Cytotoxicity test
To find out the highest concentration for each reference chemi-
cal for the angiogenesis assay, a cytotoxicity test was performed. 
Both technicians performed individually the cytotoxicity test for 
each reference chemical. As the cytotoxicity assay, the neutral red 
uptake (NRU) cell viability assay was used. The co-culture of 
fibroblasts and HUVEC was first established as described above 
(see Co-Culture Establishment). Twenty-four hours after co-culture 
establishment, the test system was treated by exposing with positive 
or negative controls (see Positive and Negative Controls), or refer-
ence chemicals (see Reference Chemicals and Table 1) for 24 h. After 
exposure for 24 h, the exposure medium was removed and the cells 
were washed with preheated PBS. Two hundred fifty microliters of 
NR-medium (25 mg NR/1 ml medium) was added into the wells 
and incubated for 2 h at 37°C. After incubation, NR-medium was 
removed and the cells were washed with 250 μl PBS. After that, 
100 μl NR-desorption medium (50% EtOH, 1% acetic acid in H
2
O) 
was added into the wells and incubated in a shaker for 20 min, 
protected from light. After shaking, the cells were allowed to settle 
down for 5 min. The absorbance was measured at 540 nm with 
Thermo Scientific Varioskan Flash Spectral Scanning Multimode 
Reader (Thermo Fisher Scientific Inc., Waltham, MA, USA).
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up in our laboratory gives comparable results. The batch to batch 
variation testing was performed in the angiogenesis assay with the 
growth factor cocktails shown in Table 1. Three HUVEC batches 
of passage 4 with 6 parallels were investigated. All of the batches 
had to follow the criteria for upper and lower limits of detection 
and to follow linearity.
Precision
To find out the maximal variation due to technicians and micro-
scopic analysts, two technicians performed the positive and negative 
control tests (each technician performed one 48-well plate of nega-
tive control and one 48-well plate of positive control). The negative 
control was tested in the angiogenesis assay with endothelial basal 
medium (EBM) without any growth factors. The positive control 
was tested in the angiogenesis assay with one VEGF and FGF-2 
dilution, i.e., positive control (10 ng/ml VEGF and 1 ng/ml FGF-2). 
Total variation in the test had to be ≤15% analyzed with CV. It is 
known, that cell culture conditions may be affected by the position 
of the well in the plate. Therefore, the whole plate was used to test 
the maximal variation including technicians, microscopic analysts, 
and cell culture conditions within plate.
Reliability
To test the reliability, two technicians repeated the test three times 
in unchanged conditions for all the reference chemicals. Reliability 
included repeatability, i.e., the positive control and the reference 
chemicals must give comparable results regardless of the testing 
time, and reproducibility, i.e., the effect of each reference chemical 
must be the same regardless of the technician. The positive control 
included altogether 24 parallels performed at three consecutive days 
by two technicians and each testing time included four parallels. 
The positive control contained four parallels and was always placed 
at the same position in a 48-well plate.
Repeatability. The test was performed by two technicians – micro-
scopic analyst – pairs three times using identical protocol (day to 
day variation).
Reproducibility. Two technician – microscopic analyst – pairs 
repeated the same identical test protocol (person to person 
 variation). In addition, each analyst analyzed all plates.
analysts with paired t-test. All statistical analyses were performed 
using GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, 
CA, USA).
test accePtance crIterIa
Technical criteria
Three wells of the positive control had to give values 6–7 at each 
testing time. One well could give value 5. Then, the calculated 
minimum value for positive control is 5.75. The negative control 
had to be always negative (0). Only one out of two parallels in one 
combination of each reference chemical during each testing time 
could be discarded based on visual inspection in case the cells were 
found to be dead or detached.
Sensitivity of detection
For sensitivity of detection, linearity as well as upper and lower 
limits of detection, were investigated. Eight different growth fac-
tor cocktail concentrations (VEGF and FGF-2, 10:1) were used 
(Table 1) and investigated in order to find the optimal cocktail for 
positive control.
Linearity. Linearity was tested in order to find out the growth factor 
cocktail concentration range that induces tubule formation in a 
linear manner. For linearity testing, the negative control, and dif-
ferent growth factor cocktails (VEGF and FGF-2, 10:1) were used 
(see Table 1). Each cocktail was tested in six parallels.
Upper and lower limits of detection. The dose–response effect of 
the growth factor cocktails were investigated, and the combination 
of growth factors (see Table 1 for the growth factor cocktails used) 
giving the maximum value in the linear part of the response curve 
was selected to be the upper limit of detection. This was also chosen 
as the fixed positive control for the test (see Positive and Negative 
Controls). For the lower limit of detection, the growth factor cock-
tail that gives value 1 in the linear range of the tubule formation 
scale was selected. Each cocktail was tested in six parallels.
Batch to batch variation
Testing of the batch to batch variation between different HUVEC 
batches (different umbilical cords, i.e., donor samples) was per-
formed to confirm that each of the Master cell bank batches set 
FiGuRE 1 | Angiogenesis in vitro assay. The BJ fibroblast HUVEC co-culture 
was immunostained with anti-vWf antibody (1:5000) and with DAB Substrate 
kit. (A) Negative control, no tubule development (value 0 in tubule formation 
grading). Endothelial cells remain as epithelial-like round areas in co-culture. 
(B) Positive control (cocktail of 10 ng/ml VEGF and 1 ng/ml FGF-2) inducing tubule 
network formation (value 7 in tubule formation grading). Cells form tubule-like 
structures connecting to each other. Extensive branching of cells and long 
structures that cover the whole area of the well. Scale bar 500 μM.
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the tubule formation remained quite constant and high. During 
cultivation, when the passage number increased, the tubule forma-
tion decreased. Thus, the passage 4 was chosen as the fixed passage 
to be used in the angiogenesis assay.
cytotoxIcIty test
The concentration giving the viability of 80% or higher was taken 
as the highest concentration to be used in the angiogenesis assay. 
Consequently, the concentration ranges were as follows: levamisole 
0.01–2000 μM, thalidomide 10–500 μM, erlotinib 0.0005–50 μM, 
2-ME 0.01–2 μM, and anti-VEGF 0.5–50 μg/ml. Only ASA showed 
toxicity. The toxicity was found at 2000 μM. Therefore the concentra-
tion range for ASA used in angiogenesis assay was 10–1500 μM.
angIogenesIs assay
Technical validity of the test
Positive control in each testing time gave the values 6–7 from 3 
out of 4 parallels. Negative control always gave 0. No wells needed 
to be discarded.
Intra-laboratory pre-validation parameters
Sensitivity of detection. The sensitivity of detection was evaluated 
by studying linearity and the upper and lower limits of detection. 
Figure 3A shows the results obtained with HUVEC in the angiogen-
esis assay (three batches). The response was linear up to the growth 
factor cocktail of 10 ng/ml VEGF and 1 ng/ml FGF-2 with all three 
batches. At cocktails with higher growth factor concentrations, the 
response decreased. The growth factor cocktail that caused maxi-
mal tubule formation in the linear part of the response curve was a 
combination of 10 ng/ml VEGF and 1 ng/ml FGF-2 (Figure 3B) and 
was the upper limit of detection. This combination was also chosen 
as the fixed positive control for the test (see Positive and Negative 
Controls). The lowest VEGF and FGF-2 cocktail combination that 
induced tubule formation (value 1 in microscopic analysis of tubule 
formation grading) was found to be a combination of 1 ng/ml VEGF 
and 0.1 ng/ml FGF-2. This was the lower limit of detection.
Batch to batch variation. The batch to batch variation was tested 
between three HUVEC batches treated with positive control (each 
batch with six parallels). The results are shown in Table 3. It was 
Performance
The overall performance of the assay was tested by repeating the 
identical protocol with six different reference chemicals three times 
by two technician – microscopic analyst – pairs.
test Method data qualIty
All work was performed according to the Good Laboratory Practice 
Regulations as set forth in OECD [ENV/MC/CHEM (98)17], in 
accordance with OECD guidelines [OECD Guidance document on 
the Validation and international Acceptance of New or Updated Test 
Methods for Hazard Assessment (OECD, 2005, No 34) and CPMP/
ICH/281/95] and ECVAM (European Centre for the Validation of 
Alternative Methods) guidance documents (http://ecvam.jrc.it/) and 
according to the standard operating procedures of FICAM.
results
PrIMary huvec Master cell bank oPtIMIzatIon
The tubule formation potency of HUVEC (treated with the positive 
control) was studied up to passage 10. The results of the passage 
optimization are seen in Figure 2. It was seen that up to passage 4 
FiGuRE 2 | Tubule formation potency of the positive control in the 
angiogenesis assay at different HuVEC passages. The results are given as 
mean ± SD. The results are averages of at least three separate experiments.
FiGuRE 3 | (A) Upper and lower limits of detection of tubule formation for three different HUVEC batches (HUVEC-12, HUVEC-15, HUVEC-16, n = 12 in each 
curve; (B) the linearity of tubule formation as tested from three different HUVEC batches with linear regression (n = 36). The growth factor concentrations are 
shown as VEGF concentrations. The concentrations of VEGF and FGF-2 used are seen in detail in Table 2. VEGF/FGF-2 ratio was always 10:1. The results are given 
as mean ± SD.
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when the results of technician 1 were analyzed and 2.37%, when 
the results of technician 2 were analyzed. No statistically significant 
difference (p = 0.2084) was observed between the analysts. When 
comparing the technicians to each other (person to person varia-
tion), a statistically significant difference was observed (p = 0.007), 
whereas no person to person variation between analysts was seen 
However, the total CV, i.e., the total variation in the assay was as 
low as CV = 1.39%.
Performance
The performance of the assay was assessed by six different refer-
ence chemicals with several concentrations of each. The results of 
the effects of reference chemicals on tubule formation are seen in 
Figure 4. All the reference chemicals inhibited tubule formation as 
expected. Although the response was reference chemical specific, 
the phenomenon was repeatable, and variation remained constant 
throughout the study. The tubule inhibition was calculated to be 
mild (20% inhibition from positive control), moderate (40–60% 
inhibition from positive control or strong (75–85% inhibition 
from control). The severity of inhibition and the concentrations 
causing mild, moderate, or strong inhibition are summarized in 
Table 6, where the reference chemical results of our in vitro assay 
are compared to other in vitro angiogenesis test methods, to the 
relevant plasma concentrations in clinical studies and to effective 
doses from animal studies.
dIscussIon
The present intra-laboratory pre-validation study showed that 
a standardized in vitro angiogenesis assay is reliable and repro-
ducible for testing the modulators of angiogenesis, and this 
human primary cell based in vitro assay mimics well the effects 
in man. Thus, it has great potency to supplement and/or replace 
animal tests.
Appropriately pre-validated human cell in vitro assays are 
urgently needed for reducing and replacing animal tests. In vitro 
angiogenesis assays are regarded as useful tools for screening com-
pounds and their effective concentrations, but due to complex 
interactions during angiogenesis, they often need to be followed 
by in vivo studies (Auerbach et al., 2003). Animal assays, although 
not necessarily predictive for effects in human, are widely used 
as they provide information on complex cellular and molecular 
interactions (Norrby, 2006). The disadvantages of the current in 
vitro assays are that they lack metabolism and are rarely completely 
based on human biology (Auerbach et al., 2003).
seen, that the criteria for positive control value were met with all 
batches and that the variation between the batches was extremely 
small (CV = 1.72%).
Precision. To find out the maximal variation, including that caused 
by technicians and microscopic analysts, the angiogenesis assay 
with positive and negative controls was performed. The results 
of the positive and negative control and their CV% are shown 
in Table 4. Negative control was always found to give the value 0 
however; the CV% of positive control was found to be between 
6.27 and 7.82%.
Reliability
Repeatability. The results of day to day variation between techni-
cians and microscopic analysts are presented in Table 5. No sig-
nificant differences were observed among technicians (p = 0.906 
and p = 0.064). The microscopic analyst–technician pairs had 
following day to day variation: microscopic analyst 1 technician 
1 CV = 0.59%, microscopic analyst 2 technician 1 CV = 0.67%, 
microscopic analyst 1 technician 2 CV = 6.38%. Microscopic ana-
lyst 2 technician 2 CV = 5.02%. We further studied whether the 
variation was due to analysis or due to technical performance (see 
Reproducibility).
Reproducibility. When the person to person variation was studied, 
each analyst analyzed all plates. Overall there was only a minor 
difference in CV% between technicians [the results of technician 
1 or technician 2 were analyzed by both (two) analysts], being 
0.64% with technician 1 and 5.63% with technician 2. The person 
to person variation is seen in Table 5. The results showed that the 
CV% between microscopic analysts was very low; CV% was 0.34% 
Table 3 | Batch to batch variation in tubule formation between three 
HuVEC batches (HuVEC-12, HuVEC-15, HuVEC-16, n = 12 with each 
batch).
 Criteria HuVEC-12 HuVEC-15 HuVEC-16
Positive control ≥5.75 7.417 7.500 7.250 
(mean)
Mean (three ≥5.75  7.389 
batches)
Variation (CV%) ≤15%  1.72%
CV%, coefficient of variation (%).
Table 4 | The precision of the in vitro angiogenesis assay. Maximal variation in the angiogenesis assay was tested with positive and negative controls (Two 
pairs of microscopic analyst–technician performing each one 48-well plate of negative control and one 48-well plate of positive control).
 Criteria Technician  Technician  Technician  Technician  
  1–microscopic 1–microscopic 2–microscopic 2–microscopic 
  analyst 1 analyst 2 analyst 1 analyst 2
Positive control (mean) ≥5.75 6.354 6.771 6.896 6.958
Negative control  0 0 0 0 0
Variation (CV%) ≤15 7.61 6.27 6.85 7.82
CV%, coefficient of variation (%).
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The optimal positive control concentration, i.e., VEGF/FGF-2 
growth factor cocktail was obtained by investigating the biologi-
cal response of several growth factor concentrations in several 
HUVEC batches. The positive control optimization resulted in 
stable and repeatable effect. The batch to batch variation for 
HUVEC was minimal due to the optimized passage and pre-set 
QC criteria for the cells stored in Master cell bank. Moreover, 
the test duration was shortened from previous methods (Bishop 
et al., 1999; Donovan et al., 2001) from 14 to 6 days of co-culture 
and the assay setup was optimized for 48-well plate to minimize 
the use of cells and to increase the capacity. A semi-quantitative 
microscopic analysis method, based on tubule formation, their 
connections and the complexity of the developed network, was 
developed. The prerequisite for the semi-quantitative grading 
was that the analysis covered the whole area of each well, con-
trary to the method of Bishop et al. (1999), where images taken 
from only five random fields in larger wells (24-well plates) were 
analyzed by computer analysis program. In optimization phase, 
the performance assay was tested with 19 reference chemicals; 
We further developed, optimized and finally intra-laboratory 
pre-validated the previously published angiogenesis assay (Bishop 
et al., 1999). Our assay is based on quality-controlled primary 
HUVEC that have been minimally expanded in vitro. The optimi-
zation of the HUVEC passage number was found to be one crucial 
factor for the adequate performance of the assay. The tubule forma-
tion ability decreased significantly after serial passaging. Based on 
the optimization phase, the use of one, fixed passage of HUVEC 
was found to be optimal. This shows, that the effect of passage 
number on the biological activity of cells has to be investigated and 
the passage number fixed in order to maintain repeatability of the 
assay. Through optimization, we could obtain a routine assay with 
minimal variation (overall CV% between the two technicians and 
microscopic analysts was 1.39%). However, statistically significant 
difference was found between technicians. The effect of this on the 
final results is avoided by using positive and negative controls as 
there was no significant difference in day to day variation among 
technicians. They are used to calculate the response of unknown 
substances, as well as used as internal controls in the assay.
Table 5 | Day to day variation (repeatability) and person to person variation (reproducibility) between the technicians and the microscopic analysts. 
Criteria set and the positive control values obtained.
Reproducibility and repeatability
 Criteria set for Obtained positive control value 
 positive control/ 
 CV%/p-value
  Technician Technician Technician Technician 
  1 –microscopic 1 – microscopic 2 –microscopic 2 –microscopic 
  analyst 1  analyst 2  analyst 1 analyst 2 
  mean (n = 24) mean (n = 24) mean (n = 24) mean (n = 24)
Day 1 (n = 48) ≥5.75 5.79 5.833 5.75 5.75
Day 2 (n = 48) ≥5.75 5.833 5.833 6.583 6.083
Day 3 (n = 48) ≥5.75 5.875 5.75 6.625 6.5
Mean between days  ≥5.75 5.833 5.805 6.319 6.111
Day to day variation among  ≤15% 0.59% 0.67% 6.38% 5.02% 
technicians (CV%)
Day to day variation among p < 0.05  ns, p = 0.906   ns, p = 0.064 
technicians (one-way ANOVA)
Day to day variation between  ≤15%  0.34%    2.37% 
analysts (CV%)
Person to person variation   0.64%    5.63% 
between technicians
Person to person variation p < 0.05    p = 0.007 
between technicians (statistical  
significance, unpaired t-test)
Person to person variation p < 0.05    ns, p = 0.2084 
between analysts (statistical  
significance, paired t-test)
Total mean of positive control ≥5.75    6.017
Total variation of positive  ≤15%    1.39% 
control (CV%)
CV, coefficient of variation, ns, non-significant.
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used (Donovan et al., 2001; Auerbach et al., 2003). However, 
compared to several previous in vitro studies, our assay shows 
improvement of sensitivity.
The relevance of the assay to man was investigated by compar-
ing the obtained reference chemical results with data from clinical 
studies. The effective concentrations observed in our assay showed 
very good concordance with the respective therapeutic plasma con-
centrations (Table 6). The plasma concentrations of anti-VEGF 
obtained from different clinical trials varied extensively. One expla-
nation is that the endogenous plasma concentrations of VEGF and 
FGF-2 differ among individuals and are also dependent on the 
disease (Kakimoto et al., 2002).
In conclusion, we here show that through thorough optimiza-
tion, it is possible to develop a cell culture assay into a reproducible 
and repeatable routine method with minimal variation and with 
easy and fast semi-quantitative quantification of the end points. 
The intra-laboratory pre-validation study was completed success-
fully, the test was technically accepted and the pre-set acceptance 
criteria were met. In comparison of the results to the data from 
clinical trials shows that this human cell based in vitro angio-
genesis assay mimics very well the effects in man, and thus it can 
be used to replace and/or supplement animal tests when testing 
angiogenesis modulators. The applicability domain contains so far 
pharmaceuticals. In addition to the chemical testing, the method 
has potency to test conditioned media of cells or even the effect of 
different cells (normal or cancer cells) with regard to their effect 
on angiogenesis.
endostatin, interleukin-1 soluble receptor 1 (IL-1 SR1), suramin, 
mevinolin, paclitaxel, fumagillin, anti-epidermal growth fac-
tor receptor (anti-EGFR) cyclooxygenase-2-specific inhibitor 
NS-398, indomethacin, VEGF, anti-VEGF, FGF-2, anti-FGF-2, 
platelet-derived growth factor beta (PDGF-BB), levamisole, erlo-
tinib, ASA, 2-ME, and thalidomide.
The performance of the in vitro angiogenesis assay was proven 
in intra-laboratory pre-validation with six different reference 
chemicals (levamisole, ASA, thalidomide, erlotinib, anti-VEGF, 
and 2-ME). The obtained results were compared to the pub-
lished data from other in vitro angiogenesis assays (Table 6). 
The table shows that comparable results were detected with 
ASA (Borthwick et al., 2006), with erlotinib (Birle and Hedley, 
2006; Jimeno et al., 2007), and with 2-ME (Dobos et al., 2004). 
However, 2-ME had previously shown low inhibition at 10 μM 
and moderate inhibition at 50 μM (Kang et al., 2006), whereas 
our assay showed low and moderate inhibition at 0.01–0.2 and 
1 μM, respectively. Moreover, compared to the method by Friis 
et al. (2003, 2005), which is a similar assay to ours, levamisole 
was reported to have mild inhibition at 500 μM (in our study 
0.01–1 μM), moderate at 750–1000 μM (in our study 100–
500 μM), and strong at 2000 μM (in our study 1000–2000 μM). 
The anti-VEGF was reported to have moderate to strong inhibi-
tion at 0.1–10 mg/ml in an in vitro model with different study 
setup (Sims et al., 2008) compared to our assay (inhibition at 
0.5–50 μg/ml). There are known to be marked differences in 
tubule formation depending on the in vitro angiogenesis assay 
FiGuRE 4 | The performance of the assay. The effects of the reference 
chemicals on tubule formation. The results are given as mean ± SD, n = 24 
including three testing times with two technicians. Microscopic analysis of all 
wells was performed individually by two analysts. The results were tested 
statistically by using one-way ANOVA with Dunnett’s post test. *p < 0.05, 
**p < 0.01 and ***p < 0.001.
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Table 6 | The comparison of the results from intra-laboratory pre-validated  assay to the results from other in vitro methods, clinical studies and 
animal models.
Mild inhibition 
(% of control) 
<20%
Moderate 
inhibition (% of 
control) 40–60%
Strong 
inhibition (% of 
control) 75–85%
inhibitory effect and 
concentration
Cmax Effective dose (ED)
Acetyl salicylic acid 1.8–8 μg/ml 
(10–100 μM)
180 μg/ml 
(1000 μM)
270 μg/ml 
(1500 μM)
Moderate 500 μM 
(Borthwick et al., 
2006)
• 260–1026 μM (Juárez 
Olguín et al., 2004)
•  26–300 μM, CAM 
model (Sharma 
et al., 2001)
• 0–25 μg/ml (Maalouf 
et al., 2009)
• 170 ± 96.7 ng/ml (Bae 
et al., 2008)
Erlotinib (EGF 
receptor tyrosine 
kinase inhibitor)
0.04–40 ng/ml 
(0.5 nM–
0.1 μM)
4 μg/ml (10 μM) 22 μg/ml (50 μM) Mild 1–20 μM (Birle 
and Hedley, 2006), 
Moderate 10 μM 
(Jimeno et al., 2007)
• 0.3–1.13 μg/ml 
(Herbst et al., 2005)
• 0.251–10.7 μg/ml 
(Ranson et al., 2010a)
• 2.93 ± 1.3 μg/ml 
(Ranson et al., 2010b)
• 0.3 μM (Clarke et al., 
2010)
• 0.56–4 μM (Kraut 
et al., 2010)
•  50 mg/kg, Mouse 
carcinoma model 
(Jimeno et al., 2007)
•  50 mg/kg, Mouse 
tumor model 
(Cerniglia et al., 
2009)
Levamisole 2–240 ng/ml 
(0.01–1 μM)
25–120 μg/ml 
(100–500 μM)
240–500 μg/ml 
(1000–2000 μM)
Mild 500 μM, 
moderate 750–
1000 μM, strong 
2000 μM (Friis et al., 
2005), strong 
2000 μM (Sylvest 
et al., 2010)
• 0.62 μg/ml–1.27 μg/ml 
(Reid et al., 1998)
• 0.716 ± 0.217 μg/ml 
(Kouassi et al., 1986)
•  1.2–12 mg/kg, Nude 
mouse tumor model 
(Friis et al., 2005)
•  Cmax 0.37 μg/ml calf 
parasite infection 
(Taylor et al., 1988
2-Methoxyestradiol 3–60 ng/ml 
(0.01–0.2 μM) 
300 ng/ml (1 μM) 600 ng/ml (2 μM) Mild 10 μM, moderate 
50 μM (Kang et al., 
2006), Mild 0.5 μM, 
moderate 1 μM 
(Dobos et al., 2004)
• 3.3 ng/ml (Tevaarwerk 
et al., 2009)
• 30.27 ± 20.18 ng/ml 
(Matei et al., 2009)
• 3.0–21.4 ng/ml (Dahut 
et al., 2006)
• 1.4–13.2 ng/ml 
(James et al., 2007)
• 2.2–9.6 ng/ml 
(Sweeney et al., 
2005)
•  100 mg/kg Murine 
rheumatoid arthritis 
model (Plum et al., 
2009)
•  7.5 mg/kg, 75 mg/kg 
Mouse tumor model 
(Dobos et al., 2004)
Thalidomide 2–25 μg/ml 
(10–100 μM)
77–100 μg/ml 
(300–400 μM)
- - • 2 μg/ml (Kakimoto 
et al., 2002)
• 1.68 ± 0.41 μg/ml 
(Murakami et al., 
2009)
• 1.44 ± 0.50 μg/ml 
(Kamikawa et al., 
2006)
• 0.43–1.03 μg/ml 
(Vieira and Valente 
Mdo, 2009)
•  100 mg/kg, Rat 
Alzheimer model 
(Ryu and McLarnon, 
2008)
•  19–1000 μM, CAM 
model (Sharma 
et al., 2001)
Reference 
chemical
Results from intra-laboratory pre-validated  
angiogenesis test method
Results using other  
in vitro angiogenesis 
test methods 
Results from clinical 
trials
Results using 
animal models
(Continued)
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Who's to say 
What's impossible 
Well they forgot 
This world keeps spinning 
And with each new day 
I can feel a change in everything 
        -- 
And as my mind begins to spread its wings 
There's no stopping curiosity 
-- 
Who's to say 
I can't do everything 
Well I can try 
And as I roll along I begin to find 
Things aren't always just what they seem 
 
I want to turn the whole thing upside down 
I'll find the things they say just can't be found 
-- 
 
 
Who's to say what's impossible and can't be found? 
 
 
 
 
from “Upside Down” 
Curious George theme 
lyrics Jack Johnson 
 
 
